Compositions and methods based on pmt engineering for producing tobacco plants and products having altered alkaloid levels

ABSTRACT

The present disclosure provides compositions and methods related to tobacco plants with altered total alkaloid and nicotine levels and commercially acceptable leaf grade, their development via breeding or transgenic approaches, and production of tobacco products from these tobacco plants.

CROSS-REFERENCE TO REPLATED APPLICATIONS AND INCORPORATION OF SEQUENCE LISTING

This application claims the benefit of U.S. Provisional Application No. 62/703,775, filed Jul. 26, 2019 and U.S. Provisional Application No. 62/848,159, filed May 15, 2019, which are incorporated by reference in its entirety herein. A sequence listing contained in the file named “P34620US02_SL.txt” which is 200,338 bytes (measured in MS-Windows®) and created on Jul. 26, 2019, is filed electronically herewith and incorporated by reference in its entirety.

FIELD

The present disclosure provides tobacco genetic engineering for modulating alkaloid and nicotine levels.

BACKGROUND

Nicotine is the predominant alkaloid, usually accounting for more than 90-95% of the total alkaloids in commercial tobacco cultivars. The remaining alkaloid fraction is primarily comprised three additional alkaloids: nornicotine, anabasine, and anatabine. Tobacco plants with reduced nicotine levels have been achieved with varying and inconsistent results by modulating different nicotine biosynthetic genes and transcriptional regulators. There is a need for new technologies to reduce nicotine levels in tobacco leaves.

SUMMARY

The present disclosure provides tobacco plants with altered total alkaloid and nicotine levels and commercially acceptable leaf grade, their development via breeding or transgenic approaches, and production of tobacco products from these tobacco plants.

In an aspect, the present disclosure provides a tobacco plant, or part thereof, comprising one or more mutant alleles in at least one PMT gene selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4, wherein the tobacco plant is capable of producing a leaf comprising a nicotine level less than the nicotine level of a leaf from a control tobacco plant not having the one or more mutant alleles when grown and processed under comparable conditions.

In another aspect, a tobacco plant comprises one or more mutant alleles in at least two PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4.

In a further aspect, a tobacco plant comprises one or more mutant alleles in at least three PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4.

In another aspect, a tobacco plant comprises one or more mutant alleles in at least four PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4.

In a further aspect, a tobacco plant comprises one or more mutant alleles in five PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4.

In an aspect, the present disclosure provides a tobacco plant selected from the group consisting of a single pmt mutant, a double pmt mutant, a triple mutant, a quadruple mutant, and a quintuple mutant, as listed in Tables 8A to 8E.

In an aspect, the present disclosure provides a tobacco plant as listed in Tables 4A to 4E or Table 10. In another aspect, the present disclosure provides a progeny plant of a tobacco plant in Tables 4A to 4E or Table 10, from either selfing or a cross with another plant in Tables 4A to 4E or Table 10.

In another aspect, the present disclosure provides a tobacco plant comprising various combinations of the pmt mutant alleles listed in Tables 5A to 5E or Tables 12A to 12E to give rise to a single pmt mutant, a double pmt mutant, a triple mutant, a quadruple mutant, or a quintuple mutant. In an aspect, the present disclosure provides a tobacco plant comprising a pmt mutant allele sequence selected from the group consisting of SEQ ID Nos. 21 to 200, 410 to 441, 474 to 505, 538 to 569, 602 to 633, and 666 to 697.

The present disclosure further provides cured tobacco, tobacco blends, tobacco products comprising plant material from tobacco plants, lines, varieties or hybrids disclosed.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID Nos: 1 to 5 set forth exemplary genomic sequences of PMT1b, PMT1a, PMT2, PMT3 and PMT4, respectfully, from a TN90 reference genome.

SEQ ID Nos: 6 to 10 set forth exemplary cDNA sequences of PMT1b, PMT1a, PMT2, PMT3 and PMT4, respectfully, from TN90.

SEQ ID Nos: 11 to 15 set forth exemplary polypeptide sequences of PMT1b, PMT1a, PMT2, PMT3 and PMT4, respectfully, from TN90.

SEQ ID Nos: 16 to 22 set forth exemplary guide RNA sequences.

SEQ ID Nos: 23 to 200, 410 to 441, 474 to 505, 538 to 569, 602 to 633, and 666 to 697 set forth exemplary edited pmt mutant sequences.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 : RNA expression of five PMT genes in TN90 roots

FIG. 2 : Nicotine levels in various low-alkaloid lines: CS15 (a quintuple pmt knock-out mutant line CS15 in the NLM (Ph Ph) background), a PMT RNAi transgenic line in the VA359 background) and a low-nicotine KY171 (“LN KY171”) variety (the KY 171 background harboring nic1 and nic2 double mutations), in comparison to their respective normal-alkaloid control line: NLM (Ph Ph), VA359, and KY171 background.

FIG. 3 : Total alkaloid levels in various low-alkaloid lines: CS15, PMT RNAi, and LN KY171, in comparison to their respective normal-alkaloid control line: NLM (Ph Ph), VA359, and KY171 background.

FIG. 4 : Leaf yield in various low-alkaloid lines: CS15, PMT RNAi, and LN KY171, in comparison to their respective normal-alkaloid control line: NLM (Ph Ph), VA359, and KY171 background.

FIG. 5 : Leaf quality in various low-alkaloid lines: CS15, PMT RNAi, and LN KY171, in comparison to their respective normal-alkaloid control line: NLM (Ph Ph), VA359, and KY171 background.

Photographs depicting mold growth on cured tobacco, including TN90 LC (FIG. 6A), LA BU 21 (FIG. 6B), TN90 comprising an RNAi construct to downregulate PR50 (FIG. 6C), TN90 comprising an RNAi construct to downregulate PMT genes (FIG. 6D), and TN90 comprising edits to all five PMT genes (FIG. 6E).

FIG. 7 : Depiction of mold infection observed in the lines examined in FIGS. 6A-6E.

DETAILED DESCRIPTION

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. One skilled in the art will recognize many methods can be used in the practice of the present disclosure. Indeed, the present disclosure is in no way limited to the methods and materials described. For purposes of the present disclosure, the following terms are defined below.

Any references cited herein, including, e.g., all patents and publications are incorporated by reference in their entirety.

As used herein, the singular form “a,” “an,’ and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.

When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth by 10%.

As used herein, phrases such as “less than”, “more than”, “at least”, “at most”, “approximately”, “below”, “above”, and “about”, when used in conjunction with a series of numerical values, modify each and every value within the series. For example, an expression of “less than 1%, 2%, or 3%” is equivalent to “less than 1%, less than 2%, or less than 3%.”

As used herein, a tobacco plant refers to a plant from the species Nicotiana tabacum.

Nicotine biosynthesis in tobacco starts with the methylation of the polyamine, putrescine, to N-methylputrescine by the enzyme, putrescine N-methyltransferase (PMT), using S-adenosyl-methionine as the co-factor. This is a step that commits precursor metabolites to nicotine biosynthesis. PMT enzymes are classified under the enzyme classification system as EC 2.1.1.53. In Nicotiana tabacum, five genes encode putrescine N-methyltransferases, designated PMT1a, PMT1b, PMT2, PMT3, and PMT4. Table 1A lists genomic DNA sequences, cDNA sequences, and protein sequences of these five PMT genes in a TN90 plant. The present disclosure describes compositions and methods that are used to edit PMT genes to produce pmt mutant plants having reduced nicotine levels while maintaining leaf quality.

As used herein, “PMT1b” or the “PMT1b gene” refers to a genic locus in tobacco encoding a polypeptide having an exemplary amino acid sequence in TN90 as set forth in SEQ ID No. 11.

As used herein, “PMT1a” or the “PMT1a gene” refers to a genic locus in tobacco encoding a polypeptide having an exemplary amino acid sequence in TN90 as set forth in SEQ ID No. 12.

As used herein, “PMT2” or the “PMT2 gene” refers to a genic locus in tobacco encoding a polypeptide having an exemplary amino acid sequence in TN90 as set forth in SEQ ID No. 13.

As used herein, “PMT3” or the “PMT3 gene” refers to a genic locus in tobacco encoding a polypeptide having an exemplary amino acid sequence in TN90 as set forth in SEQ ID No. 14.

As used herein, “PMT4” or the “PMT4 gene” refers to a genic locus in tobacco encoding a polypeptide having an exemplary amino acid sequence in TN90 as set forth in SEQ ID No. 15.

As used herein, a mutation refers to an inheritable genetic modification introduced into a gene to reduce, inhibit, or eliminate the expression or activity of a product encoded by the gene. Such a modification can be in any sequence region of a gene, for example, in a promoter, 5′ UTR, exon, intron, 3′ UTR, or terminator region. In an aspect, mutations are not natural polymorphisms that exist in a particular tobacco variety or cultivar. As used herein, a “mutant allele” refers to an allele from a locus where the allele comprises a mutation.

As used herein, a “pmt mutant” refers to a tobacco plant comprising one or more mutations in one or more PMT genes. A pmt mutant can be a single mutant, a double mutant, a triple mutant, a quadruple mutant, or a quintuple mutant. As used herein, a single, double, triple, quadruple, or quintuple pmt mutant refers to a mutant having modifications in one, two, three, four, or five PMT genes, respectively. A pmt mutant can also be a homozygous mutant, a heterozygous mutant, or a heteroallelic mutant combination in one or more PMT genes.

As used herein, a gene name or a genic locus name is capitalized and shown in italic, e.g., PMT1a, PMT1b, PMT2, PMT3, and PMT4. A protein or polypeptide name is capitalized without being italicized, e.g., PMT1a, PMT1b, PMT2, PMT3, and PMT4. A mutant name (for either referencing to a general mutation in a gene or a group of genes, or referencing to a specific mutant allele) is shown in lower case and italic, e.g., pmt, pmt1a, pmt1b, pmt2, pmt3, and pmt4.

In an aspect, the present disclosure provides a tobacco plant, or part thereof, comprising one or more mutant alleles in at least one PMT gene selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4, wherein the tobacco plant is capable of producing a leaf comprising a nicotine level less than the nicotine level of a leaf from a control tobacco plant not having the one or more mutant alleles when grown and processed under comparable conditions. In an aspect, a single pmt mutant tobacco plant is provided. In another aspect, a single pmt mutant tobacco plant comprises nicotine at a level below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, below 80%, below 90%, or below 95% of the nicotine level of a control plant not having the single pmt mutation when grown in similar growth conditions. In a further aspect, a single pmt mutant tobacco plant comprises nicotine at a level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the nicotine level of a control plant not having the single pmt mutation when grown in similar growth conditions.

In another aspect, a tobacco plant comprises one or more mutant alleles in at least two PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4. In an aspect, a double pmt mutant tobacco plant is provided. In another aspect, a double pmt mutant tobacco plant comprises nicotine at a level below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, below 80%, below 90%, or below 95% of the nicotine level of a control plant not having the double pmt mutations when grown in similar growth conditions. In a further aspect, a double pmt mutant tobacco plant comprises nicotine at a level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the nicotine level of a control plant not having the double pmt mutations when grown in similar growth conditions.

In a further aspect, a tobacco plant comprises one or more mutant alleles in at least three PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4. In an aspect, a triple pmt mutant tobacco plant is provided. In another aspect, a triple pmt mutant tobacco plant comprises nicotine at a level below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, below 80%, below 90%, or below 95% of the nicotine level of a control plant not having the triple pmt mutations when grown in similar growth conditions. In a further aspect, a triple pmt mutant tobacco plant comprises nicotine at a level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the nicotine level of a control plant not having the triple pmt mutations when grown in similar growth conditions.

In another aspect, a tobacco plant comprises one or more mutant alleles in at least four PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4. In an aspect, a quadruple pmt mutant tobacco plant is provided. In another aspect, a quadruple pmt mutant tobacco plant comprises nicotine at a level below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, below 80%, below 90%, or below 95% of the nicotine level of a control plant not having the quadruple pmt mutations when grown in similar growth conditions. In a further aspect, a quadruple pmt mutant tobacco plant comprises nicotine at a level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the nicotine level of a control plant not having the quadruple pmt mutations when grown in similar growth conditions.

In a further aspect, a tobacco plant comprises one or more mutant alleles in five PMT genes selected from the group consisting of PMT1a, PMT1b, PMT2, PMT3, and PMT4. In an aspect, a quintuplepmt mutant tobacco plant is provided. In another aspect, a quintuplepmt mutant tobacco plant comprises nicotine at a level below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, below 80%, below 90%, or below 95% of the nicotine level of a control plant not having the quintuple pmt mutations when grown in similar growth conditions. In a further aspect, a quintuple pmt mutant tobacco plant comprises nicotine at a level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the nicotine level of a control plant not having the quintuple pmt mutations when grown in similar growth conditions.

In an aspect, a tobacco plant is a single pmt mutant, a double pmt mutant, a triple mutant, a quadruple mutant, or a quintuple mutant as listed in Tables 8A to 8E. In another aspect, a tobacco plant comprises one or more pmt mutant alleles listed in Tables 5A to 5E and Tables 12A to 12E. Each and every combination of the pmt mutant alleles listed in Tables 5A to 5E and Tables 12A to 12E is also provided to give rise to a single pmt mutant, a double pmt mutant, a triple mutant, a quadruple mutant, or a quintuple mutant. Each of the mutated loci can be either homozygous or heterozygous, or comprises a heteroallelic combination. In another aspect, a tobacco plant comprises a pmt mutant genotype combination as shown for each individual line listed in Tables 4A to 4E and Table 10. In an aspect, a tobacco plant comprises a pmt mutant allele sequence selected from the group consisting of SEQ ID Nos. 21 to 200, 410 to 441, 474 to 505, 538 to 569, 602 to 633, and 666 to 697. In another aspect, the present disclosure provides a double pmt mutant, a triple mutant, a quadruple mutant, or a quintuple mutant comprising pmt mutant allele sequences selected from the group consisting of SEQ ID Nos. 21 to 200, 410 to 441, 474 to 505, 538 to 569, 602 to 633, and 666 to 697.

In an aspect, a tobacco plant is capable of producing a leaf comprising a nicotine level less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.25% of the nicotine level of a leaf from a control tobacco plant when grown and processed under comparable conditions. In another aspect, a tobacco plant is capable of producing a leaf comprising a nicotine level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the nicotine level of a control tobacco plant when grown and processed under comparable conditions.

In another aspect, a tobacco plant is capable of producing a leaf comprising a total alkaloid level less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.25% of the total alkaloid level of a leaf from a control tobacco plant when grown and processed under comparable conditions. In another aspect, a tobacco plant is capable of producing a leaf comprising a total alkaloid level between 1% and 5%, between 5% and 10%, between 10% and 20%, between 20% and 30%, between 30% and 40%, between 40% and 50%, between 50% and 60%, between 60% and 70%, between 70% and 80%, between 80% and 90%, or between 90% and 95% of the total alkaloid level of a control tobacco plant when grown and processed under comparable conditions.

In a further aspect, a tobacco plant is capable of producing a leaf comprising a total alkaloid level less than 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5% of the total alkaloid level of a leaf from a control tobacco plant when grown and processed under comparable conditions.

In an aspect, a mutant pmt allele comprises a mutation in a PMT sequence region selected from the group consisting of a promoter, 5′ UTR, first exon, first intron, second exon, second intron, third exon, third intron, fourth exon, fourth intron, fifth exon, fifth intron, sixth exon, sixth intron, seventh exon, seventh intron, eighth exon, 3′ UTR, terminator, and any combination thereof. In another aspect, a mutant pmt allele comprises a mutation in a PMT genomic sequence region listed in Tables 1D to 1H.

In another aspect, a mutant pmt allele comprises one or more mutation types selected from the group consisting of a nonsense mutation, a missense mutation, a frameshift mutation, a splice-site mutation, and any combination thereof. In an aspect, a mutant pmt allele is a null allele or a knock-out allele.

In an aspect, a mutant pmt allele results in one or more of the following: a PMT protein truncation, a non-translatable PMT gene transcript, a non-functional PMT protein, a premature stop codon in a PMT gene, and any combination thereof.

In another aspect, a mutant pmt allele comprises a mutation selected from the group consisting of a substitution, a deletion, an insertion, a duplication, and an inversion of one or more nucleotides relative to a wild-type PMT gene.

In an aspect, a pmt mutant comprises a zygosity status selected from the group consisting of homozygous, heterozygous, and heteroallelic. In another aspect, a pmt mutant is homozygous or heteroallelic in at least 1, 2, 3, 4, or 5 PMT genes. In an aspect, a pmt mutant is homozygous or heteroallelic in at least 4 PMT genes. In another aspect, a pmt mutant is homozygous or heteroallelic in all five PMT genes. In another aspect, a pmt mutant comprises mutations in PMT1a and PMT3.

In an aspect, a tobacco plant is capable of producing a leaf comprising a nicotine level selected from the group consisting of less than 0.15%, less than 0.125%, less than 0.1%, less than 0.08%, less than 0.06%, less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, and less than 0.01% dry weight.

In another aspect, a tobacco plant is capable of producing a leaf comprising a total alkaloid level selected from the group consisting of less than 1%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, and less than 0.2% dry weight.

In a further aspect, a tobacco plant is capable of producing a cured leaf comprising a total TSNA level of between 2 and 0.05, between 1.9 and 0.05, between 1.8 and 0.05, between 1.7 and 0.05, between 1.6 and 0.05, between 1.5 and 0.05, between 1.4 and 0.05, between 1.3 and 0.05, between 1.2 and 0.05, between 1.1 and 0.05, between 1.0 and 0.05, between 0.9 and 0.05, between 0.8 and 0.05, between 0.7 and 0.05, between 0.6 and 0.05, between 0.5 and 0.05, between 0.4 and 0.05, between 0.3 and 0.05, between 0.2 and 0.05, between 0.15 and 0.05, or between 0.1 and 0.05 ppm.

In an aspect, a tobacco plant is capable of producing leaves, when cured, having a USDA grade index value selected from the group consisting of 50 or more, 55 or more, 60 or more, 65 or more, 70 or more, 75 or more, 80 or more, 85 or more, 90 or more, and 95 or more. In another aspect, a tobacco plant is capable of producing leaves, when cured, having a USDA grade index value comparable to that of a control plant when grown and cured in similar conditions, where the control plant shares an essentially identical genetic background with the tobacco plant except for the modification. In a further aspect, a tobacco plant is capable of producing leaves, when cured, having a USDA grade index value of at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 98% of the USDA grade index value of a control plant when grown in similar conditions, where the control plant shares an essentially identical genetic background with the tobacco plant except the modification. In a further aspect, a tobacco plant is capable of producing leaves, when cured, having a USDA grade index value of between 65% and 130%, between 70% and 130%, between 75% and 130%, between 80% and 130%, between 85% and 130%, between 90% and 130%, between 95% and 130%, between 100% and 130%, between 105% and 130%, between 110% and 130%, between 115% and 130%, or between 120% and 130% of the USDA grade index value of a control plant. In a further aspect, a tobacco plant is capable of producing leaves, when cured, having a USDA grade index value of between 70% and 125%, between 75% and 120%, between 80% and 115%, between 85% and 110%, or between 90% and 100% of the USDA grade index value of a control plant.

In an aspect, a tobacco plant comprises nicotine at a level below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, or below 80% of the nicotine level of a control plant when grown in similar growth conditions, where the control plant shares an essentially identical genetic background with the tobacco plant except for the modification.

In a further aspect, a tobacco plant comprises one or more pmt mutant alleles and further comprises a transgene or mutation directly suppressing the expression or activity of one or more genes encoding a product selected from the group consisting of MPO, QPT, BBL, A622, aspartate oxidase, agmatine deiminase (AIC), arginase, diamine oxidase, ornithine decarboxylase, arginine decarboxylase, nicotine uptake permease (NUP), and MATE transporter.

In an aspect, a tobacco plant comprises one or more pmt mutant alleles and further comprises a mutation in an ERF gene of Nic2 locus. In an aspect, a tobacco plant further comprises one or more mutations in two or more, three or more, four or more, five or more, six or more, or all seven genes selected from the group consisting of ERF189, ERF115, ERF221, ERF104, ERF179, ERF17, and ERF168. See Shoji et al., Plant Cell, (10):3390-409 (2010); and Kajikawa et al., Plant physiol. 2017, 174:999-1011. In an aspect, a tobacco plant further comprises one or more mutations in ERF189, ERF115, or both.

In an aspect, a tobacco plant comprises one or more qpt mutant alleles and further comprises a mutation in an ERF gene of Nic1 locus (or Nic1b locus as in PCT/US2019/013345 filed on Jan. 11, 2019, published as WO/2019/140297). See also WO/2018/237107. In an aspect, a tobacco plant further comprises one or more mutations in two or more, three or more, four or more, five or more, six or more, or seven or more genes selected from the group consisting of ERF101, ERF110, ERFnew, ERF199, ERF19, ERF130, ERF16, ERF29, ERF210, and ERF91L2. See Kajikawa et al., Plant physiol. 2017, 174:999-1011. In an aspect, a tobacco plant further comprises one or more mutations in one or more, two or more, three or more, four or more, five or more, or all six genes selected from the group consisting of ERFnew, ERF199, ERF19, ERF29, ERF210, and ERF91L2.

In an aspect, the present disclosure further provides apmt mutant tobacco plant, or part thereof, comprising a nicotine or total alkaloid level selected from the group consisting of less than 3%, less than 2.75%, less than 2.5%, less than 2.25%, less than 2.0%, less than 1.75%, less than 1.5%, less than 1.25%, less than 1%, less than 0.9%, less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, less than 0.2%, less than 0.1%, less than 0.05%, less than 0.025%, less than 0.01%, and less than 0.005%, where the tobacco plant is capable of producing leaves, when cured, having a USDA grade index value of 50 or more 55 or more, 60 or more, 65 or more, 70 or more, 75 or more, 80 or more, 85 or more, 90 or more, and 95 or more. In another aspect, such pmt mutant tobacco plant comprises a nicotine level of less than 0.02% and are capable of producing leaves, when cured, having a USDA grade index value of 70 or more. In a further aspect, such tobacco plant comprises a nicotine level of less than 0.01% and are capable of producing leaves, when cured, having a USDA grade index value of 70 or more.

In an aspect, the present disclosure also provides a tobacco plant, or part thereof, comprising a non-transgenic mutation, where the non-transgenic mutation reduces the nicotine or total alkaloid level of the tobacco plant to below 1%, below 2%, below 5%, below 8%, below 10%, below 12%, below 15%, below 20%, below 25%, below 30%, below 40%, below 50%, below 60%, below 70%, or below 80% of the nicotine level of a control plant when grown in similar growth conditions, where the tobacco plant is capable of producing leaves, when cured, having a USDA grade index value comparable to the USDA grade index value of the control plant, and where the control plant shares an essentially identical genetic background with the tobacco plant except the non-transgenic mutation.

In an aspect, a tobacco plant comprises a pmt mutation introduced by an approach selected from the group consisting of random mutagenesis and targeted mutagenesis. In another aspect, a pmt mutation is introduced by a targeted mutagenesis approach selected from the group consisting of meganuclease, zinc finger nuclease, TALEN, and CRISPR.

Unless specified otherwise, measurements of alkaloid or nicotine levels (or another leaf chemistry or property characterization) or leaf grade index values mentioned herein for a tobacco plant, variety, cultivar, or line refer to average measurements, including, for example, an average of multiple leaves of a single plant or an average measurement from a population of tobacco plants from a single variety, cultivar, or line.

Unless specified otherwise, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a pooled leaf sample collected from leaf number 3, 4, and 5 after topping. As used herein, whenever a comparison between leaves from two plants (e.g., a mutant plant versus a control plant) is mentioned, leaves from the same or comparable stalk position(s) and developmental stage(s) are intended so that the comparison can demonstrate effects due to genotype differences, not from other factors. As an illustration, leaf 3 of a wild-type control plant is intended as a reference point for comparing with leaf 3 of a pmt mutant plant. In an aspect, a tobacco plant comprising at least one pmt mutation is compared to a control tobacco plant of the same tobacco variety.

Nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant can also be measured in alternative ways. In an aspect, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a leaf having the highest level of nicotine or alkaloid (or another leaf chemistry or property characterization). In an aspect, the nicotine or alkaloid level of a tobacco plant is measured after topping in leaf number 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In another aspect, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a pool of two or more leaves with consecutive leaf numbers selected from the group consisting of leaf number 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30. In another aspect, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a leaf with a leaf number selected from the group consisting of between 1 and 5, between 6 and 10, between 11 and 15, between 16 and 20, between 21 and 25, and between 26 and 30. In another aspect, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a pool of two or more leaves with leaf numbers selected from the group consisting of between 1 and 5, between 6 and 10, between 11 and 15, between 16 and 20, between 21 and 25, and between 26 and 30. In another aspect, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured after topping in a pool of three or more leaves with leaf numbers selected from the group consisting of between 1 and 5, between 6 and 10, between 11 and 15, between 16 and 20, between 21 and 25, and between 26 and 30.

As used herein, leaf numbering is based on the leaf position on a tobacco stalk with leaf number 1 being the youngest leaf (at the top) after topping and the highest leaf number assigned to the oldest leaf (at the bottom).

A population of tobacco plants or a collection of tobacco leaves for determining an average measurement (e.g., alkaloid or nicotine level or leaf grading) can be of any size, for example, 5, 10, 15, 20, 25, 30, 35, 40, or 50. Industry-accepted standard protocols are followed for determining average measurements or grad index values.

As used herein, “topping” refers to the removal of the stalk apex, including the SAM, flowers, and up to several adjacent leaves, when a tobacco plant is near vegetative maturity and around the start of reproductive growth. Typically, tobacco plants are topped in the button stage (soon after the flower begins to appear). For example, greenhouse or field-grown tobacco plants can be topped when 50% of the plants have at least one open flower. Topping a tobacco plant results in the loss of apical dominance and also induces increased alkaloid production.

Unless indicated otherwise, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured 2 weeks after topping. Alternatively, other time points can be used. In an aspect, the nicotine or alkaloid level (or another leaf chemistry or property characterization) of a tobacco plant is measured about 1, 2, 3, 4, or 5 weeks after topping. In another aspect, the nicotine, alkaloid, or polyamine level (or another leaf chemistry or property characterization) of a tobacco plant is measured about 3, 5, 7, 10, 12, 14, 17, 19 or 21 days after topping.

As used herein, “similar growth conditions” or “comparable growth conditions” refer to similar environmental conditions and/or agronomic practices for growing and making meaningful comparisons between two or more plant genotypes so that neither environmental conditions nor agronomic practices would contribute to or explain any difference observed between the two or more plant genotypes. Environmental conditions include, for example, light, temperature, water (humidity), and nutrition (e.g., nitrogen and phosphorus). Agronomic practices include, for example, seeding, clipping, undercutting, transplanting, topping, and suckering. See Chapters 4B and 4C of Tobacco, Production, Chemistry and Technology, Davis & Nielsen, eds., Blackwell Publishing, Oxford (1999), pp 70-103.

“Alkaloids” are complex, nitrogen-containing compounds that naturally occur in plants, and have pharmacological effects in humans and animals. “Nicotine” is the primary natural alkaloid in commercialized cigarette tobacco and accounts for about 90 percent of the alkaloid content in Nicotiana tabacum. Other major alkaloids in tobacco include cotinine, nornicotine, myosmine, nicotyrine, anabasine and anatabine. Minor tobacco alkaloids include nicotine-n-oxide, N-methyl anatabine, N-methyl anabasine, pseudooxynicotine, 2,3 dipyridyl and others.

Alkaloid levels can be assayed by methods known in the art, for example by quantification based on gas-liquid chromatography, high performance liquid chromatography, radio-immunoassays, and enzyme-linked immunosorbent assays. For example, nicotinic alkaloid levels can be measured by a GC-FID method based on CORESTA Recommended Method No. 7, 1987 and ISO Standards (ISO TC 126N 394 E. See also Hibi et al., Plant Physiology 100: 826-35 (1992) for a method using gas-liquid chromatography equipped with a capillary column and an FID detector.

Unless specifically indicated otherwise, alkaloids and nicotine levels are measured using a method in accordance with CORESTA Method No 62, Determination of Nicotine in Tobacco and Tobacco Products by Gas Chromatographic Analysis, February 2005, and those defined in the Centers for Disease Control and Prevention's Protocol for Analysis of Nicotine, Total Moisture and pH in Smokeless Tobacco Products, as published in the Federal Register Vol. 64, No. 55 Mar. 23, 1999 (and as amended in Vol. 74, No. 4, Jan. 7, 2009). Alternatively, tobacco total alkaloids can be measured using a segmented-flow colorimetric method developed for analysis of tobacco samples as adapted by Skalar Instrument Co (West Chester, Pa.) and described by Collins et al., Tobacco Science 13:79-81 (1969). In short, samples of tobacco can be dried, ground, and extracted prior to analysis of total alkaloids and reducing sugars. The method then employs an acetic acid/methanol/water extraction and charcoal for decolorization. Determination of total alkaloids is based on the reaction of cyanogen chloride with nicotine alkaloids in the presence of an aromatic amine to form a colored complex which is measured at 460 nm. Unless specified otherwise, total alkaloid levels or nicotine levels shown herein are on a dry weight basis (e.g., percent total alkaloid or percent nicotine).

In an aspect, a tobacco plant comprises an average nicotine or total alkaloid level selected from the group consisting of about 0.01%, 0.02%, 0.05%, 0.75%, 0.1%, 0.15%, 0.2%, 0.3%, 0.35%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 5%, 6%, 7%, 8%, and 9% on a dry weight basis. In another aspect, a tobacco plant comprises an average nicotine or total alkaloid level selected from the group consisting of about between 0.01% and 0.02%, between 0.02% and 0.05%, between 0.05% and 0.75%, between 0.75% and 0.1%, between 0.1% and 0.15%, between 0.15% and 0.2%, between 0.2% and 0.3%, between 0.3% and 0.35%, between 0.35% and 0.4%, between 0.4% and 0.5%, between 0.5% and 0.6%, between 0.6% and 0.7%, between 0.7% and 0.8%, between 0.8% and 0.9%, between 0.9% and 1%, between 1% and 1.1%, between 1.1% and 1.2%, between 1.2% and 1.3%, between 1.3% and 1.4%, between 1.4% and 1.5%, between 1.5% and 1.6%, between 1.6% and 1.7%, between 1.7% and 1.8%, between 1.8% and 1.9%, between 1.9% and 2%, between 2% and 2.1%, between 2.1% and 2.2%, between 2.2% and 2.3%, between 2.3% and 2.4%, between 2.4% and 2.5%, between 2.5% and 2.6%, between 2.6% and 2.7%, between 2.7% and 2.8%, between 2.8% and 2.9%, between 2.9% and 3%, between 3% and 3.1%, between 3.1% and 3.2%, between 3.2% and 3.3%, between 3.3% and 3.4%, between 3.4% and 3.5%, and between 3.5% and 3.6% on a dry weight basis. In a further aspect, a tobacco plant comprises an average nicotine or total alkaloid level selected from the group consisting of about between 0.01% and 0.1%, between 0.02% and 0.2%, between 0.03% and 0.3%, between 0.04% and 0.4%, between 0.05% and 0.5%, between 0.75% and 1%, between 0.1% and 1.5%, between 0.15% and 2%, between 0.2% and 3%, and between 0.3% and 3.5% on a dry weight basis.

The present disclosure also provides a tobacco plant having an altered nicotine level without negative impacts over other tobacco traits, e.g., leaf grade index value. In an aspect, a low-nicotine or nicotine-free tobacco variety provides cured tobacco of commercially acceptable grade.

Tobacco grades are evaluated based on factors including, but not limited to, the leaf stalk position, leaf size, leaf color, leaf uniformity and integrity, ripeness, texture, elasticity, sheen (related with the intensity and the depth of coloration of the leaf as well as the shine), hygroscopicity (the faculty of the tobacco leaves to absorb and to retain the ambient moisture), and green nuance or cast. Leaf grade can be determined, for example, using an Official Standard Grade published by the Agricultural Marketing Service of the US Department of Agriculture (7 U.S.C. § 511). See, e.g., Official Standard Grades for Burley Tobacco (U.S. Type 31 and Foreign Type 93), effective Nov. 5, 1990 (55 F.R. 40645); Official Standard Grades for Flue-Cured Tobacco (U.S. Types 11, 12, 13, 14 and Foreign Type 92), effective Mar. 27, 1989 (54 F.R. 7925); Official Standard Grades for Pennsylvania Seedleaf Tobacco (U.S. Type 41), effective Jan. 8, 1965 (29 F.R. 16854); Official Standard Grades for Ohio Cigar-Leaf Tobacco (U.S. Types 42, 43, and 44), effective Dec. 8, 1963 (28 F.R. 11719 and 28 F.R. 11926); Official Standard Grades for Wisconsin Cigar-Binder Tobacco (U.S. Types 54 and 55), effective Nov. 20, 1969 (34 F.R. 17061); Official Standard Grades for Wisconsin Cigar-Binder Tobacco (U.S. Types 54 and 55), effective Nov. 20, 1969 (34 F.R. 17061); Official Standard Grades for Georgia and Florida Shade-Grown Cigar-Wrapper Tobacco (U.S. Type 62), Effective April 1971. A USDA grade index value can be determined according to an industry accepted grade index. See, e.g., Bowman et al, Tobacco Science, 32:39-40(1988); Legacy Tobacco Document Library (Bates Document #523267826-523267833, Jul. 1, 1988, Memorandum on the Proposed Burley Tobacco Grade Index); and Miller et al., 1990, Tobacco Intern., 192:55-57 (all foregoing references are incorporated by inference in their entirety). In an aspect, a USDA grade index is a 0-100 numerical representation of federal grade received and is a weighted average of all stalk positions. A higher grade index indicates higher quality. Alternatively, leaf grade can be determined via hyper-spectral imaging. See e.g., WO 2011/027315 (published on Mar. 10, 2011, and incorporated by inference in its entirety).

In an aspect, a tobacco plant provided herein comprises a similar level of one or more tobacco aroma compounds compared to a control tobacco plant when grown in similar growth conditions. In another aspect, a tobacco plant provided herein comprise a similar level of one or more tobacco aroma compounds selected from the group consisting of 3-methylvaleric acid, valeric acid, isovaleric acid, a labdenoid, a cembrenoid, a sugar ester, and a reducing sugar, compared to a control tobacco plant when grown in similar growth conditions.

As used herein, tobacco aroma compounds are compounds associated with the flavor and aroma of tobacco smoke. These compounds include, but are not limited to, 3-methylvaleric acid, valeric acid, isovaleric acid, cembrenoid and labdenoid diterpenes, and sugar esters. Concentrations of tobacco aroma compounds can be measured by any known metabolite profiling methods in the art including, without limitation, gas chromatography mass spectrometry (GC-MS), Nuclear Magnetic Resonance Spectroscopy, liquid chromatography-linked mass spectrometry. See The Handbook of Plant Metabolomics, edited by Weckwerth and Kahl, (Wiley-Blackwell) (May 28, 2013).

As used herein, “reducing sugar(s)” are any sugar (monosaccharide or polysaccharide) that has a free or potentially free aldehdye or ketone group. Glucose and fructose act as nicotine buffers in cigarette smoke by reducing smoke pH and effectively reducing the amount of “free” unprotonated nicotine. Reducing sugars balances smoke flavor, for example, by modifying the sensory impact of nicotine and other tobacco alkaloids. An inverse relationship between sugar content and alkaloid content has been reported across tobacco varieties, within the same variety, and within the same plant line caused by planting conditions. Reducing sugar levels can be measured using a segmented-flow colorimetric method developed for analysis of tobacco samples as adapted by Skalar Instrument Co (West Chester, Pa.) and described by Davis, Tobacco Science 20:139-144 (1976). For example, a sample is dialyzed against a sodium carbonate solution. Copper neocuproin is added to the sample and the solution is heated. The copper neocuproin chelate is reduced in the presence of sugars resulting in a colored complex which is measured at 460 nm.

In an aspect, a tobacco plant comprises one or more non-naturally existing mutant alleles in one or more PMT gene loci which reduce or eliminate PMT enzymatic activity from the one or more PMT gene loci. In an aspect, these mutant alleles result in lower nicotine levels. Mutant pmt alleles can be introduced by any method known in the art including random or targeted mutagenesis approaches.

Such mutagenesis methods include, without limitation, treatment of seeds with ethyl methylsulfate (EMS) (Hildering and Verkerk, In, The use of induced mutations in plant breeding. Pergamon press, pp 317-320, 1965) or UV-irradiation, X-rays, and fast neutron irradiation (see, for example, Verkerk, Neth. J. Agric. Sci. 19:197-203, 1971; and Poehlman, Breeding Field Crops, Van Nostrand Reinhold, New York (3.sup.rd ed), 1987), transposon tagging (Fedoroff et al., 1984; U.S. Pat. Nos. 4,732,856 and 5,013,658), as well as T-DNA insertion methodologies (Hoekema et al., 1983; U.S. Pat. No. 5,149,645). EMS-induced mutagenesis consists of chemically inducing random point mutations over the length of the genome. Fast neutron mutagenesis consists of exposing seeds to neutron bombardment which causes large deletions through double stranded DNA breakage. Transposon tagging comprises inserting a transposon within an endogenous gene to reduce or eliminate expression of the gene. The types of mutations that may be present in a tobacco gene include, for example, point mutations, deletions, insertions, duplications, and inversions. Such mutations desirably are present in the coding region of a tobacco gene; however mutations in the promoter region, and intron, or an untranslated region of a tobacco gene may also be desirable.

In addition, a fast and automatable method for screening for chemically induced mutations, TILLING (Targeting Induced Local Lesions In Genomes), using denaturing HPLC or selective endonuclease digestion of selected PCR products is also applicable to the present disclosure. See, McCallum et al. (2000) Nat. Biotechnol. 18:455-457. Mutations that impact gene expression or that interfere with the function of genes can be determined using methods that are well known in the art. Insertional mutations in gene exons usually result in null-mutants. Mutations in conserved residues can be particularly effective in inhibiting the function of a protein. In an aspect, tobacco plants comprise a nonsense (e.g., stop codon) mutation in one or more PMT genes described herein.

It will be appreciated that, when identifying a mutation, the endogenous reference DNA sequence should be from the same variety of tobacco. For example, if a modified tobacco plant comprising a mutation is from the variety TN90, then the endogenous reference sequence must be the endogenous TN90 sequence, not a homologous sequence from a different tobacco variety (e.g., K326). Similarly, if a modified tobacco cell comprising a mutation is a TN90 cell, then the endogenous reference sequence must be the endogenous TN90 sequence, not a homologous sequence from a tobacco cell from a different tobacco variety (e.g., K326).

In an aspect, the present disclosure also provides a tobacco line with altered nicotine levels while maintaining commercially acceptable leaf quality. This line can be produced by introducing mutations into one or more PMT genes via precise genome engineering technologies, for example, Transcription activator-like effector nucleases (TALENs), meganuclease, zinc finger nuclease, and a clustered regularly-interspaced short palindromic repeats (CRISPR)/Cas9 system, a CRISPR/Cpf1 system, a CRISPR/Csm1 system, and a combination thereof (see, for example, U.S. Patent Application publication 2017/0233756). See, e.g., Gaj et al., Trends in Biotechnology, 31(7):397-405 (2013).

The screening and selection of mutagenized tobacco plants can be through any methodologies known to those having ordinary skill in the art. Examples of screening and selection methodologies include, but are not limited to, Southern analysis, PCR amplification for detection of a polynucleotide, Northern blots, RNase protection, primer-extension, RT-PCR amplification for detecting RNA transcripts, Sanger sequencing, Next Generation sequencing technologies (e.g., Illumina, PacBio, Ion Torrent, 454), enzymatic assays for detecting enzyme or ribozyme activity of polypeptides and polynucleotides, and protein gel electrophoresis, Western blots, immunoprecipitation, and enzyme-linked immunoassays to detect polypeptides. Other techniques such as in situ hybridization, enzyme staining, and immunostaining also can be used to detect the presence or expression of polypeptides and/or polynucleotides. Methods for performing all of the referenced techniques are known.

In an aspect, a tobacco plant or plant genome provided herein is mutated or edited by a nuclease selected from the group consisting of a meganuclease, a zinc-finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a CRISPR/Cas9 nuclease, a CRISPR/Cpf1 nuclease, or a CRISPR/Csm1 nuclease.

As used herein, “editing” or “genome editing” refers to targeted mutagenesis of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nucleotides of an endogenous plant genome nucleic acid sequence, or removal or replacement of an endogenous plant genome nucleic acid sequence. In an aspect, an edited nucleic acid sequence provided has at least 99.9%, at least 99.5%, at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 85%, at least 80%, or at least 75% sequence identity with an endogenous nucleic acid sequence. In an aspect, an edited nucleic acid sequence provided has at least 99.9%, at least 99.5%, at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 85%, at least 80%, or at least 75% sequence identity with a polynucleotide selected from the group consisting of SEQ ID NOs: 1 to 10, and fragments thereof. In another aspect, an edited nucleic acid sequence provided has at least 99.9%, at least 99.5%, at least 99%, at least 98%, at least 97%, at least 96%, at least 95%, at least 94%, at least 93%, at least 92%, at least 91%, at least 90%, at least 85%, at least 80%, or at least 75% sequence identity with a polynucleotide encoding a polypeptide selected from the group consisting of SEQ ID NOs: 11 to 15.

Meganucleases, ZFNs, TALENs, CRISPR/Cas9, CRISPR/Csm1 and CRISPR/Cpf1 induce a double-strand DNA break at a target site of a genomic sequence that is then repaired by the natural processes of homologous recombination (HR) or non-homologous end-joining (NHEJ). Sequence modifications then occur at the cleaved sites, which can include deletions or insertions that result in gene disruption in the case of NHEJ, or integration of donor nucleic acid sequences by HR. In an aspect, a method provided comprises editing a plant genome with a nuclease provided to mutate at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more than 10 nucleotides in the plant genome via HR with a donor polynucleotide. In an aspect, a mutation provided is caused by genome editing using a nuclease. In another aspect, a mutation provided is caused by non-homologous end-joining or homologous recombination.

Meganucleases, which are commonly identified in microbes, are unique enzymes with high activity and long recognition sequences (>14 bp) resulting in site-specific digestion of target DNA. Engineered versions of naturally occurring meganucleases typically have extended DNA recognition sequences (for example, 14 to 40 bp). The engineering of meganucleases can be more challenging than that of ZFNs and TALENs because the DNA recognition and cleavage functions of meganucleases are intertwined in a single domain. Specialized methods of mutagenesis and high-throughput screening have been used to create novel meganuclease variants that recognize unique sequences and possess improved nuclease activity.

ZFNs are synthetic proteins consisting of an engineered zinc finger DNA-binding domain fused to the cleavage domain of the FokI restriction endonuclease. ZFNs can be designed to cleave almost any long stretch of double-stranded DNA for modification of the zinc finger DNA-binding domain. ZFNs form dimers from monomers composed of a non-specific DNA cleavage domain of FokI endonuclease fused to a zinc finger array engineered to bind a target DNA sequence.

The DNA-binding domain of a ZFN is typically composed of 3-4 zinc-finger arrays. The amino acids at positions −1, +2, +3, and +6 relative to the start of the zinc finger ∞-helix, which contribute to site-specific binding to the target DNA, can be changed and customized to fit specific target sequences. The other amino acids form the consensus backbone to generate ZFNs with different sequence specificities. Rules for selecting target sequences for ZFNs are known in the art.

The FokI nuclease domain requires dimerization to cleave DNA and therefore two ZFNs with their C-terminal regions are needed to bind opposite DNA strands of the cleavage site (separated by 5-7 bp). The ZFN monomer can cute the target site if the two-ZF-binding sites are palindromic. The term ZFN, as used herein, is broad and includes a monomeric ZFN that can cleave double stranded DNA without assistance from another ZFN. The term ZFN is also used to refer to one or both members of a pair of ZFNs that are engineered to work together to cleave DNA at the same site.

Without being limited by any scientific theory, because the DNA-binding specificities of zinc finger domains can in principle be re-engineered using one of various methods, customized ZFNs can theoretically be constructed to target nearly any gene sequence. Publicly available methods for engineering zinc finger domains include Context-dependent Assembly (CoDA), Oligomerized Pool Engineering (OPEN), and Modular Assembly.

TALENs are artificial restriction enzymes generated by fusing the transcription activator-like effector (TALE) DNA binding domain to a FokI nuclease domain. When each member of a TALEN pair binds to the DNA sites flanking a target site, the FokI monomers dimerize and cause a double-stranded DNA break at the target site. The term TALEN, as used herein, is broad and includes a monomeric TALEN that can cleave double stranded DNA without assistance from another TALEN. The term TALEN is also used to refer to one or both members of a pair of TALENs that work together to cleave DNA at the same site.

Transcription activator-like effectors (TALEs) can be engineered to bind practically any DNA sequence. TALE proteins are DNA-binding domains derived from various plant bacterial pathogens of the genus Xanthomonas. The Xanthomonas pathogens secrete TALEs into the host plant cell during infection. The TALE moves to the nucleus, where it recognizes and binds to a specific DNA sequence in the promoter region of a specific DNA sequence in the promoter region of a specific gene in the host genome. TALE has a central DNA-binding domain composed of 13-28 repeat monomers of 33-34 amino acids. The amino acids of each monomer are highly conserved, except for hypervariable amino acid residues at positions 12 and 13. The two variable amino acids are called repeat-variable diresidues (RVDs). The amino acid pairs NI, NG, HD, and NN of RVDs preferentially recognize adenine, thymine, cytosine, and guanine/adenine, respectively, and modulation of RVDs can recognize consecutive DNA bases. This simple relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DNA binding domains by selecting a combination of repeat segments containing the appropriate RVDs.

Besides the wild-type FokI cleavage domain, variants of the FokI cleavage domain with mutations have been designed to improve cleavage specificity and cleavage activity. The FokI domain functions as a dimer, requiring two constructs with unique DNA binding domains for sites in the target genome with proper orientation and spacing. Both the number of amino acid residues between the TALEN DNA binding domain and the FokI cleavage domain and the number of bases between the two individual TALEN binding sites are parameters for achieving high levels of activity.

A relationship between amino acid sequence and DNA recognition of the TALE binding domain allows for designable proteins. Software programs such as DNA Works can be used to design TALE constructs. Other methods of designing TALE constructs are known to those of skill in the art. See Doyle et al., Nucleic Acids Research (2012) 40: W117-122.; Cermak et al., Nucleic Acids Research (2011). 39:e82; and tale-nt.cac.cornell.edu/about.

A CRISPR/Cas9 system, CRISPR/Csm1, or a CRISPR/Cpf1 system are alternatives to the FokI-based methods ZFN and TALEN. The CRISPR systems are based on RNA-guided engineered nucleases that use complementary base pairing to recognize DNA sequences at target sites.

CRISPR/Cas9, CRISPR/Csm1, and a CRISPR/Cpf1 systems are part of the adaptive immune system of bacteria and archaea, protecting them against invading nucleic acids such as viruses by cleaving the foreign DNA in a sequence-dependent manner. The immunity is acquired by the integration of short fragments of the invading DNA known as spacers between two adjacent repeats at the proximal end of a CRISPR locus. The CRISPR arrays, including the spacers, are transcribed during subsequent encounters with invasive DNA and are processed into small interfering CRISPR RNAs (crRNAs) approximately 40 nt in length, which combine with the trans-activating CRISPR RNA (tracrRNA) to activate and guide the Cas9 nuclease. This cleaves homologous double-stranded DNA sequences known as protospacers in the invading DNA. A prerequisite for cleavage is the presence of a conserved protospacer-adjacent motif (PAM) downstream of the target DNA, which usually has the sequence 5-NGG-3 but less frequently NAG. Specificity is provided by the so-called “seed sequence” approximately 12 bases upstream of the PAM, which must match between the RNA and target DNA. Cpf1 and Csm1 act in a similar manner to Cas9, but Cpf1 and Csm1 do not require a tracrRNA.

In still another aspect, a tobacco plant provided here comprises one or more pmt mutations and further comprises one or more mutations in one or more loci encoding a nicotine demethylase (e.g., CYP82E4, CYP82E5, CYP82E10) that confer reduced amounts of nornicotine (See U.S. Pat. Nos. 8,319,011; 8,124,851; 9,187,759; 9,228,194; 9,228,195; 9,247,706) compared to a control plant lacking one or more mutations in one or more loci encoding a nicotine demethylase. In an aspect, a tobacco plant described further comprises reduced nicotine demethylase activity compared to a control plant when grown and cured under comparable conditions.

In an aspect, a pmt mutant tobacco plant further comprises a mutation capable of producing a leaf comprising an anabasine level less than the anabasine level of a leaf from a wild-type control tobacco plant when grown and processed under comparable conditions. In another aspect, a pmt mutant tobacco plant further comprises a mutation capable of producing a leaf comprising an anabasine level less than 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, or 80% of the anabasine level of a leaf from a wild-type control tobacco plant when grown and processed under comparable conditions.

In an aspect, a pmt mutant tobacco plant comprises a further mutation capable of producing a leaf comprising a more than 2 fold reduction of the anatabine level compared to a leaf from a control tobacco plant when grown and processed under comparable conditions. In another aspect, a pmt mutant tobacco plant comprises a further mutation capable of producing a leaf comprising a more than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 fold reduction of the anatabine level compared to a leaf from a wild-type control tobacco plant when grown and processed under comparable conditions. In an aspect, a mutation providing lower level of anatabine is a mutation described in US Application Publication No. 2014/0283165 and US Application Publication No. 2016/0010103. In another aspect, a pmt mutant further comprises a mutation in a quinolate phosphoribosyl transferase (QPT) or quinolinate synthase (QS) gene. In a further aspect, a pmt mutant plant further comprises a transgene or mutation suppressing the expression or activity of a QPT or QS gene.

In an aspect, a pmt mutant tobacco plant further comprises a mutation capable of providing a nornicotine level less than 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, or 35% of the nornicotine level of a leaf from a wild-type control tobacco plant when grown and processed under comparable conditions.

In an aspect, a pmt mutant tobacco plant is capable of producing a cured leaf comprising a total N-nitrosonornicotine (NNN) level of less than 2, less than 1.9, less than 1.8, less than 1.7, less than 1.6, less than 1.5, less than 1.4, less than 1.3, less than 1.2, less than 1.1, less than 1.0, less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2, less than 0.15, less than 0.1, or less than 0.05 ppm.

In another aspect, a pmt mutant tobacco plant is capable of producing a cured leaf comprising a total NNN level of between 2 and 0.05, between 1.9 and 0.05, between 1.8 and 0.05, between 1.7 and 0.05, between 1.6 and 0.05, between 1.5 and 0.05, between 1.4 and 0.05, between 1.3 and 0.05, between 1.2 and 0.05, between 1.1 and 0.05, between 1.0 and 0.05, between 0.9 and 0.05, between 0.8 and 0.05, between 0.7 and 0.05, between 0.6 and 0.05, between 0.5 and 0.05, between 0.4 and 0.05, between 0.3 and 0.05, between 0.2 and 0.05, between 0.15 and 0.05, or between 0.1 and 0.05 parts per million (ppm).

In an aspect, a pmt mutant tobacco plant is capable of producing a cured leaf comprising a total nicotine-derived nitrosamine ketone (NNK) level of less than 2, less than 1.9, less than 1.8, less than 1.7, less than 1.6, less than 1.5, less than 1.4, less than 1.3, less than 1.2, less than 1.1, less than 1.0, less than 0.9, less than 0.8, less than 0.7, less than 0.6, less than 0.5, less than 0.4, less than 0.3, less than 0.2, less than 0.15, less than 0.1, or less than 0.05 ppm.

In another aspect, a pmt mutant tobacco plant is capable of producing a cured leaf comprising a total NNK level of between 2 and 0.05, between 1.9 and 0.05, between 1.8 and 0.05, between 1.7 and 0.05, between 1.6 and 0.05, between 1.5 and 0.05, between 1.4 and 0.05, between 1.3 and 0.05, between 1.2 and 0.05, between 1.1 and 0.05, between 1.0 and 0.05, between 0.9 and 0.05, between 0.8 and 0.05, between 0.7 and 0.05, between 0.6 and 0.05, between 0.5 and 0.05, between 0.4 and 0.05, between 0.3 and 0.05, between 0.2 and 0.05, between 0.15 and 0.05, or between 0.1 and 0.05 ppm.

In an aspect, a pmt mutant tobacco plant further comprises a mutation or transgene providing an increased level of one or more antioxidants. In another aspect, a pmt mutant tobacco plant further comprises a genetic modification in an endogenous gene and further comprises an increased level of one or more antioxidants in a cured leaf compared to a control cured tobacco leaf lacking the genetic modification, where the endogenous gene encodes an antioxidant biosynthetic enzyme, a regulatory transcription factor of an antioxidant, an antioxidant transporter, an antioxidant metabolic enzyme, or a combination thereof. In a father aspect, a pmt mutant tobacco plant further comprises a transgene and further comprises an increased level of one or more antioxidants in a cured leaf compared to a control cured tobacco leaf lacking the transgene, where the transgene encodes or directly modulates an antioxidant biosynthetic enzyme, a regulatory transcription factor of an antioxidant, an antioxidant transporter, an antioxidant metabolic enzyme, or a combination thereof. In an aspect, a pmt mutant tobacco plant further comprises a transgene or a cisgenic construct expressing one or more genes selected from the group consisting of AtPAP1, NtAN2, NtAN1, NtJAF13, NtMyb3, chorismate mutase, and arogenate dehydrotase (ADT). In another aspect, a pmt mutant tobacco plant further comprises one or more transgenes or genetic modification for increasing antioxidants or decreasing one or more TSNAs as described in WIPO Publication No. 2018/067985 or US Publication No. 2018/0119163.

In an aspect, a tobacco plant described is a modified tobacco plant. As used herein, “modified”, in the context of a plant, refers to a plant comprising a genetic alteration introduced for certain purposes and beyond natural polymorphisms.

In an aspect, a tobacco plant described is a cisgenic plant. As used herein, “cisgenesis” or “cisgenic” refers to genetic modification of a plant, plant cell, or plant genome in which all components (e.g., promoter, donor nucleic acid, selection gene) have only plant origins (i.e., no non-plant origin components are used). In an aspect, a plant, plant cell, or plant genome provided is cisgenic. Cisgenic plants, plant cells, and plant genomes provided can lead to ready-to-use tobacco lines. In another aspect, a tobacco plant provided comprises no non-tobacco genetic material or sequences.

As used herein, “gene expression” or expression of a gene refers to the biosynthesis or production of a gene product, including the transcription and/or translation of the gene product.

In an aspect, a tobacco plant provided comprises one or more pmt mutations and further comprises reduced expression or activity of one or more genes involved in nicotine biosynthesis or transport. Genes involved in nicotine biosynthesis include, but are not limited to, arginine decarboxylase (ADC), methylputrescine oxidase (MPO), NADH dehydrogenase, ornithine decarboxylase (ODC), phosphoribosylanthranilate isomerase (PRAI), quinolate phosphoribosyl transferase (QPT), and S-adenosyl-methionine synthetase (SAMS). Nicotine Synthase, which catalyzes the condensation step between a nicotinic acid derivative and methylpyrrolinium cation, has not been elucidated although two candidate genes (A622 and NBB1) have been proposed. See US 2007/0240728 A1 and US 2008/0120737A1. A622 encodes an isoflavone reductase-like protein. In addition, several transporters may be involved in the translocation of nicotine. A transporter gene, named MATE, has been cloned and characterized (Morita et al., PNAS 106:2447-52 (2009)).

In an aspect, a tobacco plant provided comprises one or more pmt mutations and further comprises a reduced level of mRNA, protein, or both of one or more genes encoding a product selected from the group consisting of MPO, QPT, ADC, ODC, PRAI, SAMS, BBL, MATE, A622, and NBB1, compared to a control tobacco plant. In another aspect, a tobacco plants provided comprises one or more pmt mutations and further comprises a transgene directly suppressing the expression of one or more genes encoding a product selected from the group consisting of MPO, QPT, ADC, ODC, PRAI, SAMS, BBL, MATE, A622, and NBB1. In another aspect, a tobacco plant provided comprises one or more pmt mutations and further comprises a transgene or mutation suppressing the expression or activity of one or more genes encoding a product selected from the group consisting of MPO, QPT, ADC, ODC, PRAI, SAMS, BBL, MATE, A622, and NBB1.

In an aspect, a tobacco plant provided is from a tobacco type selected from the group consisting of flue-cured tobacco, air-cured tobacco, dark air-cured tobacco, dark fire-cured tobacco, Galpao tobacco, and Oriental tobacco. In another aspect, a tobacco plant provided is from a tobacco type selected from the group consisting of Burley tobacco, Maryland tobacco, and dark tobacco.

In an aspect, a tobacco plant provided is in a flue-cured tobacco background or exhibits one or more flue-cured tobacco characteristic described here. Flue-cured tobaccos (also called Virginia or bright tobaccos) amount to approximately 40% of world tobacco production. Flue-cured tobaccos are often also referred to as “bright tobacco” because of the golden-yellow to deep-orange color it reaches during curing. Flue-cured tobaccos have a light, bright aroma and taste. Flue-cured tobaccos are generally high in sugar and low in oils. Major flue-cured tobacco growing countries are Argentina, Brazil, China, India, Tanzania and the U.S. In an aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in a flue-cured tobacco background selected from the group consisting of CC 13, CC 27, CC 33, CC 37, CC 65, CC 67, CC 700, GF 318, GL 338, GL 368, GL 939, K 346, K 399, K326, NC 102, NC 196, NC 291, NC 297, NC 299, NC 471, NC 55, NC 606, NC 71, NC 72, NC 92, PVH 1118, PVH 1452, PVH 2110, SPEIGHT 168, SPEIGHT 220, SPEIGHT 225, SPEIGHT 227, SPEIGHT 236, and any variety essentially derived from any one of the foregoing varieties. In another aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in a flue-cured tobacco background selected from the group consisting of Coker 48, Coker 176, Coker 371-Gold, Coker 319, Coker 347, GL 939, K 149, K326, K 340, K 346, K 358, K 394, K 399, K 730, NC 27NF, NC 37NF, NC 55, NC 60, NC 71, NC 72, NC 82, NC 95, NC 297, NC 606, NC 729, NC 2326, McNair 373, McNair 944, Ox 207, Ox 414 NF, Reams 126, Reams 713, Reams 744, RG 8, RG 11, RG 13, RG 17, RG 22, RG 81, RG H4, RG H51, Speight H-20, Speight G-28, Speight G-58, Speight G-70, Speight G-108, Speight G-111, Speight G-117, Speight 168, Speight 179, Speight NF-3, Va 116, Va 182, and any variety essentially derived from any one of the foregoing varieties. See WO 2004/041006 A1. In a further aspect, low-alkaloid or low-nicotine tobacco plants, seeds, hybrids, varieties, or lines are in any flue cured background selected from the group consisting of K326, K346, and NC196.

In an aspect, a tobacco plant provided is in an air-cured tobacco background or exhibits one or more air-cured tobacco characteristic described here. Air-cured tobaccos include Burley, Maryland, and dark tobaccos. The common factor is that curing is primarily without artificial sources of heat and humidity. Burley tobaccos are light to dark brown in color, high in oil, and low in sugar. Burley tobaccos are air-cured in barns. Major Burley growing countries are Argentina, Brazil, Italy, Malawi, and the U.S. Maryland tobaccos are extremely fluffy, have good burning properties, low nicotine and a neutral aroma. Major Maryland growing countries include the U.S. and Italy. In an aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in a Burley tobacco background selected from the group consisting of Clay 402, Clay 403, Clay 502, Ky 14, Ky 907, Ky 910, Ky 8959, NC 2, NC 3, NC 4, NC 5, NC 2000, TN 86, TN 90, TN 97, R 610, R 630, R 711, R 712, NCBH 129, Bu 21×Ky 10, HB04P, Ky 14×L 8, Kt 200, Newton 98, Pedigo 561, Pf561 and Va 509. In a further aspect, low-alkaloid or low-nicotine tobacco plants, seeds, hybrids, varieties, or lines are in any Burley background selected from the group consisting of TN 90, KT 209, KT 206, KT212, and HB 4488. In another aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in a Maryland tobacco background selected from the group consisting of Md 10, Md 40, Md 201, Md 609, Md 872 and Md 341.

In an aspect, a tobacco plant provided is in a dark air-cured tobacco background or exhibits one or more dark air-cured tobacco characteristic described here. Dark air-cured tobaccos are distinguished from other types primarily by its curing process which gives dark air-cured tobacco its medium- to dark-brown color and distinct aroma. Dark air-cured tobaccos are mainly used in the production of chewing tobacco and snuff. In an aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in a dark air-cured tobacco background selected from the group consisting of Sumatra, Jatim, Dominican Cubano, Besuki, One sucker, Green River, Virginia sun-cured, and Paraguan Passado.

In an aspect, a tobacco plant provided is in a dark fire-cured tobacco background or exhibits one or more dark fire-cured tobacco characteristic described here. Dark fire-cured tobaccos are generally cured with low-burning wood fires on the floors of closed curing barns. Their leaves have low sugar content but high nicotine content. Dark fire-cured tobaccos are used for making pipe blends, cigarettes, chewing tobacco, snuff and strong-tasting cigars. Major growing regions for dark fire-cured tobaccos are Tennessee, Kentucky, and Virginia, USA. In an aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in a dark fire-cured tobacco background selected from the group consisting of Narrow Leaf Madole, Improved Madole, Tom Rosson Madole, Newton's VH Madole, Little Crittenden, Green Wood, Little Wood, Small Stalk Black Mammoth, DT 508, DT 518, DT 592, KY 171, DF 911, DF 485, TN D94, TN D950, VA 309, and VA 359.

In an aspect, a tobacco plant provided is in an Oriental tobacco background or exhibits one or more Oriental tobacco characteristic described here. Oriental tobaccos are also referred to as Greek, aroma and Turkish tobaccos due to the fact that they are typically grown in eastern Mediterranean regions such as Turkey, Greece, Bulgaria, Macedonia, Syria, Lebanon, Italy, and Romania. The small plant and leaf size, characteristic of today's Oriental varieties, as well as its unique aroma properties are a result of the plant's adaptation to the poor soil and stressful climatic conditions in which it develop over many past centuries. In an aspect, a low-alkaloid or low-nicotine tobacco plant or seed provided is in an Oriental tobacco background selected from the group consisting of Izmir, Katerini, Samsun, Basma and Krumovgrad, Trabzon, Thesalian, Tasova, Sinop, Izmit, Hendek, Edirne, Semdinli, Adiyanman, Yayladag, Iskenderun, Duzce, Macedonian, Mavra, Prilep, Bafra, Bursa, Bucak, Bitlis, Balikesir, and any variety essentially derived from any one of the foregoing varieties.

In an aspect, low-alkaloid or low-nicotine tobacco plants, seeds, hybrids, varieties, or lines are essentially derived from or in the genetic background of BU 64, CC 101, CC 200, CC 27, CC 301, CC 400, CC 500, CC 600, CC 700, CC 800, CC 900, Coker 176, Coker 319, Coker 371 Gold, Coker 48, CU 263, DF911, Galpao tobacco, GL 26H, GL 350, GL 600, GL 737, GL 939, GL 973, HB 04P, K 149, K 326, K 346, K 358, K394, K 399, K 730, KDH 959, KT 200, KT204LC, KY 10, KY 14, KY 160, KY 17, KY 171, KY 907, KY907LC, KTY14×L8 LC, Little Crittenden, McNair 373, McNair 944, msKY 14×L8, Narrow Leaf Madole, NC 100, NC 102, NC 2000, NC 291, NC 297, NC 299, NC 3, NC 4, NC 5, NC 6, NC7, NC 606, NC 71, NC 72, NC 810, NC BH 129, NC 2002, Neal Smith Madole, OXFORD 207, ‘Perique’ tobacco, PVH03, PVH09, PVH19, PVH50, PVH51, R 610, R 630, R 7-11, R 7-12, RG 17, RG 81, RG H51, RGH 4, RGH 51, RS 1410, Speight 168, Speight 172, Speight 179, Speight 210, Speight 220, Speight 225, Speight 227, Speight 234, Speight G-28, Speight G-70, Speight H-6, Speight H20, Speight NF3, TI 1406, TI 1269, TN 86, TN86LC, TN 90, TN 97, TN97LC, TN D94, TN D950, TR (Tom Rosson) Madole, VA 309, or VA359, Maryland 609, HB3307PLC, HB4488PLC, KT206LC, KT209LC, KT210LC, KT212LC, R610LC, PVH2310, NC196, KTD14LC, KTD6LC, KTD8LC, PD7302LC, PD7305LC, PD7309LC, PD7318LC, PD7319LC, PD7312LC, ShireyLC, or any commercial tobacco variety according to standard tobacco breeding techniques known in the art.

All foregoing mentioned specific varieties of dark air-cured, Burley, Maryland, dark fire-cured, or Oriental type are listed only for exemplary purposes. Any additional dark air-cured, Burley, Maryland, dark fire-cured, Oriental varieties are also contemplated in the present application.

Also provided are populations of tobacco plants described. In an aspect, a population of tobacco plants has a planting density of between about 5,000 and about 8000, between about 5,000 and about 7,600, between about 5,000 and about 7,200, between about 5,000 and about 6,800, between about 5,000 and about 6,400, between about 5,000 and about 6,000, between about 5,000 and about 5,600, between about 5,000 and about 5,200, between about 5,200 and about 8,000, between about 5,600 and about 8,000, between about 6,000 and about 8,000, between about 6,400 and about 8,000, between about 6,800 and about 8,000, between about 7,200 and about 8,000, or between about 7,600 and about 8,000 plants per acre. In another aspect, a population of tobacco plants is in a soil type with low to medium fertility.

Also provided are containers of seeds from tobacco plants described. A container of tobacco seeds of the present disclosure may contain any number, weight, or volume of seeds. For example, a container can contain at least, or greater than, about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000 or more seeds. Alternatively, the container can contain at least, or greater than, about 1 ounce, 5 ounces, 10 ounces, 1 pound, 2 pounds, 3 pounds, 4 pounds, 5 pounds or more seeds. Containers of tobacco seeds may be any container available in the art. By way of non-limiting example, a container may be a box, a bag, a packet, a pouch, a tape roll, a tube, or a bottle.

Also provided is cured tobacco material made from a low-alkaloid or low-nicotine tobacco plant described. Further provided is cured tobacco material made from a tobacco plant described with higher levels of total alkaloid or nicotine.

“Curing” is the aging process that reduces moisture and brings about the destruction of chlorophyll giving tobacco leaves a golden color and by which starch is converted to sugar. Cured tobacco therefore has a higher reducing sugar content and a lower starch content compared to harvested green leaf. In an aspect, green leaf tobacco provided can be cured using conventional means, e.g., flue-cured, barn-cured, fire-cured, air-cured or sun-cured. See, for example, Tso (1999, Chapter 1 in Tobacco, Production, Chemistry and Technology, Davis & Nielsen, eds., Blackwell Publishing, Oxford) for a description of different types of curing methods. Cured tobacco is usually aged in a wooden drum (e.g., a hogshead) or cardboard cartons in compressed conditions for several years (e.g., two to five years), at a moisture content ranging from 10% to about 25%. See, U.S. Pat. Nos. 4,516,590 and 5,372,149. Cured and aged tobacco then can be further processed. Further processing includes conditioning the tobacco under vacuum with or without the introduction of steam at various temperatures, pasteurization, and fermentation. Fermentation typically is characterized by high initial moisture content, heat generation, and a 10 to 20% loss of dry weight. See, e.g., U.S. Pat. Nos. 4,528,993, 4,660,577, 4,848,373, 5,372,149; U.S. Publication No. 2005/0178398; and Tso (1999, Chapter 1 in Tobacco, Production, Chemistry and Technology, Davis & Nielsen, eds., Blackwell Publishing, Oxford). Cure, aged, and fermented tobacco can be further processed (e.g., cut, shredded, expanded, or blended). See, for example, U.S. Pat. Nos. 4,528,993; 4,660,577; and 4,987,907. In an aspect, the cured tobacco material of the present disclosure is sun-cured. In another aspect, the cured tobacco material of the present disclosure is flue-cured, air-cured, or fire-cured.

The presence of mold on cured tobacco can significantly reduce the quality and marketability (e.g., leaf grade) of the cured leaves. Mold growth is a common problem that can occur during extended periods of high humidity (e.g., greater than 70% relative humidity) at temperatures between approximately 10° C. (50° F.) and 32.2° C. (90° F.). Mold tends to be more prevalent at higher temperatures.

Tobacco plants, varieties, and lines provided herein comprising a mutant allele in one or more PMT genes, two or more PMT genes, three or more PMT genes, four or more PMT genes, or five PMT genes exhibit reduced mold infection as compared to the low alkaloid tobacco variety LA Burley 21 (LA BU 21). Similarly, tobacco plants, varieties, and lines provided herein comprising an RNAi construct that downregulates expression or translation of one or more PMT genes, two or more PMT genes, three or more PMT genes, four or more PMT genes, or five PMT genes exhibit reduced mold infection as compared to the low alkaloid tobacco variety LA Burley 21 (LA BU 21).

LA BU 21 is a low total alkaloid tobacco line produced by incorporation of a low alkaloid gene(s) from a Cuban cigar variety into Burley 21 through several backcrosses (Legg et al., Crop Science, 10:212 (1970)), it has approximately 0.2% total alkaloids (dry weight) compared to the about 15% (dry weight) of its parent, Burley 21. LA B 21 has a leaf grade well below commercially acceptable standards.

In an aspect, a cured tobacco leaf comprising a mutant allele of pmt1a comprises no observable mold infection. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt1b comprises no observable mold infection. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt2 comprises no observable mold infection. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt3 comprises no observable mold infection. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt4 comprises no observable mold infection. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt1a, a mutant allele of pmt1b, a mutant allele of pmt2, a mutant allele of pmt3, and a mutant allele of pmt4 comprises no observable mold infection.

In an aspect, a cured tobacco leaf comprising a mutant allele of pmt1a comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt1b comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt2 comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt3 comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt4 comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21. In another aspect, a cured tobacco leaf comprising a mutant allele of pmt1a, a mutant allele of pmt1b, a mutant allele of pmt2, a mutant allele of pmt3, and a mutant allele of pmt4 comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21.

In an aspect, a cured leaf from a tobacco plant, variety, or line provided in any one of Tables 4A to 4E, Table 10, or Table 14 comprises no observable mold infection. In another aspect, a cured leaf from a tobacco plant, variety, or line provided in any one of Tables 4A to 4E, Table 10, or Table 14 comprises a reduced mold infection as compared to a control cured tobacco leaf from the variety LA BU 21.

In an aspect, a cured leaf from a tobacco plant, variety, or line comprising one or more pmt mutations provided in any one of Tables 5A to 5E and Tables 12A to 12E comprises no observable mold infection. In another aspect, a cured leaf from a tobacco plant, variety, or line comprising one or more pmt mutations provided in any one of Tables 5A to 5E and Tables 12A to 12E comprises a reduced mold infection as compared to a control cured leaf from the variety LA BU 21.

In an aspect, a cured leaf from a tobacco plant, variety, or line comprising a mutant allele of pmt1a comprises a higher leaf grade than a control cured leaf from the variety LA BU 21. In an aspect, a cured leaf from a tobacco plant, variety, or line comprising a mutant allele of pmt1b comprises a higher leaf grade than a control cured leaf from the variety LA BU 21. In an aspect, a cured leaf from a tobacco plant, variety, or line comprising a mutant allele of pmt2 comprises a higher leaf grade than a control cured leaf from the variety LA BU 21. In an aspect, a cured leaf from a tobacco plant, variety, or line comprising a mutant allele of pmt3 comprises a higher leaf grade than a control cured leaf from the variety LA BU 21. In an aspect, a cured leaf from a tobacco plant, variety, or line comprising a mutant allele of pmt4 comprises a higher leaf grade than a control cured leaf from the variety LA BU 21. In another aspect, a cured tobacco leaf from a plant, variety, or line comprising a mutant allele of pmt1a, a mutant allele of pmt1b, a mutant allele of pmt2, a mutant allele of pmt3, and a mutant allele of pmt4 comprises a higher leaf grade than a control cured leaf from the variety LA BU 21.

In an aspect, a cured leaf from a tobacco plant, variety, or line provided in any one of Tables 4A to 4E, Table 10, or Table 14 comprises a higher leaf grade than a control cured leaf from the variety LA BU 21.

In an aspect, a cured leaf from a tobacco plant, variety, or line comprising one or more pmt mutations provided in any one of Tables 5A to 5E and Tables 12A to 12E comprises a higher leaf grade than a control cured leaf from the variety LA BU 21.

In an aspect, a “reduced mold infection” refers to a reduced area of infected leaf. In another aspect, a “reduced mold infection” refers to a reduced number of viable mold spores on an infected leaf. Standard methods of detecting and counting viable mold spores are known and available in the art.

In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 1% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 2% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 3% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 4% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 5% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 10% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 15% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 20% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 25% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 30% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 35% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 40% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 50% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 60% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 70% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 75% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 80% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 90% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of at least 95% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of 100% as compared to a control leaf.

In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 90% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 80% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 70% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 60% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 50% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 40% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 30% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 20% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 1% and 10% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 10% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 20% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 30% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 40% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 50% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 60% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 70% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 80% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 90% and 100% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 10% and 75% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 25% and 75% as compared to a control leaf. In an aspect, a reduced mold infection comprises a reduction of infected leaf area of between 25% and 50% as compared to a control leaf.

In an aspect, mold infecting, cured tobacco is of a genus selected from the group consisting of Cladosporium, Alternaria, Aspergillus, and Mucor.

Tobacco material obtained from the tobacco lines, varieties or hybrids of the present disclosure can be used to make tobacco products. As used herein, “tobacco product” is defined as any product made or derived from tobacco that is intended for human use or consumption.

Tobacco products provided include, without limitation, cigarette products (e.g., cigarettes and bidi cigarettes), cigar products (e.g., cigar wrapping tobacco and cigarillos), pipe tobacco products, products derived from tobacco, tobacco-derived nicotine products, smokeless tobacco products (e.g., moist snuff, dry snuff, and chewing tobacco), films, chewables, tabs, shaped parts, gels, consumable units, insoluble matrices, hollow shapes, reconstituted tobacco, expanded tobacco, and the like. See, e.g., U.S. Patent Publication No. US 2006/0191548.

As used herein, “cigarette” refers a tobacco product having a “rod” and “filler”. The cigarette “rod” includes the cigarette paper, filter, plug wrap (used to contain filtration materials), tipping paper that holds the cigarette paper (including the filler) to the filter, and all glues that hold these components together. The “filler” includes (1) all tobaccos, including but not limited to reconstituted and expanded tobacco, (2) non-tobacco substitutes (including but not limited to herbs, non-tobacco plant materials and other spices that may accompany tobaccos rolled within the cigarette paper), (3) casings, (4) flavorings, and (5) all other additives (that are mixed into tobaccos and substitutes and rolled into the cigarette).

As used herein, “reconstituted tobacco” refers to a part of tobacco filler made from tobacco dust and other tobacco scrap material, processed into sheet form and cut into strips to resemble tobacco. In addition to the cost savings, reconstituted tobacco is very important for its contribution to cigarette taste from processing flavor development using reactions between ammonia and sugars.

As used herein, “expanded tobacco” refers to a part of tobacco filler which is processed through expansion of suitable gases so that the tobacco is “puffed” resulting in reduced density and greater filling capacity. It reduces the weight of tobacco used in cigarettes.

Tobacco products derived from plants of the present disclosure also include cigarettes and other smoking articles, particularly those smoking articles including filter elements, where the rod of smokable material includes cured tobacco within a tobacco blend. In an aspect, a tobacco product of the present disclosure is selected from the group consisting of a cigarillo, a non-ventilated recess filter cigarette, a vented recess filter cigarette, a cigar, snuff, pipe tobacco, cigar tobacco, cigarette tobacco, chewing tobacco, leaf tobacco, hookah tobacco, shredded tobacco, and cut tobacco. In another aspect, a tobacco product of the present disclosure is a smokeless tobacco product. Smokeless tobacco products are not combusted and include, but not limited to, chewing tobacco, moist smokeless tobacco, snus, and dry snuff Chewing tobacco is coarsely divided tobacco leaf that is typically packaged in a large pouch-like package and used in a plug or twist. Moist smokeless tobacco is a moist, more finely divided tobacco that is provided in loose form or in pouch form and is typically packaged in round cans and used as a pinch or in a pouch placed between an adult tobacco consumer's cheek and gum. Snus is a heat treated smokeless tobacco. Dry snuff is finely ground tobacco that is placed in the mouth or used nasally. In a further aspect, a tobacco product of the present disclosure is selected from the group consisting of loose leaf chewing tobacco, plug chewing tobacco, moist snuff, and nasal snuff. In yet another aspect, a tobacco product of the present disclosure is selected from the group consisting of an electronically heated cigarette, an e-cigarette, an electronic vaporing device.

In an aspect, a tobacco product of the present disclosure can be a blended tobacco product. In another aspect, a tobacco product of the present disclosure can be a low nicotine tobacco product. In a further aspect, a tobacco product of the present disclosure may comprise nornicotine at a level of less than about 3 mg/g. For example, the nornicotine content in such a product can be 3.0 mg/g, 2.5 mg/g, 2.0 mg/g, 1.5 mg/g, 1.0 mg/g, 750 μg/g, 500 pg/g, 250 pg/g, 100 pg/g, 75 pg/g, 50 pg/g, 25 pg/g, 10 pg/g, 7.0 pg/g, 5.0 pg/g, 4.0 pg/g, 2.0 pg/g, 1.0 pg/g, 0.5 pg/g, 0.4 pg/g, 0.2 pg/g, 0.1 pg/g, 0.05 pg/g, 0.01 pg/g, or undetectable.

In an aspect, cured tobacco material or tobacco products provided comprise an average nicotine or total alkaloid level selected from the group consisting of about 0.01%, 0.02%, 0.05%, 0.75%, 0.1%, 0.15%, 0.2%, 0.3%, 0.35%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4%, 5%, 6%, 7%, 8%, and 9% on a dry weight basis. In another aspect, cured tobacco material or tobacco products provided comprise an average nicotine or total alkaloid level selected from the group consisting of about between 0.01% and 0.02%, between 0.02% and 0.05%, between 0.05% and 0.75%, between 0.75% and 0.1%, between 0.1% and 0.15%, between 0.15% and 0.2%, between 0.2% and 0.3%, between 0.3% and 0.35%, between 0.35% and 0.4%, between 0.4% and 0.5%, between 0.5% and 0.6%, between 0.6% and 0.7%, between 0.7% and 0.8%, between 0.8% and 0.9%, between 0.9% and 1%, between 1% and 1.1%, between 1.1% and 1.2%, between 1.2% and 1.3%, between 1.3% and 1.4%, between 1.4% and 1.5%, between 1.5% and 1.6%, between 1.6% and 1.7%, between 1.7% and 1.8%, between 1.8% and 1.9%, between 1.9% and 2%, between 2% and 2.1%, between 2.1% and 2.2%, between 2.2% and 2.3%, between 2.3% and 2.4%, between 2.4% and 2.5%, between 2.5% and 2.6%, between 2.6% and 2.7%, between 2.7% and 2.8%, between 2.8% and 2.9%, between 2.9% and 3%, between 3% and 3.1%, between 3.1% and 3.2%, between 3.2% and 3.3%, between 3.3% and 3.4%, between 3.4% and 3.5%, and between 3.5% and 3.6% on a dry weight basis. In a further aspect, cured tobacco material or tobacco products provided comprise an average nicotine or total alkaloid level selected from the group consisting of about between 0.01% and 0.1%, between 0.02% and 0.2%, between 0.03% and 0.3%, between 0.04% and 0.4%, between 0.05% and 0.5%, between 0.75% and 1%, between 0.1% and 1.5%, between 0.15% and 2%, between 0.2% and 3%, and between 0.3% and 3.5% on a dry weight basis.

The present disclosure also provides methods for breeding tobacco lines, cultivars, or varieties comprising a desirable level of total alkaloid or nicotine, e.g., low nicotine or nicotine free. Breeding can be carried out via any known procedures. DNA fingerprinting, SNP mapping, haplotype mapping or similar technologies may be used in a marker-assisted selection (MAS) breeding program to transfer or breed a desirable trait or allele into a tobacco plant. For example, a breeder can create segregating populations in a F₂ or backcross generation using F1 hybrid plants or further crossing the F1 hybrid plants with other donor plants with an agronomically desirable genotype. Plants in the F₂ or backcross generations can be screened for a desired agronomic trait or a desirable chemical profile using one of the techniques known in the art or listed herein. Depending on the expected inheritance pattern or the MAS technology used, self-pollination of selected plants before each cycle of backcrossing to aid identification of the desired individual plants can be performed. Backcrossing or other breeding procedure can be repeated until the desired phenotype of the recurrent parent is recovered. A recurrent parent in the present disclosure can be a flue-cured variety, a Burley variety, a dark air-cured variety, a dark fire-cured variety, or an Oriental variety. Other breeding techniques can be found, for example, in Wernsman, E. A., and Rufty, R. C. 1987. Chapter Seventeen. Tobacco. Pages 669-698 In: Cultivar Development. Crop Species. W. H. Fehr (ed.), MacMillan Publishing Go., Inc., New York, N.Y., incorporated herein by reference in their entirety.

Results of a plant breeding program using the tobacco plants described includes useful lines, cultivars, varieties, progeny, inbreds, and hybrids of the present disclosure. As used herein, the term “variety” refers to a population of plants that share constant characteristics which separate them from other plants of the same species. A variety is often, although not always, sold commercially. While possessing one or more distinctive traits, a variety is further characterized by a very small overall variation between individuals within that variety. A “pure line” variety may be created by several generations of self-pollination and selection, or vegetative propagation from a single parent using tissue or cell culture techniques. A variety can be essentially derived from another line or variety. As defined by the International Convention for the Protection of New Varieties of Plants (Dec. 2, 1961, as revised at Geneva on Nov. 10, 1972; on Oct. 23, 1978; and on Mar. 19, 1991), a variety is “essentially derived” from an initial variety if: a) it is predominantly derived from the initial variety, or from a variety that is predominantly derived from the initial variety, while retaining the expression of the essential characteristics that result from the genotype or combination of genotypes of the initial variety; b) it is clearly distinguishable from the initial variety; and c) except for the differences which result from the act of derivation, it conforms to the initial variety in the expression of the essential characteristics that result from the genotype or combination of genotypes of the initial variety. Essentially derived varieties can be obtained, for example, by the selection of a natural or induced mutant, a somaclonal variant, a variant individual from plants of the initial variety, backcrossing, or transformation. A first tobacco variety and a second tobacco variety from which the first variety is essentially derived, are considered as having essentially identical genetic background. A “line” as distinguished from a variety most often denotes a group of plants used non-commercially, for example in plant research. A line typically displays little overall variation between individuals for one or more traits of interest, although there may be some variation between individuals for other traits.

In an aspect, this disclosure provides a tobacco plant, variety, line, or cell comprising one or more pmt mutations provided in any one of Tables 5A to 5E and Tables 12A to 12E.

In another aspect, this disclosure provides a tobacco plant, variety, line, or cell derived from any tobacco plant, variety, or line provided in any one of Tables 4A to 4E, Table 10, or Table 14.

In an aspect, this disclosure provides the tobacco line 18GH203 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH341 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1678 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1680 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1804 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1898 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH207 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH342 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH343 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH348 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH349 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH355 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH359 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH64 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH682 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH692 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH697 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH922 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH957 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1808 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1810 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1886 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1888 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1889 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH189 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1893 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1901 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1902 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH3 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH125 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH208 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH403 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH414 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH434 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH436 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH437 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH449 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH706 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH709 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH710 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH716 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH729 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH731 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH752 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH756 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH768 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH771 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH776 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH800 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH818 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH10 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH1004 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH1033 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH132 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH134 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH217 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH456 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH457 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH460 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH465 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH71 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH830 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH831 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH836 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH841 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH974 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH981 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH994 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1905 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH128 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH130 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH131 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH133 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH136 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH216 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH227 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH5 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH6 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH65 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH66 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH69 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH72 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH73 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH74 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH78 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH79 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH8 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH9 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1696 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1717 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1719 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1729 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1736 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1737 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1739 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1740 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1835 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1848 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1849 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1912 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1937 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1940 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1943 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1944 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH1051 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH22 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH34 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH473 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH49 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH50 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH848 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH850 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH851 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1699 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1708 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1722 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1724 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1725 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1845 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1846 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1847 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1911 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1912 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1915 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1918 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1928 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1932 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1933 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1936 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH20 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH28 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH31 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH47 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH51 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH52 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS107 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS106 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS115 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1809-13 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS111 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS112 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1678-60 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS131 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH709-01 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH709-08 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH414-11 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH414-19 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH437-04 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH437-08 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH437-32 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH437-39 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH449-26 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH449-33 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH125-48 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS102 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS103 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1719-30 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1740-36 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1698-22 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1700-13 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1702-17 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1849-01 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1849-48 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 17GH1737-24 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS118 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS133 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS120 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH1108-07 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH2162 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS164 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS163 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS146 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS147 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS150 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS151 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS148 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS149 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS152 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS153 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS143 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH2169 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH2171 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS165 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line CS118 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom. In an aspect, this disclosure provides the tobacco line 18GH2254-7 and F₁ or F₂ tobacco plants, or male sterile tobacco plants, derived therefrom.

In an aspect, the present disclosure provides a method of introgressing a low nicotine trait into a tobacco variety, the method comprising: (a) crossing a first tobacco variety comprising a low nicotine trait with a second tobacco variety without the low nicotine trait to produce one or more progeny tobacco plants; (b) genotyping the one or more progeny tobacco plants for a pmt mutant allele selected from those listed in Tables 4A to 4E, Tables 5A to 5E, Table 10, and Tables 12A to 12E; and (c) selecting a progeny tobacco plant comprising the pmt mutant allele. In another aspect, these methods further comprise backcrossing the selected progeny tobacco plant with the second tobacco variety. In a further aspect, these methods further comprise: (d) crossing the selected progeny plant with itself or with the second tobacco variety to produce one or more further progeny tobacco plants; and (e) selecting a further progeny tobacco plant comprising a low nicotine trait. In an aspect, the step (e) of selecting comprises marker-assisted selection. In an aspect, these methods produce a single gene conversion comprising a low nicotine trait. In an aspect, these methods produce a single gene conversion comprising a pmt mutant allele. In an aspect, the second tobacco variety is an elite variety. In another aspect, the genotyping step of these methods involve one or more molecular marker assays. In another aspect, the genotyping may involve a polymorphic marker comprising a polymorphism selected from the group consisting of single nucleotide polymorphisms (SNPs), insertions or deletions in DNA sequence (Indels), simple sequence repeats of DNA sequence (SSRs), a restriction fragment length polymorphism (RFLP), and a tag SNP.

As used herein, “locus” is a chromosomal locus or region where a polymorphic nucleic acid, trait determinant, gene, or marker is located. A “locus” can be shared by two homologous chromosomes to refer to their corresponding locus or region. As used herein, “allele” refers to an alternative nucleic acid sequence of a gene or at a particular locus (e.g., a nucleic acid sequence of a gene or locus that is different than other alleles for the same gene or locus). Such an allele can be considered (i) wild-type or (ii) mutant if one or more mutations or edits are present in the nucleic acid sequence of the mutant allele relative to the wild-type allele. A mutant allele for a gene may have a reduced or eliminated activity or expression level for the gene relative to the wild-type allele. For diploid organisms such as tobacco, a first allele can occur on one chromosome, and a second allele can occur at the same locus on a second homologous chromosome. If one allele at a locus on one chromosome of a plant is a mutant allele and the other corresponding allele on the homologous chromosome of the plant is wild-type, then the plant is described as being heterozygous for the mutant allele. However, if both alleles at a locus are mutant alleles, then the plant is described as being homozygous for the mutant alleles. A plant homozygous for mutant alleles at a locus may comprise the same mutant allele or different mutant alleles if heteroallelic or biallelic.

As used herein, “introgression” or “introgress” refers to the transmission of a desired allele of a genetic locus from one genetic background to another.

As used herein, “crossed” or “cross” means to produce progeny via fertilization (e.g. cells, seeds or plants) and includes crosses between plants (sexual) and self-fertilization (selfing).

As used herein, “backcross” and “backcrossing” refer to the process whereby a progeny plant is repeatedly crossed back to one of its parents. In a backcrossing scheme, the “donor” parent refers to the parental plant with the desired gene or locus to be introgressed. The “recipient” parent (used one or more times) or “recurrent” parent (used two or more times) refers to the parental plant into which the gene or locus is being introgressed. The initial cross gives rise to the F1 generation. The term “BC1” refers to the second use of the recurrent parent, “BC2” refers to the third use of the recurrent parent, and so on. In an aspect, a backcross is performed repeatedly, with a progeny individual of each successive backcross generation being itself backcrossed to the same parental genotype.

As used herein, “single gene converted” or “single gene conversion” refers to plants that are developed using a plant breeding technique known as backcrossing, or via genetic engineering, where essentially all of the desired morphological and physiological characteristics of a variety are recovered in addition to the single gene transferred into the variety via the backcrossing technique or via genetic engineering.

As used herein, “elite variety” means any variety that has resulted from breeding and selection for superior agronomic performance.

As used herein, “selecting” or “selection” in the context of marker-assisted selection or breeding refer to the act of picking or choosing desired individuals, normally from a population, based on certain pre-determined criteria.

As used herein, the term “trait” refers to one or more detectable characteristics of a cell or organism which can be influenced by genotype. The phenotype can be observable to the naked eye, or by any other means of evaluation known in the art, e.g., microscopy, biochemical analysis, genomic analysis, an assay for a particular disease tolerance, etc. In some cases, a phenotype is directly controlled by a single gene or genetic locus, e.g., a “single gene trait.” In other cases, a phenotype is the result of several genes.

As used herein, “marker assay” means a method for detecting a polymorphism at a particular locus using a particular method, e.g., measurement of at least one phenotype (such as seed color, flower color, or other visually detectable trait), restriction fragment length polymorphism (RFLP), single base extension, electrophoresis, sequence alignment, allelic specific oligonucleotide hybridization (ASO), random amplified polymorphic DNA (RAPD), microarray-based technologies, and nucleic acid sequencing technologies, etc.

As used herein, “marker assisted selection” (MAS) is a process by which phenotypes are selected based on marker genotypes. “Marker assisted selection breeding” refers to the process of selecting a desired trait or traits in a plant or plants by detecting one or more nucleic acids from the plant, where the nucleic acid is linked to the desired trait, and then selecting the plant or germplasm possessing those one or more nucleic acids.

As used herein, “polymorphism” means the presence of one or more variations in a population. A polymorphism may manifest as a variation in the nucleotide sequence of a nucleic acid or as a variation in the amino acid sequence of a protein. Polymorphisms include the presence of one or more variations of a nucleic acid sequence or nucleic acid feature at one or more loci in a population of one or more individuals. The variation may comprise but is not limited to one or more nucleotide base changes, the insertion of one or more nucleotides or the deletion of one or more nucleotides. A polymorphism may arise from random processes in nucleic acid replication, through mutagenesis, as a result of mobile genomic elements, from copy number variation and during the process of meiosis, such as unequal crossing over, genome duplication and chromosome breaks and fusions. The variation can be commonly found or may exist at low frequency within a population, the former having greater utility in general plant breeding and the latter may be associated with rare but important phenotypic variation. Useful polymorphisms may include single nucleotide polymorphisms (SNPs), insertions or deletions in DNA sequence (Indels), simple sequence repeats of DNA sequence (SSRs), a restriction fragment length polymorphism (RFLP), and a tag SNP. A genetic marker, a gene, a DNA-derived sequence, a RNA-derived sequence, a promoter, a 5′ untranslated region of a gene, a 3′ untranslated region of a gene, microRNA, siRNA, a tolerance locus, a satellite marker, a transgene, mRNA, ds mRNA, a transcriptional profile, and a methylation pattern may also comprise polymorphisms. In addition, the presence, absence, or variation in copy number of the preceding may comprise polymorphisms.

As used herein, “SNP” or “single nucleotide polymorphism” means a sequence variation that occurs when a single nucleotide (A, T, C, or G) in the genome sequence is altered or variable. “SNP markers” exist when SNPs are mapped to sites on the genome.

As used herein, “marker” or “molecular marker” or “marker locus” is a term used to denote a nucleic acid or amino acid sequence that is sufficiently unique to characterize a specific locus on the genome. Any detectable polymorphic trait can be used as a marker so long as it is inherited differentially and exhibits linkage disequilibrium with a phenotypic trait of interest. Each marker is therefore an indicator of a specific segment of DNA, having a unique nucleotide sequence. The map positions provide a measure of the relative positions of particular markers with respect to one another. When a trait is stated to be linked to a given marker it will be understood that the actual DNA segment whose sequence affects the trait generally co-segregates with the marker. More precise and definite localization of a trait can be obtained if markers are identified on both sides of the trait. By measuring the appearance of the marker(s) in progeny of crosses, the existence of the trait can be detected by relatively simple molecular tests without actually evaluating the appearance of the trait itself, which can be difficult and time-consuming because the actual evaluation of the trait requires growing plants to a stage and/or under environmental conditions where the trait can be expressed.

It is understood that any tobacco plant of the present disclosure can further comprise additional agronomically desirable traits, for example, by transformation with a genetic construct or transgene using a technique known in the art. Without limitation, an example of a desired trait is herbicide resistance, pest resistance, disease resistance; high yield; high grade index value; curability; curing quality; mechanical harvestability; holding ability; leaf quality; height, plant maturation (e.g., early maturing, early to medium maturing, medium maturing, medium to late maturing, or late maturing); stalk size (e.g., a small, medium, or a large stalk); or leaf number per plant (e.g., a small (e.g., 5-10 leaves), medium (e.g., 11-15 leaves), or large (e.g., 16-21) number of leaves), or any combination. In an aspect, low-nicotine or nicotine-free tobacco plants or seeds disclosed comprise one or more transgenes expressing one or more insecticidal proteins, such as, for example, a crystal protein of Bacillus thuringiensis or a vegetative insecticidal protein from Bacillus cereus, such as VIP3 (see, for example, Estruch et al. (1997) Nat. Biotechnol. 15:137). In another aspect, tobacco plants further comprise an introgressed trait conferring resistance to brown stem rot (U.S. Pat. No. 5,689,035) or resistance to cyst nematodes (U.S. Pat. No. 5,491,081).

The present disclosure also provides pmt mutant tobacco plants comprising an altered nicotine or total alkaloid level but having a yield comparable to the yield of corresponding initial tobacco plants without such a nicotine level alternation. In an aspect, a pmt mutant variety provides a yield selected from the group consisting of about between 1200 and 3500, between 1300 and 3400, between 1400 and 3300, between 1500 and 3200, between 1600 and 3100, between 1700 and 3000, between 1800 and 2900, between 1900 and 2800, between 2000 and 2700, between 2100 and 2600, between 2200 and 2500, and between 2300 and 2400 lbs/acre. In another aspect, a pmt mutant tobacco variety provides a yield selected from the group consisting of about between 1200 and 3500, between 1300 and 3500, between 1400 and 3500, between 1500 and 3500, between 1600 and 3500, between 1700 and 3500, between 1800 and 3500, between 1900 and 3500, between 2000 and 3500, between 2100 and 3500, between 2200 and 3500, between 2300 and 3500, between 2400 and 3500, between 2500 and 3500, between 2600 and 3500, between 2700 and 3500, between 2800 and 3500, between 2900 and 3500, between 3000 and 3500, and between 3100 and 3500 lbs/acre. In a further aspect, pmt mutant tobacco plants provide a yield between 65% and 130%, between 70% and 130%, between 75% and 130%, between 80% and 130%, between 85% and 130%, between 90% and 130%, between 95% and 130%, between 100% and 130%, between 105% and 130%, between 110% and 130%, between 115% and 130%, or between 120% and 130% of the yield of a control plant having essentially identical genetic background except for pmt mutation(s). In a further aspect, pmt mutant tobacco plants provide a yield between 70% and 125%, between 75% and 120%, between 80% and 115%, between 85% and 110%, or between 90% and 100% of the yield of a control plant having essentially identical genetic background except for pmt mutations.

In an aspect, a tobacco plant disclosed (e.g., a low-nicotine, nicotine-free, or low-alkaloid tobacco variety) comprises a modification conferring a desired trait (e.g., low-nicotine, nicotine-free, or low-alkaloid) without substantially impacting a trait selected from the group consisting of yield, ripening and senescence, susceptibility to insect herbivory, polyamine content after topping, chlorophyll level, mesophyll cell number per unit leaf area, and end-product quality after curing.

In an aspect, a tobacco plant disclosed comprises a modification conferring a desired trait (e.g., low-nicotine, nicotine-free, or low-alkaloid) and further comprises a trait substantially comparable to an unmodified control plant, where the trait is selected from the group consisting of yield, ripening and senescence, susceptibility to insect herbivory, polyamine content after topping, chlorophyll level, mesophyll cell number per unit leaf area, and end-product quality after curing.

In an aspect, a tobacco plant disclosed comprises a modification conferring a desired trait (e.g., low-nicotine, nicotine-free, or low-alkaloid) and further comprises a yield which is more than 80%, more than 85%, more than 90%, more than 95%, more than 100%, more than 105%, more than 110%, more than 115%, more than 120%, more than 125%, more than 130%, more than 135%, or more than 140% relative to the yield of an unmodified control plant. In an aspect, a tobacco plant disclosed comprises a modification conferring a desired trait (e.g., low-nicotine, nicotine-free, or low-alkaloid) and further comprises a yield which is between 70% and 140%, between 75% and 135%, between 80% and 130%, between 85% and 125%, between 90% and 120%, between 95% and 115%, or between 100% and 110% relative to the yield of an unmodified control plant. In an aspect, a tobacco plant disclosed comprises a modification conferring a desired trait (e.g., low-nicotine, nicotine-free, or low-alkaloid) and further comprises a yield which is between 70% and 80%, between 75% and 85%, between 80% and 90%, between 85% and 95%, between 90% and 100%, between 95% and 105%, between 105% and 115%, between 110% and 120%, between 115% to 125%, between 120% and 130%, between 125 and 135%, or between 130% and 140% relative to the yield of an unmodified control plant.

In an aspect, a low-nicotine or nicotine-free tobacco variety disclosed is adapted for machine harvesting. In another aspect, a low-nicotine or nicotine-free tobacco variety disclosed is harvested mechanically.

In an aspect, tobacco plants provided are hybrid plants. Hybrids can be produced by preventing self-pollination of female parent plants (e.g., seed parents) of a first variety, permitting pollen from male parent plants of a second variety to fertilize the female parent plants, and allowing F1 hybrid seeds to form on the female plants. Self-pollination of female plants can be prevented by emasculating the flowers at an early stage of flower development. Alternatively, pollen formation can be prevented on the female parent plants using a form of male sterility. For example, male sterility can be produced by male sterility (MS), or transgenic male sterility where a transgene inhibits microsporogenesis and/or pollen formation, or self-incompatibility. Female parent plants containing MS are particularly useful. In aspects in which the female parent plants are MS, pollen may be harvested from male fertile plants and applied manually to the stigmas of MS female parent plants, and the resulting F1 seed is harvested.

Plants can be used to form single-cross tobacco F1 hybrids. Pollen from a male parent plant is manually transferred to an emasculated female parent plant or a female parent plant that is male sterile to form F1 seed. Alternatively, three-way crosses can be carried out where a single-cross F1 hybrid is used as a female parent and is crossed with a different male parent. As another alternative, double-cross hybrids can be created where the F1 progeny of two different single-crosses are themselves crossed. Self-incompatibility can be used to particular advantage to prevent self-pollination of female parents when forming a double-cross hybrid.

In an aspect, a low-nicotine or nicotine-free tobacco variety is male sterile. In another aspect, a low-nicotine or nicotine-free tobacco variety is cytoplasmic male sterile. Male sterile tobacco plants may be produced by any method known in the art. Methods of producing male sterile tobacco are described in Wernsman, E. A., and Rufty, R. C. 1987. Chapter Seventeen. Tobacco. Pages 669-698 In: Cultivar Development. Crop Species. W. H. Fehr (ed.), MacMillan Publishing Go., Inc., New York, N.Y. 761 pp.

In an aspect, this disclosure provides a male sterile tobacco plant, variety, or line comprising one or more pmt mutations provided in any one of Tables 5A to 5E and Tables 12A to 12E.

In another aspect, this disclosure provides a male sterile tobacco plant, variety, or line derived from any tobacco plant, variety, or line provided in any one of Tables 4A to 4E, Table 10, or Table 14.

In an aspect, this disclosure provides the male sterile line dCS11. In another aspect, this disclosure provides the male sterile line dCS12. In another aspect, this disclosure provides the male sterile line dCS13. In another aspect, this disclosure provides the male sterile line dCS14. In another aspect, this disclosure provides the male sterile line dCS15. In another aspect, this disclosure provides the male sterile line dCS16. In another aspect, this disclosure provides the male sterile line dCS17. In another aspect, this disclosure provides the male sterile line dCS18. In another aspect, this disclosure provides the male sterile line dS697.

In a further aspect, tobacco parts provided include, but are not limited to, a leaf, a stem, a root, a seed, a flower, pollen, an anther, an ovule, a pedicel, a fruit, a meristem, a cotyledon, a hypocotyl, a pod, an embryo, endosperm, an explant, a callus, a tissue culture, a shoot, a cell, and a protoplast. In an aspect, tobacco part provided does not include seed. In an aspect, this disclosure provides tobacco plant cells, tissues, and organs that are not reproductive material and do not mediate the natural reproduction of the plant. In another aspect, this disclosure also provides tobacco plant cells, tissues, and organs that are reproductive material and mediate the natural reproduction of the plant. In another aspect, this disclosure provides tobacco plant cells, tissues, and organs that cannot maintain themselves via photosynthesis. In another aspect, this disclosure provides somatic tobacco plant cells. Somatic cells, contrary to germline cells, do not mediate plant reproduction.

Cells, tissues and organs can be from seed, fruit, leaf, cotyledon, hypocotyl, meristem, embryos, endosperm, root, shoot, stem, pod, flower, infloresence, stalk, pedicel, style, stigma, receptacle, petal, sepal, pollen, anther, filament, ovary, ovule, pericarp, phloem, vascular tissue. In another aspect, this disclosure provides a tobacco plant chloroplast. In a further aspect, this disclosure provides epidermal cells, stomata cell, leaf or root hairs, a storage root, or a tuber. In another aspect, this disclosure provides a tobacco protoplast.

Skilled artisans understand that tobacco plants naturally reproduce via seeds, not via asexual reproduction or vegetative propagation. In an aspect, this disclosure provides tobacco endosperm. In another aspect, this disclosure provides tobacco endosperm cells. In a further aspect, this disclosure provides a male or female sterile tobacco plant, which cannot reproduce without human intervention.

In an aspect, the present disclosure provides a nucleic acid molecule comprising at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a sequence selected from the group consisting of SEQ ID NOs: 1 to 10, and fragments thereof. In an aspect, the present disclosure provides a polypeptide or protein comprising at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:11 to 15.

As used herein, the term “sequence identity” or “identity” in the context of two polynucleotides or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution.

The present disclosure further provides a method manufacturing a tobacco product comprising tobacco material from tobacco plants disclosed. In an aspect, methods comprise conditioning aged tobacco material made from tobacco plants to increase its moisture content from between about 12.5% and about 13.5% to about 21%, blending the conditioned tobacco material to produce a desirable blend. In an aspect, the method of manufacturing a tobacco product further comprises casing or flavoring the blend. Generally, during the casing process, casing or sauce materials are added to blends to enhance their quality by balancing the chemical composition and to develop certain desired flavor characteristics. Further details for the casing process can be found in Tobacco Production, Chemistry and Technology, Edited by L. Davis and M. Nielsen, Blackwell Science, 1999.

Tobacco material provided can be also processed using methods including, but not limited to, heat treatment (e.g., cooking, toasting), flavoring, enzyme treatment, expansion and/or curing. Both fermented and non-fermented tobaccos can be processed using these techniques. Examples of suitable processed tobaccos include dark air-cured, dark fire cured, burley, flue cured, and cigar filler or wrapper, as well as the products from the whole leaf stemming operation. In an aspect, tobacco fibers include up to 70% dark tobacco on a fresh weight basis. For example, tobacco can be conditioned by heating, sweating and/or pasteurizing steps as described in U.S. Publication Nos. 2004/0118422 or 2005/0178398.

Tobacco material provided can be subject to fermentation. Fermenting typically is characterized by high initial moisture content, heat generation, and a 10 to 20% loss of dry weight. See, e.g., U.S. Pat. Nos. 4,528,993; 4,660,577; 4,848,373; and 5,372,149. In addition to modifying the aroma of the leaf, fermentation can change either or both the color and texture of a leaf. Also during the fermentation process, evolution gases can be produced, oxygen can be taken up, the pH can change, and the amount of water retained can change. See, for example, U.S. Publication No. 2005/0178398 and Tso (1999, Chapter 1 in Tobacco, Production, Chemistry and Technology, Davis & Nielsen, eds., Blackwell Publishing, Oxford). Cured, or cured and fermented tobacco can be further processed (e.g., cut, expanded, blended, milled or comminuted) prior to incorporation into the oral product. The tobacco, in some cases, is long cut fermented cured moist tobacco having an oven volatiles content of between 48 and 50 weight percent prior to mixing with the copolymer and optionally flavorants and other additives.

In an aspect, tobacco material provided can be processed to a desired size. In an aspect, tobacco fibers can be processed to have an average fiber size of less than 200 micrometers. In an aspect, tobacco fibers are between 75 and 125 micrometers. In another aspect, tobacco fibers are processed to have a size of 75 micrometers or less. In an aspect, tobacco fibers include long cut tobacco, which can be cut or shredded into widths of about 10 cuts/inch up to about 110 cuts/inch and lengths of about 0.1 inches up to about 1 inch. Double cut tobacco fibers can have a range of particle sizes such that about 70% of the double cut tobacco fibers falls between the mesh sizes of −20 mesh and 80 mesh.

Tobacco material provided can be processed to have a total oven volatiles content of about 10% by weight or greater; about 20% by weight or greater; about 40% by weight or greater; about 15% by weight to about 25% by weight; about 20% by weight to about 30% by weight; about 30% by weight to about 50% by weight; about 45% by weight to about 65% by weight; or about 50% by weight to about 60% by weight. Those of skill in the art will appreciate that “moist” tobacco typically refers to tobacco that has an oven volatiles content of between about 40% by weight and about 60% by weight (e.g., about 45% by weight to about 55% by weight, or about 50% by weight). As used herein, “oven volatiles” are determined by calculating the percentage of weight loss for a sample after drying the sample in a pre-warmed forced draft oven at 110° C. for 3.25 hours. The oral product can have a different overall oven volatiles content than the oven volatiles content of the tobacco fibers used to make the oral product. The processing steps described can reduce or increase the oven volatiles content.

Having now generally described the disclosure, the same will be more readily understood through reference to the following examples that are provided by way of illustration, and are not intended to be limiting of the present disclosure, unless specified.

EXAMPLES Example 1: Expression Profiling of Five PMT Genes

Nicotine biosynthesis starts with conversion of polyamine putrescine to N-methylputrescine by the enzyme putrescine N-methyl transferase (PMT). This is a step that commits precursor metabolites to nicotine biosynthesis. Genes encoding PMT (PMT1a, PMT1b, PMT2, PMT3 and PMT4) are present in the tobacco (Nicotiana tabacum) genome. Table 1A lists genomic DNA sequences, cDNA sequences, and protein sequences of five PMT genes. Tables 1B and 1C provide sequence identities among five PMT genes. Pooled expression levels from before topping to harvest provide support that, without being limited by any particular theory, PMT1a and PMT3 represent two major PMT genes (FIG. 1 ).

TABLE 1A Sequences of five tobacco PMT genes. Genomic DNA Sequence (including regions such as cDNA Protein promoter, 5′ UTR, introns, Sequence Sequence Gene 3′ UTR, and terminator) (SEQ ID (SEQ ID Name (SEQ ID No.) No.) No.) PMT1b 1 6 11 PMT1a 2 7 12 PMT2 3 8 13 PMT3 4 9 14 PMT4 5 10 15

TABLE 1B cDNA sequence identity among five tobacco PMT genes determined by Clustal2.1. cDNA % identity PMT1a PMT1b PMT2 PMT3 PMT4 PMT1a 100 PMT1b 98.85 100 PMT2 91.81 91.71 100 PMT3 93.71 93.53 91.79 100 PMT4 94.24 94.06 92.75 94.59 100

TABLE 1C Protein sequence identity among five tobacco PMT genes determined by Clustal2.1. Protein % identity PMT1a PMT1b PMT2 PMT3 PMT4 PMT1a 100 PMT1b 98.4 100 PMT2 95.42 95.75 100 PMT3 97.48 97.76 96.23 100 PMT4 96.27 96.8 96.32 97.63 100

TABLE 1D PMT1b genomic sequence (SEQ ID No. 1) annotation. Element location 5′ sequence   1 . . . 1000 exon 1 1001 . . . 1292 intron 1 1293 . . . 1464 exon 2 1465 . . . 1541 intron 2 1542 . . . 1623 exon 3 1624 . . . 1851 intron 3 1852 . . . 1971 exon 4 1972 . . . 2044 intron 4 2045 . . . 2143 exon 5 2144 . . . 2215 intron 5 2216 . . . 2333 exon 6 2334 . . . 2529 intron 6 2530 . . . 3033 exon 7 3034 . . . 3166 intron 7 3167 . . . 3260 exon 8 3261 . . . 3317 3′ sequence 3318 . . . 4317

TABLE 1E PMT1b genomic sequence (SEQ ID No. 2) annotation. Element location 5′ sequence   1 . . . 1000 exon 1 1001 . . . 1294 intron 1 1295 . . . 1422 exon 2 1423 . . . 1497 intron 2 1498 . . . 1579 exon 3 1580 . . . 1810 intron 3 1811 . . . 1932 exon 4 1933 . . . 2003 intron 4 2004 . . . 2102 exon 5 2103 . . . 2175 intron 5 2176 . . . 2293 exon 6 2294 . . . 2487 intron 6 2488 . . . 2925 exon 7 2926 . . . 3058 intron 7 3059 . . . 3153 exon 8 3154 . . . 3210 3′ sequence 3211 . . . 4210

TABLE 1F PMT2 genomic sequence (SEQ ID No. 3) annotation. Element location 5′ sequence   1 . . . 792 exon 1  793 . . . 1020 intron 1 1021 . . . 1201 exon 2 1202 . . . 1276 intron 2 1277 . . . 1358 exon 3 1359 . . . 1589 intron 3 1590 . . . 1694 exon 4 1695 . . . 1765 intron 4 1766 . . . 1875 exon 5 1876 . . . 1948 intron 5 1949 . . . 2037 exon 6 2038 . . . 2231 intron 6 2232 . . . 2397 exon 7 2398 . . . 2530 intron 7 2531 . . . 2629 exon 8 2630 . . . 2686 3′ sequence 2687 . . . 3686

TABLE 1G PMT3 genomic sequence (SEQ ID No. 4) annotation. Element location 5′ sequence   1 . . . 1000 exon 1 1001 . . . 1312 intron 1 1313 . . . 1562 exon 2 1563 . . . 1637 intron 2 1638 . . . 1731 exon 3 1732 . . . 1962 intron 3 1963 . . . 2050 exon 4 2051 . . . 2121 intron 4 2122 . . . 2230 exon 5 2231 . . . 2303 intron 5 2304 . . . 2397 exon 6 2398 . . . 2591 intron 6 2592 . . . 2750 exon 7 2751 . . . 2883 intron 7 2884 . . . 2978 exon 8 2979 . . . 3035 3′ sequence 3036 . . . 4035

TABLE 1H PMT4 genomic sequence (SEQ ID No. 5) annotation. Element location 5′ sequence   1 . . . 1000 exon 1 1001 . . . 1426 intron 1 1427 . . . 1609 exon 2 1610 . . . 1684 intron 2 1685 . . . 1766 exon 3 1767 . . . 1997 intron 3 1998 . . . 2112 exon 4 2113 . . . 2183 intron 4 2184 . . . 2290 exon 5 2291 . . . 2363 intron 5 2364 . . . 2452 exon 6 2453 . . . 2646 intron 6 2647 . . . 3146 exon 7 3147 . . . 3279 intron 7 3280 . . . 3374 exon 8 3375 . . . 3431 3′ sequence 3432 . . . 4431

Example 2: PMT Genome Editing and Tobacco Line Development

PMT knockout mutants are produced by editing various PMT genes. Tobacco protoplasts are transfected using polyethylene glycol (PEG) with plasmids encoding a genome editing technology 1 (GET 1) protein or a genome editing technology (GET) 2 protein and specific guide RNAs (gRNAs) targeting PMT genes at desired positions. Table 2 lists gRNA sequences used for PMT editing. Some gRNAs (e.g., Nos. 6 and 7) are pooled together for targeting multiple PMT genes in a single transfection.

Transfected protoplasts are then immobilized in 1% agarose bead and subjected to tissue culture. When calli grow up to ˜1 mm in diameter, they are spread on TOM2 plates. Calli are screened for insertions or deletions (indels) at the target positions using fragment analysis. Candidates, showing size shifts compared to wildtype control, are selected for further culture and the consequent shoots are tested by fragment analysis again to confirm the presence of indels. Rooted shoots are potted and sequenced for the target positions to determine the exact sequences deleted. Young leaf from each plant is harvested and PCR amplified for PMT fragments using phirekit. PMT Libraries for each line is indexed and 384 lines are pooled and sequenced using Miseq.

SNP analysis is carried out to determine both the exact edited pmt mutant allele sequences and the zygosity state at each PMT gene locus. Table 3 provides the zygosity information of representative edited plants. Tables 4A to 4E provide indels sequence information in each edited line of various tobacco varieties (e.g., K326, TN90, NLM, oriental). Tables 5A to 5E provide genomic sequences of about 40 nucleotides from each pmt mutant allele with the edited site in the middle of the genomic sequence (e.g., 20 nucleotides on each side of the deleted or inserted sequence site).

TABLE 2 gRNA sequences used in 2 genome editing technologies and their target genes. “Y” represents that a gRNA targets that PMT gene, while “-” represents that a gRNA does not target that PMT gene. Genome Editing gRNA (GET) Target genes No. Technology gRNA sequence PMTlb PMT1a PMT2 PMT3 PMT4 1 GET 1 CCCATGAACGGCCACCAAAA Y Y — — — (SEQ ID NO: 16) 2 GET 1 GGCACTTCCAAACACCAAAA Y Y Y Y Y (SEQ ID NO: 17) 3 GET 1 GTTGTTCGGATGTCCCATTC Y Y — — — (SEQ ID NO: 18) 4 GET 1 CTAAACTCTGAAAACCAACC Y — Y Y — (SEQ ID NO: 19) 5 GET 1 TTTCAGAGTTTAGCGCATTA Y Y Y Y Y (SEQ ID NO: 20) 6 GET 2 GATGGAGCAATTCAACATACAGA Y Y — — — (SEQ ID NO: 21) 7 GET 2 GATGGAGCAATTCAACACACAGA — — Y Y Y (SEQ ID NO: 22)

TABLE 3 Zygosity of individual PMT genic locus in selected pmt mutants in various background produced by genome editing using GET2. Variety Line PMT1b PMT1a PMT2 PMT3 PMT4 Basma 18GH203 1 2 2 2 1 Basma 18GH341 1 2 2 2 1 K326 17GH1678 2 2 1 1 2 K326 17GH1680 1 2 1 1 1 K326 17GH1804 1 2 1 1 1 K326 17GH1898 1 2 1 1 1 K326 18GH207 1 2 1 1 1 K326 18GH342 1 2 1 1 1 K326 18GH343 1 2 1 1 1 K326 18GH348 1 1 1 1 1 K326 18GH349 1 1 1 1 1 K326 18GH355 1 2 2 3 2 K326 18GH359 1 2 1 1 1 K326 18GH64 2 1 2 1 1 K326 18GH682 1 2 2 2 2 K326 18GH692 1 2 2 2 1 K326 18GH697 1 1 1 1 1 K326 18GH922 1 1 1 1 1 K326 18GH957 1 1 2 1 1 K326 17GH1808 1 2 1 2 1 K326 17GH1810 1 1 1 2 2 K326 17GH1886 — — 2 1 — K326 17GH1888 — 1 1 — — K326 17GH1889 — 1 1 — — K326 17GH1892 3 1 2 2 — K326 17GH1893 1 1 1 1 1 K326 17GH1901 1 1 1 2 2 K326 17GH1902 1 1 1 2 2 K326 18GH3 — 1 1 1 — Katerini 18GH125 2 2 1 2 1 Katerini 18GH208 2 1 1 2 1 Katerini 18GH403 1 1 1 1 — Katerini 18GH414 2 1 1 1 1 Katerini 18GH434 2 1 1 2 1 Katerini 18GH436 2 1 1 4 1 Katerini 18GH437 1 2 1 2 2 Katerini 18GH449 2 2 1 1 1 Katerini 18GH706 2 1 1 2 1 Katerini 18GH709 2 2 1 1 1 Katerini 18GH710 1 1 2 2 1 Katerini 18GH716 2 2 1 2 2 Katerini 18GH729 1 1 2 1 1 Katerini 18GH731 1 1 1 2 1 Katerini 18GH752 2 1 1 1 1 Katerini 18GH756 1 1 1 2 2 Katerini 18GH768 1 1 1 1 2 Katerini 18GH771 1 1 2 2 1 Katerini 18GH776 2 2 1 1 2 Katerini 18GH800 2 2 1 1 2 Katerini 18GH818 1 1 1 2 — NLMz 18GH10 1 1 1 1 1 NLMz 18GH1004 2 1 1 2 2 NLMz 18GH1033 2 1 1 2 2 NLMz 18GH132 1 2 2 3 1 NLMz 18GH134 1 2 1 1 1 NLMz 18GH217 1 2 2 1 2 NLMz 18GH456 2 1 1 1 1 NLMz 18GH457 1 1 1 1 1 NLMz 18GH460 1 2 3 1 1 NLMz 18GH465 2 1 1 2 2 NLMz 18GH71 1 1 1 1 1 NLMz 18GH830 1 1 1 1 1 NLMz 18GH831 1 2 1 — 1 NLMz 18GH836 1 1 1 1 1 NLMz 18GH841 2 2 1 — 1 NLMz 18GH974 2 1 2 2 1 NLMz 18GH981 1 1 2 2 2 NLMz 18GH994 2 1 1 2 2 NLMz 17GH1905 1 2 1 2 2 NLMz 18GH128 — 2 2 — 1 NLMz 18GH130 2 2 1 1 1 NLMz 18GH131 1 3 2 — 1 NLMz 18GH133 2 3 2 — 1 NLMz 18GH136 — — 1 — — NLMz 18GH216 2 2 1 1 2 NLMz 18GH227 1 1 1 — 1 NLMz 18GH5 1 2 1 2 2 NLMz 18GH6 1 2 3 1 1 NLMz 18GH65 2 2 2 2 1 NLMz 18GH66 1 2 1 2 2 NLMz 18GH69 — 1 — 2 1 NLMz 18GH72 2 2 2 2 1 NLMz 18GH73 — 2 2 — 1 NLMz 18GH74 — 1 — — — NLMz 18GH78 1 1 1 3 2 NLMz 18GH79 — 2 2 — 1 NLMz 18GH8 1 2 2 1 2 NLMz 18GH9 1 2 1 — 1 TN90 17GH1696 1 1 1 1 1 TN90 17GH1717 1 2 2 2 1 TN90 17GH1719 1 2 1 1 1 TN90 17GH1729 2 1 1 1 1 TN90 17GH1736 1 1 2 1 1 TN90 17GH1737 1 2 2 2 1 TN90 17GH1739 1 1 1 1 2 TN90 17GH1740 1 2 1 2 1 TN90 17GH1835 2 2 2 1 1 TN90 17GH1848 1 2 1 1 1 TN90 17GH1849 1 1 1 2 2 TN90 17GH1912 1 2 1 1 1 TN90 17GH1937 1 2 1 2 1 TN90 17GH1940 1 2 1 1 1 TN90 17GH1943 1 1 1 1 2 TN90 17GH1944 1 1 1 1 2 TN90 18GH1051 2 2 2 1 2 TN90 18GH22 1 2 1 2 1 TN90 18GH34 1 1 1 1 2 TN90 18GH473 1 1 1 2 2 TN90 18GH49 1 1 1 1 1 TN90 18GH50 2 1 1 1 1 TN90 18GH848 2 2 2 1 2 TN90 18GH850 1 2 1 2 2 TN90 18GH851 1 2 1 2 2 TN90 17GH1699 3 2 2 2 1 TN90 17GH1708 1 3 1 2 — TN90 17GH1722 2 1 2 2 1 TN90 17GH1724 2 1 1 2 1 TN90 17GH1725 2 1 1 2 1 TN90 17GH1845 2 2 1 2 2 TN90 17GH1846 2 1 2 2 1 TN90 17GH1847 2 1 2 2 1 TN90 17GH1911 1 2 1 1 1 TN90 17GH1912 1 2 1 1 1 TN90 17GH1915 — 1 — 1 — TN90 17GH1918 2 2 1 1 5 TN90 17GH1928 2 2 — 2 1 TN90 17GH1932 2 2 — — 1 TN90 17GH1933 2 2 2 5 1 TN90 17GH1936 2 2 2 1 2 TN90 18GH20 — 1 2 1 2 TN90 18GH28 2 1 2 1 2 TN90 18GH31 1 3 1 1 1 TN90 18GH47 1 3 1 1 1 TN90 18GH51 — — — 1 — TN90 18GH52 — — — 1 — Number one (1) represents homozygous for a single mutant allele. Numbers 2 to 5 represent a heteroallelic combination having 2 to 5 Indels. Hyphens indicate no data. Detailed genotype information is shown in Tables 4A to 4D.

TABLE 4A Mutantpmt alleles in K326 produced by genome editing using GET2. The position of each edited site (e.g.,, indels) is relative to the nucleotide number on the corresponding cDNA sequence of each PMT gene. For example, line 17GH1678 has bi-allelic mutations in PMT1b. One of the two alleles has a four-nucleotide deletion which corresponds to nucleotides 416 to 419 of the PMT1b cDNA sequence. The other allele has a two-nucleotide deletion which corresponds to nucleotides 418 to 419 of the PMT1b cDNA sequence. SEQ ID Numbers are assigned and shown for sequences of more than 10 nucleotides. PMT1b PMT1a PMT2 PMT3 PMT4 VAR- Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted IETY LINE ition sequence ition sequence ition sequence ition sequence ition sequence K326 17GH 416.. ATAC 415.. CATAC 348.. AC 432.. ACAC 547. CACAC 1678 419 421 AG 349 435 .551 418.. AC 417.. TACA 548. ACAC 419 420 .551 K326 17GH 414.. ACAT 414.. ACAT 348.. AC 432.. ACAC 546.. AC 1680 417 417 349 435 547 416.. AT 417 K326 17GH 414.. ACAT 411.. TCAAC 348.. AC 433.. CACAC 548.. ACACA 1804 417 420 ATACA 349 437 552 (SEQ ID NO: 379) 417.. TACA 420 K326 17GH 414.. ACAT 411.. TCAAC 348.. AC 433.. CACAC 548.. ACACA 1898 417 420 ATACA 349 437 552 (SEQ ID NO: 379) 417.. TACA 420 K326 18GH 414.. ACAT 415.. C 348.. ACAC 432.. AC 546.. ACAC 207 417 415 351 433 549 417.. T 417 K326 18GH 414.. ACAT 414.. ACAT 348.. AC 432.. ACAC 546.. AC 343 417 417 349 435 547 416.. AT 417 K326 18GH 414.. ACAT 414.. ACAT 348.. AC 429.. TCAACACAC 546.. AC 348 417 417 349 439 AG 547 (SEQ ID NO: 396) K326 18GH 414.. ACAT 414.. ACAT 348.. AC 429.. TCAACACAC 546.. AC 349 417 417 349 439 AG 547 (SEQ ID  NO: 396) K326 18GH 414.. ACAT 414.. ACAT 348.. ACAC 431.. AACACACA 546.. AC 355 417 417 351 438 547 416.. AT 350.. AC 435.. CACA 550.. ACAG 417 351 438 553 440.. AGA 442 K326 18GH 414.. ACAT 411.. TCAAC 348.. AC 433.. CACAC 548.. ACACA 359 417 420 ATACA 349 437 552 (SEQ ID NO: 379) 417.. TACA 420 K326 18GH 413.. AACA 414.. ACAT 349.. CACA 432.. AC 546.. ACAC 64 420 TACA 417 352 433 549 417.. TACA 354.. AGAG 420 359 AA K326 18GH 415.. CATA 413.. AACAT 348.. ACAC 432.. ACACACAG 543.. TCAACA 682 421 CAG 422 ACAGA 351 439 554 CACAGA (SEQ ID (SEQ ID NO: 386) NO: 404) 417.. TACA 350.. AC 437.. CA 549.. CACA 420 351 438 552 K326 18GH 414.. ACAT 414.. ACATA 348.. ACAC 432.. ACACACAG 546.. ACAC 692 420 CA 351 439 549 417 416.. ATACA 350.. AC 437.. CA 420 351 438 K326 18GH 414.. ACAT 414.. ACAT 348.. ACAC 430.. CAACACA 546.. ACAC 697 417 417 351 436 549 K326 18GH 414.. ACAT 414.. ACAT 348.. ACAC 430.. CAACACA 546.. ACAC 922 417 417 351 436 549 K326 18GH 414.. ACAT 414.. ACAT 349.. CACA 431.. AACACACA 546.. AC 957 417 417 355 CAG 438 547 351.. CACA 354 K326 17G — — — — 346. CAAC 432. AC — — 6 .350 A H188 349. CA .433 .350 K326 17GH — — 418.. AC 348.. AC — — — — 1888 419 349 K326 17GH — — 418.. AC 348.. AC — — — — 1889 419 349 K326 17GH 413.. AACA 414.. ACAT 348.. ACAC 432.. ACAC 1892 419 TAC 417 351 435 414.. ACAT 350.. AC 434.. AC 419 AC 351 435 416.. ATAC 419 K326 17GH 416.. ATAC 416.. ATACA 348.. AC 430.. CAACACA 546.. AC 1893 421 AG 420 349 436 547 K326 17GH 414.. ACAT 417.. TACA 348.. ACAC 432.. ACAC 548.. ACACA 1901 417 420 355 435 552 ACAG 434.. AC 550.. ACA 435 552 K326 17GH 414.. ACAT 417.. TACA 348.. ACAC 432.. ACAC 548.. ACACA 1902 417 420 355 435 552 ACAG 434.. AC 550.. ACA 435 552 K326 17GH 414.. ACAT 413.. AACAT 352.. ACA 432.. ACAC 546.. AC 1808 417 421 ACAG 354 435 547 418.. ACAG 434.. AC 421 435 K326 17G 414.. ACAT 417.. TACA 348.. ACAC 432.. ACAC 548.. ACACA 1H810 417 420 355 435 552 ACAG 434.. AC 550.. ACA 435 552 K326 18GH3 — — 414.. ACAT 348.. AC 432.. ACAC — — 417 349 435 K326 18GH4 — — 414.. ACAT 348.. AC 429.. TCAACACAC 546.. AC 417 349 439 AG 547 (SEQ ID NO: 396)

TABLE 4B Mutantpmt alleles in TN90 produced by genome editing using GET2. PMT1b PMT1a PMT2 PMT3 PMT4 VAR- Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted IETY LINE ition sequence ition sequence ition sequence ition sequence ition sequence TN90 17GH 414.. ACAT 414.. ACAT 348.. AC 436.. ACAG 546.. AC 1696 417 417 349 439 547 TN90 17GH 414.. ACAT 414.. ACAT 346.. CAACACA 432.. ACAC 546.. AC 1717 417 417 352 435 547 415.. CA 349.. CACA 434.. AC 416 352 435 TN90 17GH 414.. ACAT 417.. TACA 348.. AC 432.. AC 546.. ACA 1719 417 420 349 433 549 C 417.. TACA 423 GAG TN90 17GH 412.. CAAC 412.. CAAC 348.. ACAC 432.. AC 546.. AC 1729 421 ATACAG 418 ATA 351 433 547 (SEQ ID NO: 380) 414.. ACAT 420 ACA TN90 17GH 418.. ACAG 414.. ACAT 347.. AACACACA 432.. AC 546.. AC 1736 421 417 357 GAG (SEQ 433 547 ID NO: 391) 351.. CACA 354 TN90 17GH 414.. ACAT 414.. ACAT 346.. CAACACA 432.. ACAC 546.. AC 1737 417 417 352 435 547 415.. CA 349.. CACA 434.. AC 416 352 435 TN90 17GH 414.. ACAT 414.. ACAT 348.. AC 432.. AC 546.. ACA 1739 417 417 349 433 549 C 548.. AC 549 TN90 17GH 414 ACAT 416.. ATAC 348.. ACAC 435.. CACA 546.. AC 1740 417.. 419 351 438 547 418.. AC 436.. ACAG 419 439 TN90 17GH 413.. AACA 417.. TACA 350.. ACACA 432.. ACAC 546.. AC 1835 421 TACA 420 354 435 547 G 417.. TACA 418.. ACAG 351.. CACAGAGA 420 421 362 ATGG (SEQ ID NO: 394) TN90 17GH 414.. ACAT 417.. TACA 348.. AC 432.. AC 546.. ACA 1848 417 420 349 433 549 C 417.. TACA 423 GAG TN90 17G 414 ACAT 414 ACAT 348 ACAC 430 CAACACA 546 ACA 49 7 7 1 ..43 ..54 C 6 9 H18 ..41 ..41 ..35 433 CACA 548 AC ..43 ..54 6 9 TN90 17GH 414.. ACAT 417.. TACA 348.. AC 432.. AC 546.. ACA 1912 417 420 349 433 549 C 417.. TACA 423 GAG TN90 17GH 416.. ATAC 412.. CAAC 348.. ACAC 432.. ACAC 546.. AC 1937 419 421 ATACAG 351 435 547 (SEQ ID NO: 380) 417.. TACA 434.. AC 420 435 TN90 17GH 414.. ACAT 417.. TACA 348.. AC 432.. AC 546.. ACA 1940 417 420 349 433 549 C 417.. TACA 423 GAG TN90 17GH 414.. ACAT 414.. ACAT 348.. AC 432.. AC 546.. ACA 1943 417 417 349 433 549 C 548.. AC 549 TN90 17GH 414.. ACAT 414.. ACAT 348.. AC 432.. AC 546.. ACA 1944 417 417 349 433 549 C 548.. AC 549 TN90 18GH 414.. ACAT 412.. CAAC 348.. ACAC 432.. AC 546.. ACA 1051 418 A 418 ATA 351 433 549 C 415.. CATA 415.. CATA 350.. AC 548.. AC 421 CAG 418 351 549 TN90 18GH 416.. ATAC 412.. CAAC 348.. ACAC 432.. ACAC 546.. AC 22 419 421 ATACAG 351 435 547 (SEQ ID NO: 380) 417.. TACA 434.. AC 420 435 TN90 18GH 414.. ACAT 414.. ACAT 348.. AC 432.. AC 546.. ACA 34 417 417 349 433 549 C 548.. AC 549 TN90 18GH 414.. ACAT 414.. ACAT 348.. ACAC 430.. CAACACA 546.. ACA 473 417 417 351 436 549 C 433.. CACA 548.. AC 436 549 TN90 18GH 412.. CAAC 412.. CAAC 348.. ACAC 432.. AC 546.. AC 49 421 ATACAG 418 ATA 351 433 547 (SEQ ID NO: 380) TN90 18GH 412.. CAAC 412.. CAAC 348 ACAC 432.. AC 546.. AC 50 421 ATACAG 418 ATA 351.. 433 547 (SEQ ID NO: 380) 414.. ACAT 420 ACA TN90 18GH 414.. ACAT 412.. CAAC 348.. ACAC 432.. AC 546.. ACA 848 418 A 418 ATA 351 433 549 C 415.. CATA 415.. CATA 350.. AC 548.. AC 421 CAG 418 351 549 TN90 18GH 414.. ACAT 416.. ATAC 348.. AC 435.. CACA 546.. AC 850 417 422 AGA 349 438 547 417.. TACA 436.. ACAG 550.. ACA 420 439 553 G TN90 18GH 414.. ACAT 416.. ATAC 348.. AC 435.. CACA 546.. AC 851 417 422 AGA 349 438 547 417.. TACA 436.. ACAG 550.. ACA 420 439 553 G TN90 17GH 419.. CA 413.. AACA 348.. ACAC 429.. TCAACACA 546.. AC 1699 420 420 TACA 351 438 CA 547 (SEQ ID  NO: 395) 418.. ACAG 419.. CA 349.. C 432.. ACACACAG 423 AG 420 349 446 AGAAT GG (SEQ 427.. G ID NO: 427 399) TN90 17GH 414.. ACAT 414.. AC 346.. CAACACA 432.. ACACAC - - 1708 417 415 355 CAG 437 418.. ACAG (SEQ ID 440.. AGAA 424 AGA NO: 390) 443 419.. CA 420 TN90 17GH 415.. CATA 414.. ACAT 348.. ACAC 432.. AC 546.. ACA 1722 420 CA 417 351 433 549 C 418.. ACAG 350.. AC 435.. CACAG 421 351 439 TN90 17GH 416.. ATAC 414.. ACAT 348.. ACAC 432.. ACAC 550.. ACA 1724 421 AG 417 351 435 553 G 417.. TACA 434.. AC 420 435 TN90 17GH 416.. ATAC 414.. ACAT 348.. ACAC 432.. ACAC 550.. ACA 1725 421 AG 417 351 435 553 G 417.. TACA 434.. AC 420 435 TN90 17GH 416.. ATA 412.. CAAC 348.. ACAC 433.. CACAC 546.. ACA 1845 418 418 ATA 351 437 551 CAC 418.. AC 415.. CATA 436.. AC 550.. AC 419 418 437 551 TN90 17GH 415.. CATA 414.. ACAT 348.. ACAC 432.. AC 546.. ACA 1846 420 CA 417 351 433 549 418.. ACAG 350.. AC 435.. CACAG C 421 351 439 TN90 17GH 415.. CATA 414.. ACAT 348.. ACAC 432.. AC 546.. ACA 1847 420 CA 417 351 433 549 C 418.. ACAG 350.. AC 435.. CACAG 421 351 439 TN90 17GH 414.. ACAT 417.. TACA 348.. AC 432.. AC 546.. ACA 1911 417 420 349 433 549 C 417.. TACA 423 GAG TN90 17GH 414.. ACAT 417.. TACA 348.. AC 432.. AC 546.. ACA 1912 417 420 349 433 549 C 417.. TACA 423 GAG TN90 17GH — — 414.. ACAT — — 432.. ACAC — — 1915 417 435 TN90 17GH 414.. ACAT 417.. TACA 353.. CAGAGAAT 432.. ACAC 544.. CAA 1918 419 AC 420 361 G 435 550 CACA 554.. A 554 416.. ATAC 418.. ACAG 558.. TGG 419 421 563 TGG 565.. TT 566 569.. CAT 572 A TN90 17GH 412.. CAAC 414.. ACAT 432.. ACACACAG 546.. AC 1928 418 ATA 417 448 AGAATGGT  547 G (SEQ ID NO: 400) 415.. CATA 419.. CAG 437.. CA 418 421 438 TN90 17GH 414.. ACAT 416.. ATAC — — — — 546.. ACA 1932 419 AC 419 551 CAC 416.. ATAC 418.. AC 419 419 TN90 17GH 414.. ACAT 416.. ATAC 350.. ACACAG 413.. CT 546.. ACA 1933 419 AC 419 355 414 551 CAC 418.. GA 419 416.. ATAC 418.. AC 351.. CACA 426.. AA 419 419 354 427 431.. AA 432 432.. ACAC 435 TN90 17GH 413.. AACA 416.. ATAC 348.. ACAC 432.. AC 544.. CAA 1936 421 TACA 419 351 433 550 CAC G A 417.. TACA 418.. AC 350.. AC 547.. CAC 420 419 351 550 A TN90 18GH 414.. ACAT 348.. AC 432.. AC 546.. ACA 20 419 AC 349 433 549 C 352.. ACAG 548.. AC 355 549 TN90 18GH 414.. ACAT 416.. ATAC 348.. AC 436.. ACAG 546.. ACA 47 419 AC 419 349 439 549 C 418.. AC 419 424.. AA 425 TN90 18GH 414.. ACAT 414.. ACAT 348.. ACAC 433.. CACAC 546.. ACA 28 419 AC 417 351 437 549 C 416.. ATAC 350.. AC 548.. AC 419 351 549 TN90 18GH 414.. ACAT 416.. ATAC 348.. AC 436.. ACAG 546.. ACA 31 419 AC 419 349 439 549 C 418.. AC 419 424.. AA 425

TABLE 4C Mutant pmt alleles in NLMz produced by genome editing using GET2. NLMz refers to the Narrow Leaf Madole variety containing triple loss-of-function mutations in three nicotine demethylase genes (CYP82E4, CYP82E5v2, and CYP82E10). PMT1b PMT1a PMT2 PMT3 PMT4 VA- Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted RIETY LINE ition sequence ition sequence ition sequence ition sequence ition sequence NL 18GH10 414.. ACAT 414.. ACAT 350.. AC 431.. AACACACA 546.. ACAC Mz 417 417 351 441 GAG (SEQ 549 ID NO: 391) NL 18GH 414.. ACAT 412.. CAACATA 348.. AC 430.. CAACACA 546.. ACAC Mz 1004 417 418 349 436 553 ACAG 416.. A 435.. CA 551.. CA 416 436 552 NL 18GH 414.. ACAT 412.. CAACATA 348.. AC 430.. CAACACA 546.. ACAC Mz 1033 417 418 349 436 553 ACAG 416.. A 435.. CA 551.. CA 416 436 552 NL 18GH 417.. TA 416.. ATAC 348.. ACACA 432.. ACACAC 546.. AC Mz 132 418 419 352 437 547 418.. AC 348.. ACACAC 434.. ACAC 419 353 437 436.. AC 437 NL 18GH 414.. ACAT 414.. ACATACAG 348.. ACAC 433.. CACACAG 550.. ACAG Mz 134 417 423 AG (SEQ 351 439 556 AGA ID NO: 388) 419.. CA 420 NL 18GH 414.. ACAT 415.. CATAC 346.. CAACACA 432.. ACAC 545.. AACA Mz 217 417 419 352 435 557 CACA GAGA A (SEQ ID NO: 407) 417.. TA 351.. CA 551.. CA 418 352 552 NL 18GH 416.. ATAC 414.. ACAT 348.. AC 432.. AC 546.. ACAC Mz 456 419 417 349 433 549 418.. AC 419 NL 18GH 414.. ACAT 414.. ACAT 348.. AC 432.. AC 546.. ACAC Mz 457 417 417 349 433 549 NL 18GH 414.. ACAT 409.. ATTCAACA 350.. ACACAGAG 436.. ACAG 550.. ACAG Mz 460 417 420 TACA (SEQ 363 AATGGT 439 553 ID NO: (SEQ ID 383) NO: 393) 416.. ATACAGAG 351.. CACA 429 AATGGT 354 (SEQ ID 353.. CA NO: 389) 354 NL 18GH 414.. ACAT 412.. CAACATA 348.. AC 430.. CAACACA 546.. ACAC Mz 465 417 418 349 436 553 ACAG 416.. A 435.. CA 551.. CA 416 436 552 NL 18GH 414.. ACAT 414.. ACAT 348.. ACAC 432.. ACAC 550.. ACAG Mz 830 417 417 351 435 553 NL 18GH 413.. AACATACA 413.. AACATACA 348.. ACAC 546.. AC Mz 831 428 GAGAATGG 428 GAGAATGG 351 547 (SEQ ID (SEQ ID NO: 381) NO: 381) 417.. TACA 420 NL 18GH 414.. ACAT 414.. ACAT 348.. AC 432.. AC 546.. ACAC Mz 836 417 417 349 433 549 NL 18GH 415.. CATACAG 413.. AACATACA 347.. AACACACA 546.. AC Mz 841 421 420 357 GAG (SEQ 547 ID NO: 391) 419.. CA 414.. ACATACA 420 420 NL 18GH 411.. TCAACATA 411.. TCAACATA 351.. CACA 432.. AC 546.. ACAC Mz 974 420 CA (SEQ 420 CA (SEQ 354 433 549 ID NO: ID NO: 379) 379) 417.. TACA 353.. CA 436.. ACAG 420 354 439 NL 18GH 412.. CAACATA 414.. ACAT 346.. CAACACA 429.. TCAACACA 546.. ACAC Mz 981 418 417 352 439 CAG (SEQ 552 ACA ID NO: 396) 349.. CACA 431.. AACACACA 546.. ACAC 352 441 GAG (SEQ 553 ACAG ID NO: 391) NL 18GH 414.. ACAT 412.. CAACATA 348.. AC 430.. CAACACA 546.. ACAC Mz 994 417 418 349 436 553 ACAG 416.. A 435.. CA 551.. CA 416 436 552 NL 18GH 414.. ACATACA 348.. ACAC 546.. AC Mz 128 420 351 547 417.. TACAG 350.. AC 421 351 NL 18GH 414.. ACATACAG 412.. CAACATA 349.. CACACAG 430.. CAACACA 546.. ACAC Mz 130 437 AGAATGGT 418 355 436 549 GGATTTCC (SEQ ID NO: 382) 417.. TACA 415.. CATA 420 418 NL 18GH 417.. TA 416.. ATAC 348.. ACACAC — — 546.. AC Mz 131 418 419 353 547 417.. TAC 350.. ACAC 419 353 418.. AC 419 NL 18GH 413.. AACATAC 414.. ACATACA 348.. ACAC — — 546.. AC Mz 133 419 420 351 547 414.. ACATAC 417.. TACA 350.. AC 419 420 351 417.. TACAG 421 NL 18GH — — — — 348.. AC — — — — Mz 136 349 NL 18GH 412.. CAACATA 414.. ACATAC 347.. AACACACA 432.. AC 546.. ACAC Mz 216 418 419 354 433 549 415.. CATA 416.. ATAC 548.. AC 418 419 549 NL 18GH 418.. AC 414.. ACAT 348.. ACAC 546.. ACAC Mz 227 419 417 351 549 NL 18GH 414.. ACAT 414.. ACATACA 352.. ACAG 429.. TCAACAC 546.. ACAC Mz 5 417 420 355 435 551 AC 415.. CATACAG 432.. ACAC 548.. ACAC 421 435 551 NL 18GH 414.. ACAT 416.. ATACAGAG 350.. ACACAGAG 436.. ACAG 550.. ACAG Mz 6 417 429 AATGGT 363 AATGGT 439 553 (SEQ ID (SEQ ID NO: 389) NO: 393) 417.. TACAGA 351.. CACAGA 422 356 353.. CAGA 356 NL 18GH 416.. ATACAGAG 414.. ACATAC 348.. ACAC 433.. CACAC 546.. ACAC Mz 65 423 419 351 437 549 418.. ACA 417.. TAC 350.. AC 436.. AC 420 419 351 437 NL 18GH 414.. ACAT 414.. ACATACA 352.. ACAG 429.. TCAACAC 546.. ACAC Mz 66 417 420 355 435 551 AC 415.. CATACAG 432.. ACAC 548.. ACAC 421 435 551 NL 18GH 411.. TCAACATA 432.. AC 546.. ACAC Mz 69 420 CA (SEQ 433 549 ID NO: 436.. ACAG 379) 439 NL 18GH 416.. ATACAGAG 414.. ACATAC 348.. ACAC 433.. CACAC 546.. ACAC Mz 72 423 419 351 437 549 418.. ACA 417.. TAC 350.. AC 436.. AC 420 419 351 437 NL 18GH — — 414.. ACATACA 348.. ACAC — — 546.. AC Mz 73 420 351 547 417.. TACAG 350.. AC 421 351 NL 18GH — — 412.. CAACATA — — — — — — Mz 74 418 NL 18GH 414.. ACATAC 414.. ACAT 348.. AC 431.. A 546.. ACAC Mz 78 419 417 349 431 549 434.. ACACA 548.. AC 438 549 435.. CACA 438 NL 18GH — — 414.. ACATACA 348.. ACAC — — 546.. AC Mz 79 420 351 547 417.. TACAG 350.. AC 421 351 NL 18GH 417.. TACA 416.. ATACAG 348.. ACACACA 435.. CACAGAG 549.. CACA Mz 8 420 421 354 447 AATGGT 552 (SEQ ID NO: 401) 417.. TACA 350.. ACACA 549.. CACA 420 354 553 G NL 18GH 417.. TA 416.. ATAC 348.. ACACAC — — 546.. AC Mz 9 418 419 353 547 418.. AC 419 NL 18GH 414.. ACAT 414.. ACAT 348.. ACAC 431.. AACACACA 546.. ACAC Mz 71 417 417 351 441 GAG (SEQ 549 ID NO: 391) NL 17GH 414.. ACAT 414.. ACATACA 352.. ACAG 429.. TCAACAC 546.. ACAC Mz 1905 417 420 355 435 551 AC 415.. CATACAG 432.. ACAC 548.. ACAC 421 435 551

TABLE 4D Mutant pmt alleles in oriental tobacco produced by genome editing using GET2. PMT1b PMT1a PMT2 PMT3 PMT4 Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted Pos- Deleted VARIETY LINE ition sequence ition sequence ition sequence ition sequence ition sequence Kat- 18GH 412.. CAAC 416.. ATAC 348.. ACACA 432.. ACAC 546.. AC erini 125 418 ATA 419 355 CAG 435 547 414.. ACAT 418.. AC 434.. AC 418 A 419 435 Basma 18GH 414.. ACAT 412.. CAAC 348.. ACACA 432.. ACAC 546.. ACAC 203 417 418 ATA 357 CAGAG 435 549 (SEQ ID NO: 392) 415.. CATA 353.. CA 434.. AC 418 354 435 Kat- 18GH 416.. ATAC 414.. ACAT 352.. ACAG 432.. ACACAC 546.. ACACACAG erini 208 419 417 355 441 AGAG 553 (SEQ ID NO: 392) 418.. AC 435.. CACA 419 438 Basma 18GH 414.. ACAT 412.. CAAC 348.. ACACA 432.. ACAC 546.. ACAC 134 417 418 ATA 357 CAGAG 435 549 (SEQ ID NO: 392) 415.. CATA 353.. CA 434.. AC 418 354 435 Kat- 18GH 414.. ACAT 414.. ACAT 348.. ACAC 432.. ACAC erini 403 417 417 351 435 Kat- 18GH 412.. CAAC 414.. ACAT 348.. AC 430.. CAACAC 546.. AC erini 414 418 ATA 417 349 436 A 547 415.. CATA 418 Kat- 18GH 413.. AACA 414.. ACAT 351.. CACAG 433.. CACACA 546.. AC erini 434 420 TACA 417 357 AG 439 G 547 417.. TACA 437.. CA 420 438 Kat- 18GH 412.. CAAC 414.. ACAT 346.. CAACA 432.. AC 546.. AC erini 436 418 ATA 421 ACAG 352 CA 433 547 415.. CA 436.. ACAGAG 416 443 AA 445.. GGTGG 449 451.. TTTCCAT 463 ACACTG (SEQ ID NO: 402) Kat- 18GH 414.. ACAT 414.. ACAT 348. AC 433.. CACACA 544.. CAACACAC erini 437 417 417 439 G 553 AG (SEQ ID NO: 390) 416.. AT .349 435.. CACA 551.. CA 417 438 552 Kat- H18G 414.. ACAT 413.. AACA 348.. AC 432.. ACAC 546.. ACAC erini 449 417 419 TAC 349 435 549 415.. CA 418.. AC 416 419 Kat- 18GH 416.. ATAC 414.. ACAT 348.. ACAC 432.. ACACAC 545.. AACACACA erini 706 420 A 417 351 439 AG 555 GAG 419.. CA 435.. CACA (SEQ ID 420 438 NO: 391) Kat- 18GH 412.. CAAC 414.. ACAT 348.. AC 432.. ACAC 546.. AC erini 709 418 ATA 417 349 435 547 417.. TA 416.. AT 418 417 Kat- 18GH 414.. ACAT 414.. ACAT 351.. CACA 432.. ACAC 546.. AC erini 710 417 417 354 435 547 352.. ACAG 434.. AC 355 435 Kat- 18GH 416.. ATAC 417.. TACA 348.. ACAC 432.. ACACAC 546.. ACAC erini 716 419 420 351 439 AG 549 418.. AC 417.. TACA 435.. CACA 548.. AC 419 421 G 438 549 Kat- 18GH 414.. ACAT 414.. ACAT 350.. ACACA 432.. ACAC 546.. AC erini 729 417 417 357 GAG 435 547 353.. CA 354 Kat- 18GH 414.. ACAT 414.. ACAT 348.. ACAC 433.. C 544.. CAACACAC erini 731 417 417 351 433 553 AG (SEQ 435.. CACAG ID NO: 439 390) Kat- 18GH 416.. ATAC 414.. ACAT 348.. AC 432.. ACAC 546.. ACAC erini 752 419 417 349 435 549 418.. AC 419 Kat- 18GH 416.. ATAC 414.. ACAT 353.. CA 433.. CACACA 545.. AACACACA erini 756 419 417 354 439 G 555 GAG (SEQ ID NO: 391) 416.. ATAC 414.. ACAT 353.. CA 433.. CACACA 545.. AACACACA 419 417 354 439 G 555 GAG (SEQ ID NO: 391) 437.. CA 549.. CACA 438 552 Kat- 18GH 416.. ATAC 414.. ACAT 348.. ACAC 432.. AC 544.. CAACACA erini 768 419 417 351 433 550 547.. CACA 550 Kat- 18GH 416.. ATAC 414.. ACAT 346.. CAACA 432.. ACAC 546.. AC erini 771 419 417 352 CA 435 547 349.. CACA 434.. AC 352 435 Kat- 18GH 409.. ATTC 411.. TCAA 348.. ACAC 441.. G 546.. ACAC erini 776 415 AAC 417 CAT 351 441 549 418.. AC 414.. ACAT 548.. AC 419 417 549 Kat- 18GH 412.. CAAC 414.. ACAT 348.. ACAC 432.. ACAC 541.. ATTCAACA erini 800 418 ATA 420 ACA 351 435 551 CAC (SEQ ID NO: 403) 415.. CATA 416.. ATAC 548.. ACAC 418 420 A 551 Kat- 18GH 414.. ACAT 409.. ATTC 348.. ACAC 432.. ACAC — — erini 818 417 415 AAC 351 435 434.. AC 435

TABLE 4E Mutant pmt alleles in NLM (Ph Ph) tobacco produced by genome editing using GET1. PMT1b PMT1a PMT2 PMT3 PMT4 Position Position Position Position Position from from from from from LINE Modification ATG ATG ATG ATG ATG CS15 A-deleted 131 A-inserted 132 A-deleted 98 A-deleted 98 A-del 131 T-deleted 262 T-deleted 196 T-deleted 282

TABLE 5A A list of exemplary mutant alleles obtained in the PMTIb gene. Mutant allele sequences listed here and Tables 5B to 5E represent about 40-nucleotide-long genomic sequences from each edited PMT gene with the edited site in the middle of the genomic sequence (e.g., 20 nucleotides on each side of the deleted or inserted sequence site). These mutant alleles corresponds to those listed in Tables 4A to 4E. PMT1b Mutant Reference Deleted Allele Allele sequence Sequence Sequence Pos- (SEQ ID (SEQ ID Mutant (SEQ ID ition No.) No.) Allele Sequence No.) Reference Allele Sequence 131... A 23 TGGCATTTCCAAACACCAA 201 TGGCATTTCCAAACACCAAAaCGGGCACCA 131 ACGGGCACCAGAATGGCAC GAATGGCACTT TT 262... T 24 CCAACTCTATTAAGCCTGGT 202 CCAACTCTATTAAGCCTGGTtGGTTTTCAGA 262 GGTTTTCAGAGTTTAGCGCA GTTTAGCGCA 409.. ATTCAAC 25 TTCTGACTTTGGATGGAGCA 203 TTCTGACTTTGGATGGAGCAattcaacATACAG 415 ATACAGAGAATGGTGGATT AGAATGGTGGATTT T 411.. TCAACATACA 26 CTGACTTTGGATGGAGCAA 204 CTGACTTTGGATGGAGCAATtcaacatacaGAGA 420 (379) TGAGAATGGTGGATTTCCA ATGGTGGATTTCCATA TA 412.. CAACATA 27 TGACTTTGGATGGAGCAAT 205 TGACTTTGGATGGAGCAATTcaacataCAGAGA 418 TCAGAGAATGGTGGATTTC ATGGTGGATTTCCA CA 412.. CAACATACAG 28 TGACTTTGGATGGAGCAAT 206 TGACTTTGGATGGAGCAATTcaacatacagAGAA 421 (380) TAGAATGGTGGATTTCCAT TGGTGGATTTCCATAC AC 413.. AACATAC 29 GACTTTGGATGGAGCAATT 207 GACTTTGGATGGAGCAATTCaacatacAGAGAA 419 CAGAGAATGGTGGATTTCC TGGTGGATTTCCAT AT 413.. AACATACA 30 GACTTTGGATGGAGCAATT 208 GACTTTGGATGGAGCAATTCaacatacaGAGAA 420 CGAGAATGGTGGATTTCCA TGGTGGATTTCCATA TA 413.. AACATACAG 31 GACTTTGGATGGAGCAATT 209 GACTTTGGATGGAGCAATTCaacatacagAGAA 421 CAGAATGGTGGATTTCCAT TGGTGGATTTCCATAC AC 413.. AACATACAGAGA 32 GACTTTGGATGGAGCAATT 210 GACTTTGGATGGAGCAATTCaacatacagagaa 428 ATGG(381) CTGGATTTCCATACACTGAA tggTGGATTTCCATACACTGAAA A 414.. ACAT 33 ACTTTGGATGGAGCAATTC 211 ACTTTGGATGGAGCAATTCAacatACAGAGA 417 AtACAGAGAATGGTGGATTT ATGGTGGATTTCC CC 414.. ACATA 34 ACTTTGGATGGAGCAATTC 212 ACTTTGGATGGAGCAATTCAacataCAGAGAA 418 ACAGAGAATGGTGGATTTC TGGTGGATTTCCA CA 414.. ACATAC 35 ACTTTGGATGGAGCAATTC 213 ACTTTGGATGGAGCAATTCAacatacAGAGAA 419 AAGAGAATGGTGGATTTCC TGGTGGATTTCCAT AT 414.. ACATACA 36 ACTTTGGATGGAGCAATTC 214 ACTTTGGATGGAGCAATTCAacatacaGAGAAT 420 AGAGAATGGTGGATTTCCA GGTGGATTTCCATA TA 414.. ACATACAGAGAA 37 ACTTTGGATGGAGCAATTC 215 ACTTTGGATGGAGCAATTCAacatacagagaat 437 TGGTGGATTTCC AATACACTGAAATGATTGT ggtggatttccATACACTGAAATGATTGTTC (382) TC 415.. CA 38 CTTTGGATGGAGCAATTCA 216 CTTTGGATGGAGCAATTCAAcaTACAGAGAA 416 ATACAGAGAATGGTGGATT TGGTGGATTTC TC 415.. CATA 39 CTTTGGATGGAGCAATTCA 217 CTTTGGATGGAGCAATTCAAcataCAGAGAAT 418 ACAGAGAATGGTGGATTTC GGTGGATTTCCA CA 415.. CATACA 40 CTTTGGATGGAGCAATTCA 218 CTTTGGATGGAGCAATTCAAcatacaGAGAAT 420 AGAGAATGGTGGATTTCCA GGTGGATTTCCATA TA 415.. CATACAG 41 CTTTGGATGGAGCAATTCA 219 CTTTGGATGGAGCAATTCAAcatacagAGAATG 421 AAGAATGGTGGATTTCCAT GTGGATTTCCATAC AC 416.. A 42 TTTGGATGGAGCAATTCAA 220 TTTGGATGGAGCAATTCAACaTACAGAGAA 416 CTACAGAGAATGGTGGATT TGGTGGATTTC TC 416.. ATA 43 TTTGGATGGAGCAATTCAA 221 TTTGGATGGAGCAATTCAACataCAGAGAAT 418 CCAGAGAATGGTGGATTTC GGTGGATTTCCA CA 416.. ATAC 44 TTTGGATGGAGCAATTCAA 222 TTTGGATGGAGCAATTCAACatacAGAGAATG 419 CAGAGAATGGTGGATTTCC GTGGATTTCCAT AT 416.. ATACA 45 TTTGGATGGAGCAATTCAA 223 TTTGGATGGAGCAATTCAACatacaGAGAATG 420 CGAGAATGGTGGATTTCCA GTGGATTTCCATA TA 416.. ATACAG 46 TTTGGATGGAGCAATTCAA 224 TTTGGATGGAGCAATTCAACatacagAGAATG 421 CAGAATGGTGGATTTCCAT GTGGATTTCCATAC AC 416.. ATACAGAG 47 TTTGGATGGAGCAATTCAA 225 TTTGGATGGAGCAATTCAACatacagagAATGG 423 CAATGGTGGATTTCCATAC TGGATTTCCATACAC AC 417.. TA 48 TTGGATGGAGCAATTCAAC 226 TTGGATGGAGCAATTCAACAtaCAGAGAATG 418 ACAGAGAATGGTGGATTTC GTGGATTTCCA CA 417.. TACA 49 TTGGATGGAGCAATTCAAC 227 TTGGATGGAGCAATTCAACAtacaGAGAATG 420 AGAGAATGGTGGATTTCCA GTGGATTTCCATA TA 418.. AC 50 TGGATGGAGCAATTCAACA 228 TGGATGGAGCAATTCAACATacAGAGAATG 419 TAGAGAATGGTGGATTTCC GTGGATTTCCAT AT 418.. ACA 51 TGGATGGAGCAATTCAACA 229 TGGATGGAGCAATTCAACATacaGAGAATGG 420 TGAGAATGGTGGATTTCCA TGGATTTCCATA TA 418.. ACAG 52 TGGATGGAGCAATTCAACA 230 TGGATGGAGCAATTCAACATacagAGAATGG 421 TAGAATGGTGGATTTCCAT TGGATTTCCATAC AC 418.. ACAGAG 53 TGGATGGAGCAATTCAACA 231 TGGATGGAGCAATTCAACATacagagAATGGT 423 TAATGGTGGATTTCCATACA GGATTTCCATACAC c 419.. CA 54 GGATGGAGCAATTCAACAT 232 GGATGGAGCAATTCAACATAcaGAGAATGG 420 AGAGAATGGTGGATTTCCA TGGATTTCCATA TA 427.. G 55 CAATTCAACATACAGAGAA 233 CAATTCAACATACAGAGAATgGTGGATTTC 427 TGTGGATTTCCATACACTGA CATACACTGAA A

TABLE 5B A list of exemplary mutant alleles obtained in the PMTla gene. PMT1a Mutant Reference Allele Allele Deleted Sequence Sequence Pos- sequence (SEQ ID Mutant (SEQ ID ition (SEQ ID No.) No.) Allele Sequence No.) Reference Allele Sequence 132... A inserted 56 GCACTTCCAAACACCAAAACa 234 GCACTTCCAAACACCAAAACGGGCA 132 GGGCACCAGAATGGCACTTT CCAGAATGGCACTTT 409.. ATTCAAC 57 TTCTGACTTTGGATGGAGCAA 235 TTCTGACTTTGGATGGAGCAattcaacAT 415 TACAGAGAATGGTGGATTT ACAGAGAATGGTGGATTT 409.. ATTCAACATACA 58 TTCTGACTTTGGATGGAGCAG 236 TTCTGACTTTGGATGGAGCAattcaacatac 420 (383) AGAATGGTGGATTTCCATA aGAGAATGGTGGATTTCCATA 411.. TCAACAT 59 CTGACTTTGGATGGAGCAATA 237 CTGACTTTGGATGGAGCAATtcaacatAC 417 CAGAGAATGGTGGATTTCC AGAGAATGGTGGATTTCC 411.. TCAACATACA 60 CTGACTTTGGATGGAGCAATG 238 CTGACTTTGGATGGAGCAATtcaacataca 420 (384) AGAATGGTGGATTTCCATA GAGAATGGTGGATTTCCATA 412.. CAACATA 61 TGACTTTGGATGGAGCAATTC 239 TGACTTTGGATGGAGCAATTcaacataCA 418 AGAGAATGGTGGATTTCCA GAGAATGGTGGATTTCCA 412.. CAACATACAG 62 TGACTTTGGATGGAGCAATTA 240 TGACTTTGGATGGAGCAATTcaacatacag 421 (385) GAATGGTGGATTTCCATAC AGAATGGTGGATTTCCATAC 413.. AACATAC 63 GACTTTGGATGGAGCAATTCA 241 GACTTTGGATGGAGCAATTCaacatacA 419 GAGAATGGTGGATTTCCAT GAGAATGGTGGATTTCCAT 413.. AACATACA 64 GACTTTGGATGGAGCAATTCG 242 GACTTTGGATGGAGCAATTCaacatacaG 420 AGAATGGTGGATTTCCATA AGAATGGTGGATTTCCATA 413.. AACATACAG 65 GACTTTGGATGGAGCAATTCA 243 GACTTTGGATGGAGCAATTCaacatacag 421 GAATGGTGGATTTCCATAC AGAATGGTGGATTTCCATAC 413.. AACATACAGA 66 GACTTTGGATGGAGCAATTCG 244 GACTTTGGATGGAGCAATTCaacatacag 422 (386) AATGGTGGATTTCCATACA aGAATGGTGGATTTCCATACA 413.. AACATACAGAG 67 GACTTTGGATGGAGCAATTCT 245 GACTTTGGATGGAGCAATTCaacatacag 428 AATGG (387) GGATTTCCATACACTGAAA agaatggTGGATTTCCATACACTGAAA 414.. AC 68 ACTTTGGATGGAGCAATTCAA 246 ACTTTGGATGGAGCAATTCAacATAC 415 TACAGAGAATGGTGGATTT AGAGAATGGTGGATTT 414.. ACAT 69 ACTTTGGATGGAGCAATTCAA 247 ACTTTGGATGGAGCAATTCAacatACA 417 CAGAGAATGGTGGATTTCC GAGAATGGTGGATTTCC 414.. ACATAC 70 ACTTTGGATGGAGCAATTCAA 248 ACTTTGGATGGAGCAATTCAacatacAG 419 GAGAATGGTGGATTTCCAT AGAATGGTGGATTTCCAT 414.. ACATACA 71 ACTTTGGATGGAGCAATTCAG 249 ACTTTGGATGGAGCAATTCAacatacaG 420 AGAATGGTGGATTTCCATA AGAATGGTGGATTTCCATA 414.. ACATACAG 72 ACTTTGGATGGAGCAATTCAA 250 ACTTTGGATGGAGCAATTCAacatacagA 421 GAATGGTGGATTTCCATAC GAATGGTGGATTTCCATAC 414.. ACATACAGAG 73 ACTTTGGATGGAGCAATTCAA 251 ACTTTGGATGGAGCAATTCAacatacaga 423 (388) ATGGTGGATTTCCATACAC gAATGGTGGATTTCCATACAC 415.. C 74 CTTTGGATGGAGCAATTCAAA 252 CTTTGGATGGAGCAATTCAAcATACA 415 TACAGAGAATGGTGGATTT GAGAATGGTGGATTT 415.. CA 75 CTTTGGATGGAGCAATTCAAT 253 CTTTGGATGGAGCAATTCAAcaTACA 416 ACAGAGAATGGTGGATTTC GAGAATGGTGGATTTC 415.. CATA 76 CTTTGGATGGAGCAATTCAAC 254 CTTTGGATGGAGCAATTCAAcataCAG 418 AGAGAATGGTGGATTTCCA AGAATGGTGGATTTCCA 415.. CATAC 77 CTTTGGATGGAGCAATTCAAA 255 CTTTGGATGGAGCAATTCAAcatacAGA 419 GAGAATGGTGGATTTCCAT GAATGGTGGATTTCCAT 415.. CATACAG 78 CTTTGGATGGAGCAATTCAAA 256 CTTTGGATGGAGCAATTCAAcatacagA 421 GAATGGTGGATTTCCATAC GAATGGTGGATTTCCATAC 416.. AT 79 TTTGGATGGAGCAATTCAACtA 257 TTTGGATGGAGCAATTCAACatACAGA 417 CAGAGAATGGTGGATTTCC GAATGGTGGATTTCC 416.. ATAC 80 TTTGGATGGAGCAATTCAACA 258 TTTGGATGGAGCAATTCAACatacAGA 419 GAGAATGGTGGATTTCCAT GAATGGTGGATTTCCAT 416.. ATACA 81 TTTGGATGGAGCAATTCAACG 259 TTTGGATGGAGCAATTCAACatacaGAG 420 AGAATGGTGGATTTCCATA AATGGTGGATTTCCATA 416.. ATACAG 82 TTTGGATGGAGCAATTCAACA 260 TTTGGATGGAGCAATTCAACatacagAG 421 GAATGGTGGATTTCCATAC AATGGTGGATTTCCATAC 416.. ATACAGA 83 TTTGGATGGAGCAATTCAACG 261 TTTGGATGGAGCAATTCAACatacagaG 422 AATGGTGGATTTCCATACA AATGGTGGATTTCCATACA 416.. ATACAGAGAAT 84 TTTGGATGGAGCAATTCAACG 262 TTTGGATGGAGCAATTCAACatacagaga 429 GGT (389) GATTTCCATACACTGAAAT atggtGGATTTCCATACACTGAAAT 417.. T 85 TTGGATGGAGCAATTCAACAA 263 TTGGATGGAGCAATTCAACAtACAGA 417 CAGAGAATGGTGGATTTCC GAATGGTGGATTTCC 417.. TA 86 TTGGATGGAGCAATTCAACAC 264 TTGGATGGAGCAATTCAACAtaCAGA 418 AGAGAATGGTGGATTTCCA GAATGGTGGATTTCCA 417.. TAC 87 TTGGATGGAGCAATTCAACAA 265 TTGGATGGAGCAATTCAACAtacAGAG 419 GAGAATGGTGGATTTCCAT AATGGTGGATTTCCAT 417.. TACA 88 TTGGATGGAGCAATTCAACAG 266 TTGGATGGAGCAATTCAACAtacaGAG 420 AGAATGGTGGATTTCCATA AATGGTGGATTTCCATA 417.. TACAG 89 TTGGATGGAGCAATTCAACAA 267 TTGGATGGAGCAATTCAACAtacagAG 421 GAATGGTGGATTTCCATAC AATGGTGGATTTCCATAC 417.. TACAGA 90 TTGGATGGAGCAATTCAACAG 268 TTGGATGGAGCAATTCAACAtacagaGA 422 AATGGTGGATTTCCATACA ATGGTGGATTTCCATACA 417.. TACAGAG 91 TTGGATGGAGCAATTCAACAA 269 TTGGATGGAGCAATTCAACAtacagagA 423 ATGGTGGATTTCCATACAC ATGGTGGATTTCCATACAC 418.. AC 92 TGGATGGAGCAATTCAACATA 270 TGGATGGAGCAATTCAACATacAGAG 419 GAGAATGGTGGATTTCCAT AATGGTGGATTTCCAT 418.. ACAG 93 TGGATGGAGCAATTCAACATA 271 TGGATGGAGCAATTCAACATacagAGA 421 GAATGGTGGATTTCCATAC ATGGTGGATTTCCATAC 418.. ACAGAGA 94 TGGATGGAGCAATTCAACATA 272 TGGATGGAGCAATTCAACATacagagaA 424 TGGTGGATTTCCATACACT TGGTGGATTTCCATACACT 419.. CA 95 GGATGGAGCAATTCAACATAG 273 GGATGGAGCAATTCAACATAcaGAGA 420 AGAATGGTGGATTTCCATA ATGGTGGATTTCCATA 419.. CAG 96 GGATGGAGCAATTCAACATAA 274 GGATGGAGCAATTCAACATAcagAGA 421 GAATGGTGGATTTCCATAC ATGGTGGATTTCCATAC 424.. AA 97 GAGCAATTCAACATACAGAGT 275 GAGCAATTCAACATACAGAGaaTGGT 425 GGTGGATTTCCATACACTG GGATTTCCATACACTG

TABLE 5C A list of exemplary mutant alleles obtained in the PMT2 gene. PMT2 Mutant Reference Deleted Allele Allele sequence Sequence Sequence (SEQ (SEQ ID Mutant Allele (SEQ ID Position ID No.) No.) Sequence No.) Reference Allele Sequence  98...98 A  98 TGGCACTTCCAAACACCA 276 TGGCACTTCCAAACACCAAAaCG AACGGCCACAAGAATGGG GCCACAAGAATGGGACTT ACTT 196...196 T  99 CCAATTGTATTAAGCCTGG 277 CCAATTGTATTAAGCCTGGTtGG TGGTTTTCAGAGTTTAGCG TTTTCAGAGTTTAGCGCA CA 346..350 CAACA 100 TGACTTTGGATGGAGCAAT 278 TGACTTTGGATGGAGCAATTcaac TCACAGAGAATGGTGGAT aCACAGAGAATGGTGGATTTC TTC 346..352 CAACACA 101 TGACTTTGGATGGAGCAAT 279 TGACTTTGGATGGAGCAATTcaac TCAGAGAATGGTGGATTTC acaCAGAGAATGGTGGATTTCCA CA 346..355 CAACACACA 102 TGACTTTGGATGGAGCAAT 280 TGACTTTGGATGGAGCAATTcaac G (390) TAGAATGGTGGATTTCCAT acacagAGAATGGTGGATTTCCATA AC C 347..354 AACACACA 103 GACTTTGGATGGAGCAATT 281 GACTTTGGATGGAGCAATTCaaca CGAGAATGGTGGATTTCC cacaGAGAATGGTGGATTTCCATA ATA 347..357 AACACACAG 104 GACTTTGGATGGAGCAATT 282 GACTTTGGATGGAGCAATTCaaca AG (391) CAATGGTGGATTTCCATAC cacagagAATGGTGGATTTCCATAC AC AC 348..349 AC 105 ACTTTGGATGGAGCAATTC 283 ACTTTGGATGGAGCAATTCAacA AACACAGAGAATGGTGGA CACAGAGAATGGTGGATTT TTT 348..351 ACAC 106 ACTTTGGATGGAGCAATTC 284 ACTTTGGATGGAGCAATTCAacac AACAGAGAATGGTGGATT ACAGAGAATGGTGGATTTCC TCC 348..352 ACACA 107 ACTTTGGATGGAGCAATTC 285 ACTTTGGATGGAGCAATTCAacac ACAGAGAATGGTGGATTT aCAGAGAATGGTGGATTTCCA CCA 348..353 ACACAC 108 ACTTTGGATGGAGCAATTC 286 ACTTTGGATGGAGCAATTCAacac AAGAGAATGGTGGATTTC acAGAGAATGGTGGATTTCCAT CAT 348..354 ACACACA 109 ACTTTGGATGGAGCAATTC 287 ACTTTGGATGGAGCAATTCAacac AGAGAATGGTGGATTTCC acaGAGAATGGTGGATTTCCATA ATA 348..355 ACACACAG 110 ACTTTGGATGGAGCAATTC 288 ACTTTGGATGGAGCAATTCAacac AAGAATGGTGGATTTCCAT acagAGAATGGTGGATTTCCATAC AC 348..357 ACACACAGA 111 ACTTTGGATGGAGCAATTC 289 ACTTTGGATGGAGCAATTCAacac G (392) AAATGGTGGATTTCCATAC acagagAATGGTGGATTTCCATACA AC C 349..349 C 112 CTTTGGATGGAGCAATTCA 290 CTTTGGATGGAGCAATTCAAcAC AACACAGAGAATGGTGGA ACAGAGAATGGTGGATTT TTT 349..350 CA 113 CTTTGGATGGAGCAATTCA 291 CTTTGGATGGAGCAATTCAAcaC ACACAGAGAATGGTGGAT ACAGAGAATGGTGGATTTC TTC 349..352 CACA 114 CTTTGGATGGAGCAATTCA 292 CTTTGGATGGAGCAATTCAAcaca ACAGAGAATGGTGGATTT CAGAGAATGGTGGATTTCCA CCA 349..355 CACACAG 115 CTTTGGATGGAGCAATTCA 293 CTTTGGATGGAGCAATTCAAcaca AAGAATGGTGGATTTCCAT cagAGAATGGTGGATTTCCATAC AC 350..351 AC 116 TTTGGATGGAGCAATTCAA 294 TTTGGATGGAGCAATTCAACacA CACAGAGAATGGTGGATT CAGAGAATGGTGGATTTCC TCC 350..353 ACAC 117 TTTGGATGGAGCAATTCAA 295 TTTGGATGGAGCAATTCAACacac CAGAGAATGGTGGATTTC AGAGAATGGTGGATTTCCAT CAT 350..354 ACACA 118 TTTGGATGGAGCAATTCAA 296 TTTGGATGGAGCAATTCAACacac CGAGAATGGTGGATTTCC aGAGAATGGTGGATTTCCATA ATA 350..355 ACACAG 119 TTTGGATGGAGCAATTCAA 297 TTTGGATGGAGCAATTCAACacac CAGAATGGTGGATTTCCAT agAGAATGGTGGATTTCCATAC AC 350..357 ACACAGAG 120 TTTGGATGGAGCAATTCAA 298 TTTGGATGGAGCAATTCAACacac CAATGGTGGATTTCCATAC agagAATGGTGGATTTCCATACAC AC 350..363 ACACAGAGA 121 TTTGGATGGAGCAATTCAA 299 TTTGGATGGAGCAATTCAACacac ATGGT (393) CGGATTTCCATACACTGAA agagaatggtGGATTTCCATACACT AT GAAAT 351..352 CA 122 TTGGATGGAGCAATTCAA 300 TTGGATGGAGCAATTCAACAcaC CACAGAGAATGGTGGATT AGAGAATGGTGGATTTCCA TCCA 351..354 CACA 123 TTGGATGGAGCAATTCAA 301 TTGGATGGAGCAATTCAACAcaca CAGAGAATGGTGGATTTC GAGAATGGTGGATTTCCATA CATA 351..356 CACAGA 124 TTGGATGGAGCAATTCAA 302 TTGGATGGAGCAATTCAACAcaca CAGAATGGTGGATTTCCAT gaGAATGGTGGATTTCCATACA ACA 351..357 CACAGAG 125 TTGGATGGAGCAATTCAA 303 TTGGATGGAGCAATTCAACAcaca CAAATGGTGGATTTCCATA gagAATGGTGGATTTCCATACAC CAC 351..362 CACAGAGAA 126 TTGGATGGAGCAATTCAA 304 TTGGATGGAGCAATTCAACAcaca TGG (394) CATGGATTTCCATACACTG gagaatggTGGATTTCCATACACTG AAA AAA 352..354 ACA 127 TGGATGGAGCAATTCAAC 305 TGGATGGAGCAATTCAACACaca ACGAGAATGGTGGATTTC GAGAATGGTGGATTTCCATA CATA 352..355 ACAG 128 TGGATGGAGCAATTCAAC 306 TGGATGGAGCAATTCAACACacag ACAGAATGGTGGATTTCC AGAATGGTGGATTTCCATAC ATAC 353..354 CA 129 GGATGGAGCAATTCAACA 307 GGATGGAGCAATTCAACACAcaG CAGAGAATGGTGGATTTC AGAATGGTGGATTTCCATA CATA 353..356 CAGA 130 GGATGGAGCAATTCAACA 308 GGATGGAGCAATTCAACACAcaga CAGAATGGTGGATTTCCAT GAATGGTGGATTTCCATACA ACA 353..361 CAGAGAATG 131 GGATGGAGCAATTCAACA 309 GGATGGAGCAATTCAACACAcaga CAGTGGATTTCCATACACT gaatgGTGGATTTCCATACACTGAA GAA 354..359 AGAGAA 132 GATGGAGCAATTCAACAC 310 GATGGAGCAATTCAACACACagag ACTGGTGGATTTCCATACA aaTGGTGGATTTCCATACACTG CTG

TABLE 5D A list of exemplary mutant alleles obtained in the PMT3 gene. PMT3 Mutant Reference Deleted Allele Allele sequence Sequence Sequence Pos- (SEQ (SEQ ID Mutant  (SEQ ID ition ID No.) No.) Allele Sequence No.) Reference Allele Sequence  98... A 133 TGGCACTTCCAAACACCAAACGGC 311 TGGCACTTCCAAACACCAAAaCGGCCA 98 CACCAGAATGGCACTT CCAGAATGGCACTT 280... T 134 CCAACTCTATTAAGCCTGGTGGTTT 312 CCAACTCTATTAAGCCTGGTtGGTTTTC 280 TCAGAGTTTAGCGCA AGAGTTTAGCGCA 413.. CT 135 AACATATGGGAAGGTTCTGATTGG 313 AACATATGGGAAGGTTCTGActTTGGAT 414 ATGGAGCAATTCAACA GGAGCAATTCAACA 418.. GA 136 ATGGGAAGGTTCTGACTTTGTGGA 314 ATGGGAAGGTTCTGACTTTGgaTGGAGC 419 GCAATTCAACACACAG AATTCAACACACAG 426.. AA 137 GTTCTGACTTTGGATGGAGCTTCA 315 GTTCTGACTTTGGATGGAGCaaTTCAAC 427 ACACACAGAGAATGGT ACACAGAGAATGGT 429.. TCAACAC 138 CTGACTTTGGATGGAGCAATACAG 316 CTGACTTTGGATGGAGCAATtcaacacACA 435 AGAATGGTGGATTTCC GAGAATGGTGGATTTCC 429.. TCAACACACA 139 CTGACTTTGGATGGAGCAATGAGA 317 CTGACTTTGGATGGAGCAATtcaacacaca 438 (395) ATGGTGGATTTCCATA GAGAATGGTGGATTTCCATA 429.. TCAACACACA 140 CTGACTTTGGATGGAGCAATAGAA 318 CTGACTTTGGATGGAGCAATtcaacacaca 439 G (396) TGGTGGATTTCCATAC gAGAATGGTGGATTTCCATAC 430.. CAACACA 141 TGACTTTGGATGGAGCAATTCAGA 319 TGACTTTGGATGGAGCAATTcaacacaCAG 436 GAATGGTGGATTTCCA AGAATGGTGGATTTCCA 431.. A 142 GACTTTGGATGGAGCAATTCACAC 320 GACTTTGGATGGAGCAATTCaACACACA 431 ACAGAGAATGGTGGAT GAGAATGGTGGAT 431.. AA 143 GACTTTGGATGGAGCAATTCCACA 321 GACTTTGGATGGAGCAATTCaaCACACA 432 CAGAGAATGGTGGATT GAGAATGGTGGATT 431.. AACACACA 144 GACTTTGGATGGAGCAATTCGAGA 322 GACTTTGGATGGAGCAATTCaacacacaGA 438 ATGGTGGATTTCCATA GAATGGTGGATTTCCATA 431.. AACACACAGA 145 GACTTTGGATGGAGCAATTCAATG 323 GACTTTGGATGGAGCAATTCaacacacaga 441 G (397) GTGGATTTCCATACAC gAATGGTGGATTTCCATACAC 432.. AC 146 ACTTTGGATGGAGCAATTCAACAC 324 ACTTTGGATGGAGCAATTCAacACACAG 433 AGAGAATGGTGGATTT AGAATGGTGGATTT 432.. ACAC 147 ACTTTGGATGGAGCAATTCAACAG 325 ACTTTGGATGGAGCAATTCAacacACAGA 435 AGAATGGTGGATTTCC GAATGGTGGATTTCC 432.. ACACAC 148 ACTTTGGATGGAGCAATTCAAGAG 326 ACTTTGGATGGAGCAATTCAacacacAGA 437 AATGGTGGATTTCCAT GAATGGTGGATTTCCAT 432.. ACACACAG 149 ACTTTGGATGGAGCAATTCAAGAA 327 ACTTTGGATGGAGCAATTCAacacacagAG 439 TGGTGGATTTCCATAC AATGGTGGATTTCCATAC 432.. ACACACAGAG 150 ACTTTGGATGGAGCAATTCAAATG 328 ACTTTGGATGGAGCAATTCAacacacagag 441 (398) GTGGATTTCCATACAC AATGGTGGATTTCCATACAC 432.. ACACACAGAG 151 ACTTTGGATGGAGCAATTCATGGA 329 ACTTTGGATGGAGCAATTCAacacacagag 446 AATGG(399) TTTCCATACACTGAAA aatggTGGATTTCCATACACTGAAA 432.. ACACACAGAG 152 ACTTTGGATGGAGCAATTCAGATT 330 ACTTTGGATGGAGCAATTCAacacacagag 448 AATGGTG TCCATACACTGAAATG aatggtgGATTTCCATACACTGAAATG (400) 433.. C 153 CTTTGGATGGAGCAATTCAAACAC 331 CTTTGGATGGAGCAATTCAAcACACAG 433 AGAGAATGGTGGATTT AGAATGGTGGATTT 433.. CACA 154 CTTTGGATGGAGCAATTCAACAGA 332 CTTTGGATGGAGCAATTCAAcacaCAGAG 436 GAATGGTGGATTTCCA AATGGTGGATTTCCA 433.. CACAC 155 CTTTGGATGGAGCAATTCAAAGAG 333 CTTTGGATGGAGCAATTCAAcacacAGAG 437 AATGGTGGATTTCCAT AATGGTGGATTTCCAT 433.. CACACAG 156 CTTTGGATGGAGCAATTCAAAGAA 334 CTTTGGATGGAGCAATTCAAcacacagAGA 439 TGGTGGATTTCCATAC ATGGTGGATTTCCATAC 434.. AC 157 TTTGGATGGAGCAATTCAACACAG 335 TTTGGATGGAGCAATTCAACacACAGAG 435 AGAATGGTGGATTTCC AATGGTGGATTTCC 434.. ACAC 158 TTTGGATGGAGCAATTCAACAGAG 336 TTTGGATGGAGCAATTCAACacacAGAG 437 AATGGTGGATTTCCAT AATGGTGGATTTCCAT 434.. ACACA 159 TTTGGATGGAGCAATTCAACGAGA 337 TTTGGATGGAGCAATTCAACacacaGAGA 438 ATGGTGGATTTCCATA ATGGTGGATTTCCATA 435.. CA 160 TTGGATGGAGCAATTCAACACAGA 338 TTGGATGGAGCAATTCAACAcaCAGAGA 436 GAATGGTGGATTTCCA ATGGTGGATTTCCA 435.. CACA 161 TTGGATGGAGCAATTCAACAGAGA 339 TTGGATGGAGCAATTCAACAcacaGAGA 438 ATGGTGGATTTCCATA ATGGTGGATTTCCATA 435.. CACAG 162 TTGGATGGAGCAATTCAACAAGAA 340 TTGGATGGAGCAATTCAACAcacagAGAA 439 TGGTGGATTTCCATAC TGGTGGATTTCCATAC 435.. CACAGAGAAT 163 TTGGATGGAGCAATTCAACAGGAT 341 TTGGATGGAGCAATTCAACAcacagagaat 447 GGT (401) TTCCATACACTGAAAT ggtGGATTTCCATACACTGAAAT 436.. AC 164 TGGATGGAGCAATTCAACACAGAG 342 TGGATGGAGCAATTCAACACacAGAGA 437 AATGGTGGATTTCCAT ATGGTGGATTTCCAT 436.. ACAG 165 TGGATGGAGCAATTCAACACAGAA 343 TGGATGGAGCAATTCAACACacagAGAA 439 TGGTGGATTTCCATAC TGGTGGATTTCCATAC 436.. ACAGAGAA 166 TGGATGGAGCAATTCAACACTGGT 344 TGGATGGAGCAATTCAACACacagagaaTG 443 GGATTTCCATACACTG GTGGATTTCCATACACTG 437.. CA 167 GGATGGAGCAATTCAACACAGAG 345 GGATGGAGCAATTCAACACAcaGAGAA 438 AATGGTGGATTTCCATA TGGTGGATTTCCATA 440.. AGA 168 TGGAGCAATTCAACACACAGATGG 346 TGGAGCAATTCAACACACAGagaATGGT 442 TGGATTTCCATACACT GGATTTCCATACACT 440.. AGAA 169 TGGAGCAATTCAACACACAGTGGT 347 TGGAGCAATTCAACACACAGagaaTGGT 443 GGATTTCCATACACTG GGATTTCCATACACTG 441.. G 170 GGAGCAATTCAACACACAGAAATG 348 GGAGCAATTCAACACACAGAgAATGGT 441 GTGGATTTCCATACAC GGATTTCCATACAC 445.. GGTGG 171 CAATTCAACACACAGAGAATATTT 349 CAATTCAACACACAGAGAATggtggATTT 449 CCATACACTGAAATGA CCATACACTGAAATGA 451.. TTTCCATACA 172 AACACACAGAGAATGGTGGAAAA 350 AACACACAGAGAATGGTGGAtttccataca 463 CTG (402) TGATTGTTCATCTTCCA ctgAAATGATTGTTCATCTTCCA

TABLE 5E A list of exemplary mutant alleles obtained in the PMT4 gene. PMT4 Mutant Reference Deleted Allele Allele sequence Sequence Sequence Pos- (SEQ ID (SEQ ID (SEQ ID ition No.) No.) Mutant Allele Sequence No.) Reference Allele Sequence 131... A 173 CGGCACTTCCAAACACCAAACGGCCA 351 CGGCACTTCCAAACACCAAAaCGGCCAC 131 CCATAATGGCACTT CATAATGGCACTT 541.. ATTCAACACA 174 TTTTGACTTTGGATGGAGCAAGAGAAT 352 TTTTGACTTTGGATGGAGCAattcaacacacA 551 C (403) GGTGGATTTCCAT GAGAATGGTGGATTTCCAT 543.. TCAACACACA 175 TTGACTTTGGATGGAGCAATGAATGGT 353 TTGACTTTGGATGGAGCAATtcaacacacaga 554 GA (404) GGATTTCCATACA GAATGGTGGATTTCCATACA 544.. CAACACA 176 TGACTTTGGATGGAGCAATTCAGAGA 354 TGACTTTGGATGGAGCAATTcaacacaCAG 550 ATGGTGGATTTCCA AGAATGGTGGATTTCCA 544.. CAACACACAG 177 TGACTTTGGATGGAGCAATTAGAATGG 355 TGACTTTGGATGGAGCAATTcaacacacagA 553 (405) TGGATTTCCATAC GAATGGTGGATTTCCATAC 545.. AACACACAGA 178 GACTTTGGATGGAGCAATTCAATGGTG 356 GACTTTGGATGGAGCAATTCaacacacagag 555 G (406) GATTTCCATACAC AATGGTGGATTTCCATACAC 545.. AACACACAGA 179 GACTTTGGATGGAGCAATTCTGGTGGA 357 GACTTTGGATGGAGCAATTCaacacacagaga 557 GAA (407) TTTCCATACACTG aTGGTGGATTTCCATACACTG 546.. AC 180 ACTTTGGATGGAGCAATTCAACACAG 358 ACTTTGGATGGAGCAATTCAacACACAG 547 AGAATGGTGGATTT AGAATGGTGGATTT 546.. ACAC 181 ACTTTGGATGGAGCAATTCAACAGAG 359 ACTTTGGATGGAGCAATTCAacacACAGA 549 AATGGTGGATTTCC GAATGGTGGATTTCC 546.. ACACAC 182 ACTTTGGATGGAGCAATTCAAGAGAA 360 ACTTTGGATGGAGCAATTCAacacacAGAG 551 TGGTGGATTTCCAT AATGGTGGATTTCCAT 546.. ACACACA 183 ACTTTGGATGGAGCAATTCAGAGAAT 361 ACTTTGGATGGAGCAATTCAacacacaGAG 552 GGTGGATTTCCATA AATGGTGGATTTCCATA 546.. ACACACAG 184 ACTTTGGATGGAGCAATTCAAGAATG 362 ACTTTGGATGGAGCAATTCAacacacagAG 553 GTGGATTTCCATAC AATGGTGGATTTCCATAC 547.. CACA 185 CTTTGGATGGAGCAATTCAACAGAGA 363 CTTTGGATGGAGCAATTCAAcacaCAGAG 550 ATGGTGGATTTCCA AATGGTGGATTTCCA 547.. CACAC 186 CTTTGGATGGAGCAATTCAAAGAGAA 364 CTTTGGATGGAGCAATTCAAcacacAGAG 551 TGGTGGATTTCCAT AATGGTGGATTTCCAT 548.. AC 187 TTTGGATGGAGCAATTCAACACAGAG 365 TTTGGATGGAGCAATTCAACacACAGAG 549 AATGGTGGATTTCC AATGGTGGATTTCC 548.. ACAC 188 TTTGGATGGAGCAATTCAACAGAGAA 366 TTTGGATGGAGCAATTCAACacacAGAGA 551 TGGTGGATTTCCAT ATGGTGGATTTCCAT 548.. ACACA 189 TTTGGATGGAGCAATTCAACGAGAAT 367 TTTGGATGGAGCAATTCAACacacaGAGA 552 GGTGGATTTCCATA ATGGTGGATTTCCATA 549.. CACA 190 TTGGATGGAGCAATTCAACAGAGAAT 368 TTGGATGGAGCAATTCAACAcacaGAGAA 552 GGTGGATTTCCATA TGGTGGATTTCCATA 549.. CACAG 191 TTGGATGGAGCAATTCAACAAGAATG 369 TTGGATGGAGCAATTCAACAcacagAGAA 553 GTGGATTTCCATAC TGGTGGATTTCCATAC 550.. AC 192 TGGATGGAGCAATTCAACACAGAGAA 370 TGGATGGAGCAATTCAACACacAGAGAA 551 TGGTGGATTTCCAT TGGTGGATTTCCAT 550.. ACA 193 TGGATGGAGCAATTCAACACGAGAAT 371 TGGATGGAGCAATTCAACACacaGAGAA 552 GGTGGATTTCCATA TGGTGGATTTCCATA 550.. ACAG 194 TGGATGGAGCAATTCAACACAGAATG 372 TGGATGGAGCAATTCAACACacagAGAAT 553 GTGGATTTCCATAC GGTGGATTTCCATAC 550.. ACAGAGA 195 TGGATGGAGCAATTCAACACATGGTG 373 TGGATGGAGCAATTCAACACacagagaATG 556 GATTTCCATACACT GTGGATTTCCATACACT 551.. CA 196 GGATGGAGCAATTCAACACAGAGAAT 374 GGATGGAGCAATTCAACACAcaGAGAAT 552 GGTGGATTTCCATA GGTGGATTTCCATA 554.. A 197 TGGAGCAATTCAACACACAGGAATGG 375 TGGAGCAATTCAACACACAGaGAATGGT 554 TGGATTTCCATACA GGATTTCCATACA 558.. TGGTGG 198 GCAATTCAACACACAGAGAAATTTCC 376 GCAATTCAACACACAGAGAAtggtggATTT 563 ATACACTGAAATGA CCATACACTGAAATGA 565.. TT 199 AACACACAGAGAATGGTGGATCCATA 377 AACACACAGAGAATGGTGGAttTCCATAC 566 CACTGAAATGATTG ACTGAAATGATTG 569.. CATA 200 CACAGAGAATGGTGGATTTCCACTGA 378 CACAGAGAATGGTGGATTTCcataCACTG 572 AATGATTGTTCATC AAATGATTGTTCATC

Example 3: Alkaloid Analysis of PMT Edited Lines

Genome edited tobacco plants along with controls are grown in 10″ pots in green house with 75 PPM fertilizer. At flowering stage, plants are topped and 2 weeks post topping lamina samples were collected from 3, 4, 5 leaves from top and alkaloid levels are measured (Tables 6A to 6C) using a method in accordance with CORESTA Method No 62, Determination of Nicotine in Tobacco and Tobacco Products by Gas Chromatographic Analysis, February 2005, and those defined in the Centers for Disease Control and Prevention's Protocol for Analysis of Nicotine, Total Moisture and pH in Smokeless Tobacco Products, as published in the Federal Register Vol. 64, No. 55 Mar. 23, 1999 (and as amended in Vol. 74, No. 4, Jan. 7, 2009).

Briefly, approximately 0.5 g of tobacco is extracted using liquid/liquid extraction into an organic solvent containing an internal standard and analyzed by gas chromatography (GC) with flame ionization detection (FID). Results can be reported as weight percent (Wt %) on either an as is or dry weight basis. Reporting data on a dry weight basis requires an oven volatiles (OV) determination. Unless specified otherwise, total or individual alkaloid levels or nicotine levels shown herein are on a dry weight basis (e.g., percent total alkaloid or percent nicotine).

Plants are also planted in the field, harvested, and tested for alkaloids and TSNA levels in cured tobacco. Both leaf yield and leaf grade are also assessed for PMT edited plants. Further, different mutant combinations of individual PMT genes are generated and tested (e.g., single, double, triple, or quadruple mutants).

Example 4: Comparing a Quintuple Pmt Knock-Out Mutant with Other Low-Alkaloid Tobacco Plants

A quintuple pmt knock-out mutant line CS15 (see Table 4E for genotype, in the NLM (Ph Ph) background) is grown side by side with a PMT RNAi transgenic line (in the VA359 background, as described in US 2015/0322451) and a low-nicotine KY171 (“LN KY171”) variety (the KY 171 background harboring nic1 and nic2 double mutations). Leaves are harvested and cured via a dark fire curing method. Each line is analyzed for nicotine and total alkaloid levels, leaf yield, and leaf quality (FIGS. 2 to 5 ). The data shows that suppressing PMT gene activity by editing all five PMT genes reduces nicotine level without comprising leaf yield or quality.

Example 5: Obtaining Tobacco Lines with Edited Mutant Alleles in One or More PMT Genes

Tobacco lines with mutations in individual PMT genes or selected combinations of PMT genes are obtained from the tobacco lines listed in Table 3. Crossing a quintuple, quadruple, triple, or double mutant (having mutations in five, four, three, or two PMT genes, respectively) to a non-mutated control line and selecting segregating progeny plants for specific PMT mutation combinations. Tables 7A to 7E represents possible mutant combinations being obtained. Each mutated gene can be either homozygous or heterozygous for the mutation. Each of the mutant alleles listed in Tables 4A to 4E and Table 10 can be used to generate single, double, triple, quintuple, or quadruple mutants. Exemplary individual pmt mutant alleles are listed in Tables 9A to 9E.

Example 6: Further Reduction of Total Alkaloids by Combining pmt Mutations with Mutations in Other Genes

To further reduce total alkaloids and/or selected individual alkaloids, pmt mutants are combined with mutations in additional genes related to alkaloid biosynthesis in tobacco, such as quinolate phosphoribosyl transferase (QPT) or quinolinate synthase (QS). Briefly, gene editing is used to mutant selected QPT and/or QS genes in a desired pmt mutant background (e.g., a quadruple or quintuple pmt mutant). In the resulting combined qpt/pmt or qs/pmt mutants, alkaloids and TSNA levels are tested in cured tobacco. Both leaf yield and leaf grade are also assessed.

TABLE 6A Alkaloid levels in PMT edited lines in K326 (shown here and Tables 6B, 6C, and 7 as weight percentage per gram leaf lamina (dry weight)) % Alkaloids Variety Plant ID Nicotine Total Alkaloids K326 17GH1811 1.17 1.23 Control 17GH1822 1.63 1.71 17GH1806 1.69 1.76 17GH1899 1.7893 1.9194 17GH1812 1.91 2 17GH1900 2.088 2.239 17GH1821 2.16 2.26 17GH1896 2.6006 2.7359 K326 17GH1810 0.0013 0.3 Edited 17GH1808 0.0044 0.24 17GH1901 0.006 0.6958 17GH1893 0.0072 0.7351 17GH1804 0.0078 0.44 17GH1902 0.008 0.6245 18GH4 0.0102 0.2688 17GH1892 0.0209 0.1281

TABLE 6B Alkaloid levels in PMT edited lines in TN90 % Alkaloids Variety Plant ID Nicotine Total Alkaloids TN90 17GH1838 1.88 1.98 Control 17GH1923 2.0868 2.2136 17GH1924 2.2099 2.3394 17GH1718 2.29 2.42 17GH1839 2.6 2.74 17GH1909 2.7639 2.9429 17GH1910 2.9346 3.1283 TN90 17GH1699 0.0011 0.58 Edited 17GH1708 0.0014 0.56 17GH1847 0.0016 0.6 17GH1848 0.0018 0.42 17GH1724 0.0022 0.59 17GH1846 0.0022 0.41 17GH1722 0.0023 0.62 17GH1725 0.003 0.69 17GH1717 0.0035 0.7 17GH1719 0.0042 0.75 17GH1845 0.0047 0.45 17GH1943 0.007 0.3464 18GH47 0.0072 1.0455 17GH1944 0.0074 0.403 17GH1932 0.0074 0.4758 17GH1936 0.0074 1.4394 17GH1918 0.0075 0.458 17GH1912 0.0078 0.5234 18GH31 0.0079 1.0902 18GH28 0.008 0.8748 17GH1928 0.0081 1.1024 17GH1933 0.0083 0.6517 17GH1911 0.0088 0.281

TABLE 6C Alkaloid levels in PMT edited lines in Narrow Leaf Madole (NLM) % Alkaloids Variety Plant ID Nicotine Total Alkaloids NLM 18GH126 2.0844 2.1734 Control 18GH7 3.3504 3.5136 NLM 18GH10 0.001 1.14 Edited 18GH9 0.0012 0.92 18GH6 0.0019 1.46 18GH8 0.0022 1.46 17GH1905 0.0032 1.49 18GH5 0.0038 0.92 18GH130 0.0041 0.8756 18GH132 0.0044 0.6335 18GH79 0.0045 0.6182 18GH69 0.0069 0.7495 18GH71 0.007 0.7726 18GH131 0.0077 0.4289 18GH66 0.0081 0.6951 18GH227 0.0086 0.8726 18GH78 0.0086 0.662 18GH72 0.0087 1.0048 18GH216 0.0089 1.2758 18GH65 0.0094 0.7018

TABLE 7 Relative changes in nicotine and total alkaloid levels in quintuple pmt knock-out mutants in various varieties. Average percent levels of nicotine and total alkaloids are calculated based on percent level data from individual lines as shown in Tables 6A to 6C. Relative changes reflect the nicotine or total alkaloid level in a quintuple pmt mutant relative to its control. Nicotine Total Alkaloids K326 Control 1.880 1.982 K326 quintuple 0.008 0.429 pmt mutant Relative change 0.44% 21.65% TN90 Control 2.395 2.538 TN90 quintuple 0.005 0.655 pmt mutant Relative change 0.22% 25.80% NLM Control 2.717 2.844 NLM quintuple 0.006 0.927 pmt mutant Relative change 0.20% 32.59%

TABLE 8A A list of mutants obtained with various genotypic combinations for five PMT genes: single gene mutations PMT1a PMT1b PMT2 PMT3 PMT4 1 Mutant WT WT WT WT 2 WT Mutant WT WT WT 3 WT WT Mutant WT WT 4 WT WT WT Mutant WT 5 WT WT WT WT Mutant

TABLE 8B A list of mutants obtained with various genotypic combinations for five PMT genes: double gene mutations PMT1a PMT1b PMT2 PMT3 PMT4 1 Mutant Mutant WT WT WT 2 Mutant WT Mutant WT WT 3 Mutant WT WT Mutant WT 4 Mutant WT WT WT Mutant 5 WT Mutant Mutant WT WT 6 WT Mutant WT Mutant WT 7 WT Mutant WT WT Mutant 8 WT WT Mutant Mutant WT 9 WT WT Mutant WT Mutant 10 WT WT WT Mutant Mutant

TABLE 8C A list of mutants obtained with various genotypic combinations for five PMT genes: triple gene combinations PMT1a PMT1b PMT2 PMT3 PMT4 1 Mutant Mutant Mutant WT WT 2 Mutant Mutant WT Mutant WT 3 Mutant Mutant WT WT Mutant 4 Mutant WT Mutant Mutant WT 5 Mutant WT Mutant WT Mutant 6 Mutant WT WT Mutant Mutant 7 WT Mutant Mutant Mutant WT 8 WT Mutant Mutant WT Mutant 9 WT WT Mutant Mutant Mutant 10 WT Mutant Mutant WT Mutant

TABLE 8D A list of mutants obtained with various genotypic combinations for five PMT genes: quadruple gene combinations PMT1a PMT1b PMT2 PMT3 PMT4 1 Mutant Mutant Mutant Mutant WT 2 WT Mutant Mutant Mutant Mutant 3 Mutant WT Mutant Mutant Mutant 4 Mutant Mutant WT Mutant Mutant 5 Mutant Mutant Mutant WT Mutant

TABLE 8E A list of mutants obtained with various genotypic combinations for five PMT genes: quintuple gene combinations PMT1a PMT1b PMT2 PMT3 PMT4 1 Mutant Mutant Mutant Mutant Mutant

Example 7: PMT Genome Editing and Tobacco Line Development

Additional PMT knockout mutants are produced by editing all five PMT genes (PMT1a, PMT1b, PMT2, PMT3, and PMT4) in different tobacco lines. Tobacco protoplasts are transfected using polyethylene glycol (PEG) with plasmids encoding a a genome editing technology (GET2) protein and specific guide RNAs (gRNAs) targeting PMT genes at desired positions. Table 9 lists gRNA sequences used for PMT editing. Some gRNAs (e.g., Nos. 6 and 7) are pooled together for targeting multiple PMT genes in a single transfection.

TABLE 9 Guide RNAs for GET2 used in Example 7. “Y” indicates that a gRNA is capable of targeting that PMT gene, while represents that a gRNA does not target that PMT gene. gRNA Sequence PMT1a PMT1b PMT2 PMT3 PMT4 GATGGAGCAATTCAACATACAGA Y Y — — — (SEQ ID NO: 730) GATGGAGCAATTCAACACACAGA — — Y Y Y (SEQ ID NO: 731)

Transfected protoplasts are then immobilized in 1% agarose bead and subjected to tissue culture. When calli grow up to ˜1 mm in diameter, they are spread on TOM2 plates. Calli are screened for insertions or deletions (indels) at the target positions using fragment analysis. Candidates, showing size shifts compared to wildtype control, are selected for further culture and the consequent shoots are tested by fragment analysis again to confirm the presence of indels. Rooted shoots are potted and sequenced for the target positions to determine the exact sequences deleted. Young leaf from each plant is harvested and PCR amplified for PMT fragments using phirekit. PMT Libraries for each line is indexed and 384 lines are pooled and sequenced using Miseq.

SNP analysis is carried out to determine both the exact edited pmt mutant allele sequences and the zygosity state at each PMT gene locus. Table 10 provides indels sequence information in each edited line of various tobacco varieties (e.g., Basma, K326, Katerini, TN90, Izmir).

TABLE 10 Mutant pmt alleles in various lines produced by genome editing using GET2. The position of each edited site (e.g., indels) is relative to the nucleotide number on the corresponding cDNA sequence of each PMT gene (e.g, SEQ ID NO: 6 for PMT1a; SEQ ID NO: 7 for PMT1b; SEQ ID NO: 8 for PMT2; SEQ ID NO: 9 for PMTT SEQ ID NO: 10 for PMT4). SEQ ID Numbers are assigned and shown for sequences of more than 10 nucleotides. PMT1a PMT1b PMT2 PMT3 PMT4 Geno Deleted Posi- Deleted Posi- Deleted Posi- Deleted Posi- Deleted Posi- type Line Sequence tion Sequence tion Sequence tion Sequence tion Sequence tion BAS CS107 CAACATA 412 . . . ACAT 414 . . . 417 AC 348 . . . ACAC 432 . . . ACAC 546 . . . MA 418 349 435 549 BAS CS106 ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . ACAC 432 . . . ACAC 546 . . . MA 417 349 435 549 K326 CS115 TCAACA 411 . . . ACAT 414 . . . 417 AC 348 . . . CACA 433 . . . ACACA 548 . . . TACA 420 349 C 437 552 (SEQ ID NO: 379) K326 18GH ACAT 414 . . . ACAT 414 . . . 417 ACAC 348 . . . AC 432 . . . ACACA 548 . . . 2162 417 ACAG 355 433 552 K326 CS111 ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . ACAC 432 . . . CACAC 547 . . . 417 349 435 551 K326 CS112 CATACAG 415 . . . AC 418 . . . 419 AC 348 . . . ACAC 432 . . . CACAC 547 . . . 421 349 435 551 K326 17GH CATACAG 415 . . . AC 418 . . . 419 AC 348 . . . ACAC 432 . . . ACAC 546 . . . 1678- 421 349 435 549 60 K326 CS131 ACAT 414 . . . ACAT 414 . . . 417 ACAC 348 . . . AACA 431 . . . ACAC 546 . . . 417 351 CACA 439 549 G KAT CS164 AT 416 . . . CAACA 412 . . . 418 AC 348 . . . ACAC 432 . . . AC 546 . . . ERIN 417 TA 349 435 547 I KAT CS163 ACAT 414 . . . AT 416 . . . 417 AC 348 . . . ACAC 432 . . . AC 546 . . . ERIN 417 349 435 547 I KAT CS146 GAGCAA 404 . . . ACAT 414 . . . 417 AC 348 . . . CAAC 430 . . . AC 546 . . . ERIN TTCAAC 422 349 ACA 436 547 I ATACAG A (SEQ ID NO: 408) KAT CS147 ACAT 414 . . . CAACA 412 . . . 418 AC 348 . . . CAAC 430 . . . AC 546 . . . ERIN 417 TA 349 ACA 436 547 I KAT CS150 AT 416 . . . ACAT 414 . . . 417 AC 348 . . . CACA 433 . . . AC 546 . . . ERIN 417 349 CAG 439 547 I KAT CS151 AT 416 . . . ACAT 414 . . . 417 AC 348 . . . ACAC 432 . . . CAACA 544 . . . ERIN 417 349 435 CACAG 553 I (SEQ ID NO: 390) KAT CS148 ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . CACA 433 . . . AC 546 . . . ERIN 417 349 CAG 439 547 I KAT CS149 ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . ACAC 432 . . . CAACA 544 . . . ERIN 417 349 435 CACAG 553 I (SEQ ID NO: 390) KAT CS152 AC 418 . . . ACAT 414 . . . 417 AC 348 . . . ACAC 432 . . . ACAC 546 . . . ERIN 419 349 435 549 I KAT CS153 CAACATA 412 . . . AC 414 . . . 415 AC 348 . . . ACAC 432 . . . ACAC 546 . . . ERIN 418 349 435 549 I KAT CS102 ACAT 414 . . . AACAT 413 . . . 417 ACAC 348 . . . AC 432 . . . AC 546 . . . ERIN 417 ACAG 355 433 547 I KAT CS103 AC 418 . . . CAACA 412 . . . 418 ACAC 348 . . . AC 432 . . . AC 546 . . . ERIN 419 TA ACAG 355 433 547 I TN90 CS143 TACAGAG 417 . . . ACAT 414 . . . 417 AC 348 . . . AC 432 . . . ACAC 546 . . . 423 349 433 549 TN90 18GH AC 418 . . . ACAT 414 . . . 417 ACAC 348 . . . ACAC 432 . . . AC 546 . . . 2169 419 351 435 547 TN90 CS120 ACAT 414 . . . ACAG 418 . . . 421 ACAC 348 . . . AC 432 . . . AC 546 . . . 417 351 433 547 TN90 17GH ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . ACAG 436 . . . AC 546 . . . 1698- 417 349 439 547 22 TN90 17GH ACAT 414 . . . AACAT 413 . . . 417 AC 348 . . . AC 432 . . . ACAC 546 . . . 1700- 417 349 433 549 13 TN90 17GH ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . AC 432 . . . CACAG 549 . . . 1702- 417 349 433 553 17 TN90 18GH ACAT 414 . . . ACAT 414 . . . 417 ACAC 348 . . . CAAC 430 . . . AC 546 . . . 2171 417 351 ACA 436 547 TN90 CS165 ACAT 414 . . . ACAT 414 . . . 417 ACAC 348 . . . ACAC 432 . . . ACAC 546 . . . 417 351 435 549 TN90 CS118 ACAT 414 . . . ACAT 414 . . . 417 AC 348 . . . AC 432 . . . ACAC 546 . . . 417 349 433 549 TN90 CS133 GGAGC 403 . . . CAACA 412 . . . 421 ACAC 348 . . . AC 432 . . . AC 546 . . . AATTC 415 TACAG 351 433 547 AAC (SEQ ID (SEQ ID NO: NO: 409) 380) TN90 17GH CA 415 . . . ACAT 414 . . . 417 ACAC 348 . . . AC 432 . . . AC 546 . . . 1737- 416 351 433 547 24 IZMI 18GH CAACATA 412 . . . ATAGA 416 . . . 417 ACAC 348 . . . ACAC 432 . . . ACACA 546 . . . R 2254- 418 GAA & 351 435 CAG 553 7 420 . . . 425

Table 11 provides the length (in nucleotides) of each PMT indel for each gene in each line as provided in Table 10.

TABLE 11 The length (in nucleotides) of each indel for selected lines provided in Table 10. Genotype Line Seed Ids PMT1a PMT1b PMT2 PMT3 PMT4 BASMA CS107 CS107 7 4 2 4 4 BASMA CS106 CS106 4 4 2 4 4 K326 CS115 CS115 10 4 2 5 5 K326 17GH1809-13 18GH2162 4 4 8 2 5 K326 CS111 CS111 4 4 2 4 5 K326 CS112 CS112 7 2 2 4 5 K326 17GH1678-60 17GH1678-60 7 2 2 4 4 K326 CS131 CS131 4 4 4 9 4 KATERINI 18GH709-01 CS164 2 7 2 4 2 KATERINI 18GH709-08 CS163 4 2 2 4 2 KATERINI 18GH414-11 CS146 19 4 2 7 2 KATERINI 18GH414-19 CS147 4 7 2 7 2 KATERINI 18GH437-04 CS150 2 4 2 7 2 KATERINI 18GH437-08 CS151 2 4 2 4 10 KATERINI 18GH437-32 CS148 4 4 2 7 2 KATERINI 18GH437-39 CS149 4 4 2 4 10 KATERINI 18GH449-26 CS152 2 4 2 4 4 KATERINI 18GH449-33 CS153 7 2 2 4 4 KATERINI 18GH125-48 CS162 2 7 8 2 2 KATERINI CS102 CS102 4 5 8 2 2 KATERINI CS103 CS103 2 7 8 2 2 TN90 17GH1719-30 CS143 7 4 2 2 4 TN90 17GH1740-36 18GH2169 2 4 4 4 2 TN90 17GH1698-22 17GH1698-22 4 4 2 4 2 TN90 17GH1700-13 17GH1700-13 4 5 2 2 4 TN90 17GH1702-17 17GH1702-17 4 4 2 2 5 TN90 17GH1849-01 18GH2171 4 4 4 7 2 TN90 17GH1849-48 CS165 4 4 4 4 4 TN90 17GH1737-24 17GH1737-24 2 4 4 2 2 TN90 CS118 CS118 4 4 2 2 4 TN90 CS133 CS133 13 10 4 2 2 TN90 CS120 CS120 4 4 4 2 2 IZMIR 18GH1108-07 18GH2254-7 7 8 4 4 8

Tables 12A to 12E provide genomic sequences of approximately 90 nucleotides from each pmt mutant allele with the edited site in the middle of the genomic sequence (e.g., 45 nucleotides on each side of the deleted or inserted sequence site).

TABLE 12A A list of exemplary mutant alleles obtained in the PMTla gene. Mutant allele sequences listed here represent approximately 90- nucleotide-long genomic sequences from each edited PMT1a gene with the edited site in the middle of the genomic sequence (e.g., 45 nucleotides on each side of the deleted sequence site). The mutant allele corresponds to the indel provided for each line in Table 10. The lowercase letters in the reference allele sequence (SEQ ID NO: 6) denote which nucleotides are deleted in the mutant allele. Mutant Reference Allele  Reference Allele  Geno- Mutant Allele SEQ Allele SEQ type Line Sequence ID NO. Sequence ID NO. BASMA CS107 TCAGCAACTTATGGG 410 TCAGCAACTTATGGG 442 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa GAGAATGGTGGATTT catacaGAGAATGGT CCATACACTGAAATG GGATTTCCATACACT ATTGTTCATCTA GAAATGATTGTTCAT CTA BASMA CS106 TCAGCAACTTATGGG 411 TCAGCAACTTATGGG 443 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 CS115 TCAGCAACTTATGGG 412 TCAGCAACTTATGGG 444 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATGAG GATGGAGCAATtcaaca AATGGTGGATTTCCA tacaGAGAATGGTGGA TACACTGAAATGATT TTTCCATACACTGAA GTTCATCTA ATGATTGTTCATCTA K326 18GH TCAGCAACTTATGGG 413 TCAGCAACTTATGGG 445 2162 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 CS111 TCAGCAACTTATGGG 414 TCAGCAACTTATGGG 446 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 CS112 TCAGCAACTTATGGG 415 TCAGCAACTTATGGG 447 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA AAGAATGGTGGATTT AcatacagAGAATGGTG CCATACACTGAAATG GATTTCCATACACTG ATTGTTCATCTA AAATGATTGTTCATC TATCAAAGAATGG K326 17GH TCAGCAACTTATGGG 416 TCAGCAACTTATGGG 448 1678- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 60 GATGGAGCAATTCA GATGGAGCAATTCA AAGAATGGTGGATTT AcatacagAGAATGGTG CCATACACTGAAATG GATTTCCATACACTG ATTGTTCATCTA AAATGATTGTTCATC TATCAAAGAATGG K326 CS131 TCAGCAACTTATGGG 417 TCAGCAACTTATGGG 449 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS164 TCAGCAACTTATGGG 418 TCAGCAACTTATGGG 450 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACACAGAGAATGGT ACatACAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA KATERI CS163 TCAGCAACTTATGGG 419 TCAGCAACTTATGGG 451 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS146 TCAGCAACTTATGGG 420 TCAGCAACTTATGGG 452 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAATGGTGGA GATGGAgcaattcaa TTTCCATACACTGAA catacagagaATGGT ATGATTGTTCATCTA GGATTTCCATACACT GAAATGATTGTTCAT CTA KATERI CS147 TCAGCAACTTATGGG 421 TCAGCAACTTATGGG 453 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS150 TCAGCAACTTATGGG 422 TCAGCAACTTATGGG 454 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACACAGAGAATGGT ACatACAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA KATERI CS151 TCAGCAACTTATGGG 423 TCAGCAACTTATGGG 455 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACACAGAGAATGGT ACatACAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA KATERI CS148 TCAGCAACTTATGGG 424 TCAGCAACTTATGGG 456 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS149 TCAGCAACTTATGGG 425 TCAGCAACTTATGGG 457 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS152 TCAGCAACTTATGGG 426 TCAGCAACTTATGGG 458 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAGAATGGT ACATacAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA KATERI CS153 TCAGCAACTTATGGG 427 TCAGCAACTTATGGG 459 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa GAGAATGGTGGATTT catacaGAGAATGGTGG CCATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTA AATGATTGTTCATCT A KATERI CS102 TCAGCAACTTATGGG 428 TCAGCAACTTATGGG 460 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS103 TCAGCAACTTATGGG 429 TCAGCAACTTATGGG 461 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAGAATGGT ACATacAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA TN90 CS143 TCAGCAACTTATGGG 430 TCAGCAACTTATGGG 462 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACAAATGGTGGATTT ACAtacagagAATGGTG CCATACACTGAAATG GATTTCCATACACTG ATTGTTCATCTA AAATGATTGTTCATC TA TN90 18GH TCAGCAACTTATGGG 431 TCAGCAACTTATGGG 463 2169 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAGAATGGT ACATacAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA TN90 CS120 TCAGCAACTTATGGG 432 TCAGCAACTTATGGG 464 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 17GH TCAGCAACTTATGGG 433 TCAGCAACTTATGGG 465 1698- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 22 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 17GH TCAGCAACTTATGGG 434 TCAGCAACTTATGGG 466 1700- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 13 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 17GH TCAGCAACTTATGGG 435 TCAGCAACTTATGGG 467 1702- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 17 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 18GH TCAGCAACTTATGGG 436 TCAGCAACTTATGGG 468 2171 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 CS165 TCAGCAACTTATGGG 437 TCAGCAACTTATGGG 469 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 CS118 TCAGCAACTTATGGG 438 TCAGCAACTTATGGG 470 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATATACAGAGAAT GATggagcaattcaa GGTGGATTTCCATAC cATACAGAGAATGGT ACTGAAATGATTGTT GGATTTCCATACACT CATCTA GAAATGATTGTTCAT CTA TN90 CS113 TCAGCAACTTATGGG 439 TCAGCAACTTATGGG 471 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT A CTA TN90 17GH TCAGCAACTTATGGG 440 TCAGCAACTTATGGG 472 1737- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 24 GATGGAGCAATTCA GATGGAGCAATTCA ATACAGAGAATGGT AcaTACAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA IZMIR 18GH TCAGCAACTTATGGG 441 TCAGCAACTTATGGG 473 2254-7 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa GAGAATGGTGGATTT catacaGAGAATGGT CCATACACTGAAATG GGATTTCCATACACT ATTGTTCATCTA GAAATGATTGTTCAT CTA

TABLE 12B A list of exemplary mutant alleles obtained in the PMT1b gene. Mutant allele sequences listed here represent approximately 90- nucleotide-long genomic sequences from each edited PMT1b gene with the edited site in the middle of the genomic sequence (e.g., 45 nucleotides on each side of the deleted sequence site). The mutant allele corresponds to the indel provided for each line in Table 10. The lowercase letters in the reference allele sequence (SEQ ID NO: 7) denote which nucleotides are deleted in the mutant allele. Mutant Reference Allele  Reference Allele  Mutant Allele SEQ Allele SEQ Genotype Line Sequence ID NO. Sequence ID NO. BASMA CS107 TCAGCAACTTATGGG 474 TCAGCAACTTATGGG 506 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA BASMA CS106 TCAGCAACTTATGGG 475 TCAGCAACTTATGGG 507 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 CS115 TCAGCAACTTATGGG 476 TCAGCAACTTATGGG 508 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 18GH TCAGCAACTTATGGG 477 TCAGCAACTTATGGG 509 2162 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 CS111 TCAGCAACTTATGGG 478 TCAGCAACTTATGGG 510 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA K326 CS112 TCAGCAACTTATGGG 479 TCAGCAACTTATGGG 511 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAGAATGGT ACATacAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA K326 17GH TCAGCAACTTATGGG 480 TCAGCAACTTATGGG 512 1678- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 60 GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAGAATGGT ACATacAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA K326 CS131 TCAGCAACTTATGGG 481 TCAGCAACTTATGGG 513 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS164 TCAGCAACTTATGGG 482 TCAGCAACTTATGGG 514 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa GAGAATGGTGGATTT catacaGAGAATGGTGG CCATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTA AATGATTGTTCATCT A KATERI CS163 TCAGCAACTTATGGG 483 TCAGCAACTTATGGG 515 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACACAGAGAATGGT ACatACAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA KATERI CS146 TCAGCAACTTATGGG 484 TCAGCAACTTATGGG 516 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS147 TCAGCAACTTATGGG 485 TCAGCAACTTATGGG 517 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa GAGAATGGTGGATTT catacaGAGAATGGTGG CCATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTA AATGATTGTTCATCT A KATERI CS150 TCAGCAACTTATGGG 486 TCAGCAACTTATGGG 518 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS151 TCAGCAACTTATGGG 487 TCAGCAACTTATGGG 519 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS148 TCAGCAACTTATGGG 488 TCAGCAACTTATGGG 520 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS149 TCAGCAACTTATGGG 489 TCAGCAACTTATGGG 521 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS152 TCAGCAACTTATGGG 490 TCAGCAACTTATGGG 522 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA KATERI CS153 TCAGCAACTTATGGG 491 TCAGCAACTTATGGG 523 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ATACAGAGAATGGT AcaTACAGAGAATGG GGATTTCCATACACT TGGATTTCCATACAC GAAATGATTGTTCAT TGAAATGATTGTTCA CTA TCTA KATERI CS102 TCAGCAACTTATGGG 492 TCAGCAACTTATGGG 524 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa CAGAGAATGGTGGA cataCAGAGAATGGTG TTTCCATACACTGAA GATTTCCATACACTG ATGATTGTTCATCTA AAATGATTGTTCATC TA KATERI CS103 TCAGCAACTTATGGG 493 TCAGCAACTTATGGG 525 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa GAGAATGGTGGATTT catacaGAGAATGGTGG CCATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTA AATGATTGTTCATCT A TN90 CS143 TCAGCAACTTATGGG 494 TCAGCAACTTATGGG 526 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 18GH TCAGCAACTTATGGG 495 TCAGCAACTTATGGG 527 2169 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 CS120 TCAGCAACTTATGGG 496 TCAGCAACTTATGGG 528 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAATGGTGG ACATacagAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT A CTA TN90 17GH TCAGCAACTTATGGG 497 TCAGCAACTTATGGG 529 1698- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 22 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 17GH TCAGCAACTTATGGG 498 TCAGCAACTTATGGG 530 1700- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 13 GATGGAGCAATTCA GATGGAGCAATTCAa CAGAGAATGGTGGA cataCAGAGAATGGTG TTTCCATACACTGAA GATTTCCATACACTG ATGATTGTTCATCTA AAATGATTGTTCATC TA TN90 17GH TCAGCAACTTATGGG 499 TCAGCAACTTATGGG 531 1702- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 17 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 18GH TCAGCAACTTATGGG 500 TCAGCAACTTATGGG 532 2171 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 CS165 TCAGCAACTTATGGG 501 TCAGCAACTTATGGG 533 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA TN90 CS118 TCAGCAACTTATGGG 502 TCAGCAACTTATGGG 534 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTAG GATGGAGCAATTcaac AATGGTGGATTTCCA atacagAGAATGGTGGA TACACTGAAATGATT TTTCCATACACTGAA GTTCATCTA ATGATTGTTCATCTA TN90 CS113 TCAGCAACTTATGGG 503 TCAGCAACTTATGGG 535 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACATAGAATGGTGG ACATacagAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT A CTA TN90 17GH TCAGCAACTTATGGG 504 TCAGCAACTTATGGG 536 1737- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 24 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG catACAGAGAATGGTG ATTTCCATACACTGA GATTTCCATACACTG AATGATTGTTCATCT AAATGATTGTTCATC A TA IZMIR 18GH TCAGCAACTTATGGG 505 TCAGCAACTTATGGG 537 2254-7 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCA ACACTGGTGGATTTC AcatacagagACTGGTGG CATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTA AATGATTGTTCATCT A

TABLE 12C A list of exemplary mutant alleles obtained in the PMT2 gene. Mutant allele sequences listed here represent approximately 90-nucleotide-long genomic sequences from each edited PMT2 gene with the edited site in the middle of the genomic sequence (e.g., 45 nucleotides on each side of the deleted sequence site). The mutant allele corresponds to the indel provided for each line in Table 10. The lowercase letters in the reference allele sequence (SEQ ID NO: 8) denote which nucleotides are deleted in the mutant allele. Mutant Reference Allele  Reference Allele  Mutant Allele SEQ Allele SEQ Genotype Line Sequence ID NO. Sequence ID NO. BASMA CS107 TCAGCAACTTATGGG 538 TCAGCAACTTATGGG 570 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT BASMA CS106 TCAGCAACTTATGGG 539 TCAGCAACTTATGGG 571 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT K326 CS115 TCAGCAACTTATGGG 540 TCAGCAACTTATGGG 572 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT K326 18GH TCAGCAACTTATGGG 541 TCAGCAACTTATGGG 573 2162 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa AGAATGGTGGATTTC cacacagAGAATGGTGG CATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTT AATGATTGTTCATCT T K326 CS111 TCAGCAACTTATGGG 542 TCAGCAACTTATGGG 574 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT K326 CS112 TCAGCAACTTATGGG 543 TCAGCAACTTATGGG 575 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT K326 17GH TCAGCAACTTATGGG 544 TCAGCAACTTATGGG 576 1678- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 60 GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT K326 CS131 TCAGCAACTTATGGG 545 TCAGCAACTTATGGG 577 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT KATERI CS164 TCAGCAACTTATGGG 546 TCAGCAACTTATGGG 578 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS163 TCAGCAACTTATGGG 547 TCAGCAACTTATGGG 579 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT CACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS146 TCAGCAACTTATGGG 548 TCAGCAACTTATGGG 580 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT CACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS147 TCAGCAACTTATGGG 549 TCAGCAACTTATGGG 581 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT CACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS150 TCAGCAACTTATGGG 550 TCAGCAACTTATGGG 582 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT CACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS151 TCAGCAACTTATGGG 551 TCAGCAACTTATGGG 583 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT CACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS148 TCAGCAACTTATGGG 552 TCAGCAACTTATGGG 584 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT CACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS149 TCAGCAACTTATGGG 553 TCAGCAACTTATGGG 585 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS152 TCAGCAACTTATGGG 554 TCAGCAACTTATGGG 586 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS153 TCAGCAACTTATGGG 555 TCAGCAACTTATGGG 587 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT KATERI CS102 TCAGCAACTTATGGG 556 TCAGCAACTTATGGG 588 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa AGAATGGTGGATTTC cacacagAGAATGGTGG CATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTT AATGATTGTTCATCT T KATERI CS103 TCAGCAACTTATGGG 557 TCAGCAACTTATGGG 589 NI AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa AGAATGGTGGATTTC cacacagAGAATGGTGG CATACACTGAAATG ATTTCCATACACTGA ATTGTTCATCTT AATGATTGTTCATCT T TN90 CS143 TCAGCAACTTATGGG 558 TCAGCAACTTATGGG 590 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT TN90 18GH TCAGCAACTTATGGG 559 TCAGCAACTTATGGG 591 2169 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT TN90 CS120 TCAGCAACTTATGGG 560 TCAGCAACTTATGGG 592 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT TN90 17GH TCAGCAACTTATGGG 561 TCAGCAACTTATGGG 593 1698- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 22 GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT TN90 17GH TCAGCAACTTATGGG 562 TCAGCAACTTATGGG 594 1700- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 13 GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT TN90 17GH TCAGCAACTTATGGG 563 TCAGCAACTTATGGG 595 1702- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 17 GATGGAGCAATTCA GATGGAGCAATTCAa ACACAGAGAATGGT cACACAGAGAATGGT GGATTTCCATACACT GGATTTCCATACACT GAAATGATTGTTCAT GAAATGATTGTTCAT CTT CTT TN90 18GH TCAGCAACTTATGGG 564 TCAGCAACTTATGGG 596 2171 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT TN90 CS165 TCAGCAACTTATGGG 565 TCAGCAACTTATGGG 597 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT TN90 CS118 TCAGCAACTTATGGG 566 TCAGCAACTTATGGG 598 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT TN90 CS113 TCAGCAACTTATGGG 567 TCAGCAACTTATGGG 599 AAGGTTCTGACTTTG AAGGTTCTGACTTTG GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT TN90 17GH TCAGCAACTTATGGG 568 TCAGCAACTTATGGG 600 1737- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 24 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT IZMIR 18GH TCAGCAACTTATGGG 569 TCAGCAACTTATGGG 601 2254- AAGGTTCTGACTTTG AAGGTTCTGACTTTG 7 GATGGAGCAATTCA GATGGAGCAATTCAa ACAGAGAATGGTGG cacACAGAGAATGGT ATTTCCATACACTGA GGATTTCCATACACT AATGATTGTTCATCT GAAATGATTGTTCAT T CTT

TABLE 12D A list of exemplary mutant alleles obtained in the PMT3 gene. Mutant allele sequences listed here represent approximately 90-nucleotide-long genomic sequences from each edited PMT3 gene with the edited site in the middle of the genomic sequence (e.g., 45 nucleotides on each side of the deleted sequence site). The mutant allele corresponds to the indel provided for each line in Table 10. The lowercase letters in the reference allele sequence (SEQ ID NO: 9) denote which nucleotides are deleted in the mutant allele. Mutant Reference Allele  Reference Allele  Mutant Allele SEQ Allele SEQ Genotype Line Sequence ID NO. Sequence ID NO. BASMA CS107 TCAGCAACATATGG 602 TCAGCAACATATGG 634 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT BASMA CS106 TCAGCAACATATGG 603 TCAGCAACATATGG 635 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT K326 CS115 TCAGCAACATATGG 604 TCAGCAACATATGG 636 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AAAGAGAATGGTGG AACacacAGAGAATGG ATTTCCATACACTGA TGGATTTCCATACAC AATGATTGTTCATCT TGAAATGATTGTTCA T TCTT K326 18GH TCAGCAACATATGG 605 TCAGCAACATATGG 637 2162 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT K326 CS111 TCAGCAACATATGG 606 TCAGCAACATATGG 638 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT K326 CS112 TCAGCAACATATGG 607 TCAGCAACATATGG 639 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT K326 17GH TCAGCAACATATGG 608 TCAGCAACATATGG 640 1678- GAAGGTTCTGACTTT GAAGGTTCTGACTTT 60 GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT K326 CS131 TCAGCAACATATGG 609 TCAGCAACATATGG 641 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTCa AGAATGGTGGATTTC acacacagAGAATGGTG CATACACTGAAATG GATTTCCATACACTG ATTGTTCATCTT AAATGATTGTTCATC TT KATERI CS164 TCAGCAACATATGG 610 TCAGCAACATATGG 642 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS163 TCAGCAACATATGG 611 TCAGCAACATATGG 643 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS146 TCAGCAACATATGG 612 TCAGCAACATATGG 644 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTca AGAGAATGGTGGAT acacaCAGAGAATGGT TTCCATACACTGAAA GGATTTCCATACACT TGATTGTTCATCTT GAAATGATTGTTCAT CTT KATERI CS147 TCAGCAACATATGG 613 TCAGCAACATATGG 645 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTca AGAGAATGGTGGAT acacaCAGAGAATGGT TTCCATACACTGAAA GGATTTCCATACACT TGATTGTTCATCTT GAAATGATTGTTCAT CTT KATERI CS150 TCAGCAACATATGG 614 TCAGCAACATATGG 646 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AAAGAATGGTGGAT AAcacacagAGAATGGT TTCCATACACTGAAA GGATTTCCATACACT TGATTGTTCATCTT GAAATGATTGTTCAT CTT KATERI CS151 TCAGCAACATATGG 615 TCAGCAACATATGG 647 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS148 TCAGCAACATATGG 616 TCAGCAACATATGG 648 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AAAGAATGGTGGAT AAcacacagAGAATGGT TTCCATACACTGAAA GGATTTCCATACACT TGATTGTTCATCTT GAAATGATTGTTCAT CTT KATERI CS149 TCAGCAACATATGG 617 TCAGCAACATATGG 649 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS152 TCAGCAACATATGG 618 TCAGCAACATATGG 650 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS153 TCAGCAACATATGG 619 TCAGCAACATATGG 651 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS102 TCAGCAACATATGG 620 TCAGCAACATATGG 652 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS103 TCAGCAACATATGG 621 TCAGCAACATATGG 653 NI GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 CS143 TCAGCAACATATGG 622 TCAGCAACATATGG 654 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 18GH TCAGCAACATATGG 623 TCAGCAACATATGG 655 2169 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT TN90 CS120 TCAGCAACATATGG 624 TCAGCAACATATGG 656 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 17GH TCAGCAACATATGG 625 TCAGCAACATATGG 657 1698- GAAGGTTCTGACTTT GAAGGTTCTGACTTT 22 GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAATGGTG AACACacagAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT TN90 17GH TCAGCAACATATGG 626 TCAGCAACATATGG 658 1700- GAAGGTTCTGACTTT GAAGGTTCTGACTTT 13 GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 17GH TCAGCAACATATGG 627 TCAGCAACATATGG 659 1702- GAAGGTTCTGACTTT GAAGGTTCTGACTTT 17 GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 18GH TCAGCAACATATGG 628 TCAGCAACATATGG 660 2171 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTca AGAGAATGGTGGAT acacaCAGAGAATGGT TTCCATACACTGAAA GGATTTCCATACACT TGATTGTTCATCTT GAAATGATTGTTCAT CTT TN90 CS165 TCAGCAACATATGG 629 TCAGCAACATATGG 661 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT TN90 CS118 TCAGCAACATATGG 630 TCAGCAACATATGG 662 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 CS113 TCAGCAACATATGG 631 TCAGCAACATATGG 663 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 17GH TCAGCAACATATGG 632 TCAGCAACATATGG 664 1737- GAAGGTTCTGACTTT GAAGGTTCTGACTTT 24 GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT IZMIR 18GH TCAGCAACATATGG 633 TCAGCAACATATGG 665 2254-7 GAAGGTTCTGACTTT GAAGGTTCTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT

TABLE 12E A list of exemplary mutant alleles obtained in the PMT4 gene. Mutant allele sequences listed here represent approximately 90-nucleotide-long genomic sequences from each edited PMT4 gene with the edited site in the middle of the genomic sequence (e.g., 45 nucleotides on each side of the deleted sequence site). The mutant allele corresponds to the indel provided for each line in Table 10. The lowercase letters in the reference allele sequence (SEQ ID NO: 10) denote which nucleotides are deleted in the mutant allele.  Mutant Reference Allele  Reference Allele  Mutant Allele SEQ Allele SEQ Genotype Line Sequence ID NO. Sequence ID NO. BASMA CS107 TCAGCAACATATGG 666 TCAGCAACATATGG 698 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT BASMA CS106 TCAGCAACATATGG 667 TCAGCAACATATGG 699 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT K326 CS115 TCAGCAACATATGG 668 TCAGCAACATATGG 700 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACGAGAATGGTGG AACacacaGAGAATGG ATTTCCATACACTGA TGGATTTCCATACAC AATGATTGTTCATCT TGAAATGATTGTTCA T TCTT K326 18GH TCAGCAACATATGG 669 TCAGCAACATATGG 701 2162 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACGAGAATGGTGG AACacacaGAGAATGG ATTTCCATACACTGA TGGATTTCCATACAC AATGATTGTTCATCT TGAAATGATTGTTCA T TCTT K326 CS111 TCAGCAACATATGG 670 TCAGCAACATATGG 702 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AAAGAGAATGGTGG AAcacacAGAGAATGG ATTTCCATACACTGA TGGATTTCCATACAC AATGATTGTTCATCT TGAAATGATTGTTCA T TCTT K326 CS112 TCAGCAACATATGG 671 TCAGCAACATATGG 703 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AAAGAGAATGGTGG AAcacacAGAGAATGG ATTTCCATACACTGA TGGATTTCCATACAC AATGATTGTTCATCT TGAAATGATTGTTCA T TCTT K326 17GH TCAGCAACATATGG 672 TCAGCAACATATGG 704 1678- GAAGGTTTTGACTTT GAAGGTTTTGACTTT 60 GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT K326 CS131 TCAGCAACATATGG 673 TCAGCAACATATGG 705 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS164 TCAGCAACATATGG 674 TCAGCAACATATGG 706 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS163 TCAGCAACATATGG 675 TCAGCAACATATGG 707 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS146 TCAGCAACATATGG 676 TCAGCAACATATGG 708 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS147 TCAGCAACATATGG 677 TCAGCAACATATGG 709 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS150 TCAGCAACATATGG 678 TCAGCAACATATGG 710 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS151 TCAGCAACATATGG 679 TCAGCAACATATGG 711 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTA GGATGGAGCAATTca GAATGGTGGATTTCC acacacagAGAATGGTG ATACACTGAAATGAT GATTTCCATACACTG TGTTCATCTT AAATGATTGTTCATC TT KATERI CS148 TCAGCAACATATGG 680 TCAGCAACATATGG 712 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS149 TCAGCAACATATGG 681 TCAGCAACATATGG 713 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTA GGATGGAGCAATTca GAATGGTGGATTTCC acacacagAGAATGGTG ATACACTGAAATGAT GATTTCCATACACTG TGTTCATCTT AAATGATTGTTCATC TT KATERI CS152 TCAGCAACATATGG 682 TCAGCAACATATGG 714 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS153 TCAGCAACATATGG 683 TCAGCAACATATGG 715 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT KATERI CS102 TCAGCAACATATGG 684 TCAGCAACATATGG 716 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT KATERI CS103 TCAGCAACATATGG 685 TCAGCAACATATGG 717 NI GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 CS143 TCAGCAACATATGG 686 TCAGCAACATATGG 718 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT TN90 18GH TCAGCAACATATGG 687 TCAGCAACATATGG 719 2169 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 CS120 TCAGCAACATATGG 688 TCAGCAACATATGG 720 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 17GH TCAGCAACATATGG 689 TCAGCAACATATGG 721 1698- GAAGGTTTTGACTTT GAAGGTTTTGACTTT 22 GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 17GH TCAGCAACATATGG 690 TCAGCAACATATGG 722 1700- GAAGGTTTTGACTTT GAAGGTTTTGACTTT 13 GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT TN90 17GH TCAGCAACATATGG 691 TCAGCAACATATGG 723 1702- GAAGGTTTTGACTTT GAAGGTTTTGACTTT 17 GGATGGAGCAATTC GGATGGAGCAATTC AACAAGAATGGTGG AACAcacagAGAATGG ATTTCCATACACTGA TGGATTTCCATACAC AATGATTGTTCATCT TGAAATGATTGTTCA T TCTT TN90 18GH TCAGCAACATATGG 692 TCAGCAACATATGG 724 2171 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 CS165 TCAGCAACATATGG 693 TCAGCAACATATGG 725 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACAGAGAATGGTG AacacACAGAGAATGG GATTTCCATACACTG TGGATTTCCATACAC AAATGATTGTTCATC TGAAATGATTGTTCA TT TCTT TN90 CS118 TCAGCAACATATGG 694 TCAGCAACATATGG 726 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 CS113 TCAGCAACATATGG 695 TCAGCAACATATGG 727 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT TN90 17GH TCAGCAACATATGG 696 TCAGCAACATATGG 728 1737- GAAGGTTTTGACTTT GAAGGTTTTGACTTT 24 GGATGGAGCAATTC GGATGGAGCAATTC AACACAGAGAATGG AacACACAGAGAATG TGGATTTCCATACAC GTGGATTTCCATACA TGAAATGATTGTTCA CTGAAATGATTGTTC TCTT ATCTT IZMIR 18GH TCAGCAACATATGG 697 TCAGCAACATATGG 729 2254-7 GAAGGTTTTGACTTT GAAGGTTTTGACTTT GGATGGAGCAATTC GGATGGAGCAATTC AAGAATGGTGGATTT AacacacagAGAATGGT CCATACACTGAAATG GGATTTCCATACACT ATTGTTCATCTT GAAATGATTGTTCAT CTT

Example 8. Alkaloid Analysis of PMT Edited Lines

Homozygous genome edited tobacco lines from Example 7, along with control lines, are grown in in a field. At flowering stage, plants are topped and two-weeks post topping, lamina samples are collected from the third, fourth, and fifth leaves from the top of the plant and alkaloid levels are measured (see Tables 13A-13C) using a method in accordance with CORESTA Method No 62, Determination of Nicotine in Tobacco and Tobacco Products by Gas Chromatographic Analysis, February 2005, and those defined in the Centers for Disease Control and Prevention's Protocol for Analysis of Nicotine, Total Moisture and pH in Smokeless Tobacco Products, as published in the Federal Register Vol. 64, No. 55 Mar. 23, 1999 (and as amended in Vol. 74, No. 4, Jan. 7, 2009).

Approximately 0.5 g of tobacco is extracted using liquid/liquid extraction into an organic solvent containing an internal standard and analyzed by gas chromatography (GC) with flame ionization detection (FID). Results can be reported as weight percent (Wt %) on either on as is or dry weight basis. Reporting data on a dry weight basis requires an oven volatiles (OV) determination. Unless specified otherwise, total or individual alkaloid levels or nicotine levels shown herein are on a dry weight basis (e.g., percent total alkaloid or percent nicotine).

Plants are also planted in the field, harvested, and tested for alkaloids and TSNA levels in cured tobacco. Both leaf yield and leaf grade are also assessed for PMT edited plants.

TABLE 13A Nicotine analysis of K326 and TN90 PMT edited lines after two weeks after flowering. Nicotine Variety Line Replicate (mg/g tissue) K 326 CS111 1 0.023 2 0.024 CS131 1 0.022 2 0.018 3 0.021 CS115 1 0.023 2 0.015 Control 1 16.8 2 17.2 3 16.6 TN 90 LC CS116 1 0.029 2 0.022 CS133 1 0.016 2 0.018 CS135 1 0.027 2 0.031 CS120 1 0.022 2 0.045 CS137 1 0.07 2 0.048 Control 1 29.5 2 29.8 3 24.2

TABLE 13B Nicotine analysis of K326 and TN90 PMT edited lines after two-weeks after topping. Nicotine Variety Group Replicate (mg/g tissue) K 326 CS111 1 0.024 2 0.025 CS131 1 0.021 2 0.02 3 0.019 CS115 1 0.018 Control 1 16.771 2 17.212 3 16.581 4 22.734 TN 90 LC CS116 1 0.015 CS133 1 0.036 2 0.018 CS135 1 0.018 2 0.019 CS120 1 0.04 2 0.025 CS137 1 0.051 2 0.057 Control 1 29.472 2 29.776 3 24.22 4 24.939

TABLE 13C Nicotine analysis of Katerini and Basma PMT edited lines after two-weeks after flowering. Nicotine Variety Group Replicate (mg/g tissue) Katerini CS102 1 0.032 2 0.028 CS103 1 0.017 Control 1 26.109 2 26.466 3 27.091 Basma CS107 1 0.029 CS108 1 0.014 2 0.018 Control 1 21.979 2 20.88 3 23.499

Example 9. Development of Male Sterile PMT Edited Lines

PMT edited hybrid lines are developed using the lines from Example 7. Hybrid lines are grown in the field and used as progenitors for male sterile lines. See Table 14.

TABLE 14 PMT edited very low nicotine male sterile lines Male Sterile Pollen source F1 hybrid seed Variety (line) (line) MS Katerini CS102 dCS11 CS103 dCS12 MS Basma CS106 dCS13 CS107 dCS14 MS K326 CS111 dCS15 CS115 dCS16 MS TN90 CS118 dCS17 CS120 dCS18 MS Izmir 18GH2254 dS2697

Example 10. PMT Edited Lines Resist Mold During Curing

Tobacco leaf harvested from several low alkaloid tobacco lines is subjected to standard air curing practices. The tobacco leaves are examined for mold after the completion of curing.

Tobacco from the LA BU 21 exhibits more mold infestation than TN90 LC, a TN90 variety comprising an RNAi construct to downregulate all five PMT genes, a TN90 variety comprising an RNAi construct to downregulate the alkaloid biosynthesis gene PR50, and four PMT edited lines (CS47, CS59, CS63, and CS64) in a TN90 genetic background. See Table 15 and FIGS. 6A to 6E and 7 .

TABLE 15 Mold damage exhibited by tobacco lines. Mold Rating Percentage of Mold Replicate Replicate Replicate Replicate Significant Some Little/No Variety 1 2 3 4 Mold Mold Mold TN90 LC G G G G G G G G G G G G 0% 0% 100% LA BU 21 G S G B S G S S S B S S 17%  58%   25% TN90 G G G G G G G G G G G G 0% 0% 100% (PMT RNAi) TN90 G G G G G G G G G G G G 0% 0% 100% (PR50 RNai) CS47 G G G G G G G G G G G G 0% 0% 100% CS59 G G G G G G G G G G G G 0% 0% 100% CS63 G G G G G G G G G G G G 0% 0% 100% CS64 G G G G G G G G G S S G 0% 17%   83% “G” refers to little/no mold; “S” refers to some mold; and “B” refers to significant mold. Percentage of Mold refers to the percentage of air cured sticks of tobacco exhibited each category of mold damage. 

1.-32. (canceled)
 33. Cured tobacco material from a tobacco plant comprising: (a) a first knockout mutant allele in a putrescine N-methyltransferase (PMT)1a gene (PMT1a), wherein a wildtype allele of the PMT1a gene encodes the polypeptide of SEQ ID NO: 12, and wherein the first knockout mutant allele in the PMT1a gene comprises the sequence of SEQ ID NO: 432; and (b) a second knockout mutant allele in a PMT1b gene, wherein a wildtype allele of the PMT1b gene encodes the polypeptide of SEQ ID NO: 11; and (c) a third knockout mutant allele in a PMT2 gene, wherein a wildtype allele of the PMT2 gene encodes the polypeptide of SEQ ID NO: 13; and (d) a fourth knockout mutant allele in a PMT3 gene, wherein a wildtype allele of the PMT3 gene encodes the polypeptide of SEQ ID NO: 14; and (e) a fifth knockout mutant allele in a PMT4 gene, wherein a wildtype allele of the PMT4 gene encodes the polypeptide of SEQ ID NO: 15; wherein the tobacco plant produces a leaf comprising a nicotine level less than the nicotine level of a leaf from a control tobacco plant not having each of the first, second, third, fourth, and fifth knockout mutant alleles when grown and processed under comparable conditions.
 34. The cured tobacco material of claim 33, wherein the cured tobacco material comprises cured tobacco leaf.
 35. The cured tobacco material of claim 33, wherein the tobacco plant is of a tobacco type selected from the group consisting of flue-cured tobacco, air-cured tobacco, dark air-cured tobacco, dark fire-cured tobacco, Galpão tobacco, and Oriental tobacco.
 36. The cured tobacco material of claim 33, wherein the tobacco plant is of a tobacco type selected from the group consisting of Burley tobacco, Maryland tobacco, and dark tobacco.
 37. The cured tobacco material of claim 34, wherein the cured tobacco material exhibits reduced mold infection as compared to control cured tobacco material from the variety LA Burley
 21. 38. The cured tobacco material of claim 37, wherein the mold is from a genus selected from the group consisting of Cladosporium, Penicillium, Alternaria, Aspergillus, and Mucor.
 39. The cured tobacco material of claim 33, wherein the tobacco plant is derived from or in the genetic background of a tobacco variety selected from the group consisting of BU 64, CC 101, CC 200, CC 27, CC 301, CC 400, CC 500, CC 600, CC 700, CC 800, CC 900, Coker 176, Coker 319, Coker 371 Gold, Coker 48, CU 263, DF911, Galpao tobacco, GL 26H, GL 350, GL 600, GL 737, GL 939, GL 973, HB 04P, K 149, K 326, K 346, K 358, K394, K 399, K 730, KDH 959, KT 200, KT204LC, KY 10, KY 14, KY 160, KY 17, KY 171, KY 907, KY907LC, KTY14×L8 LC, Little Crittenden, McNair 373, McNair 944, msKY 14×L8, Narrow Leaf Madole, NC 100, NC 102, NC 2000, NC 291, NC 297, NC 299, NC 3, NC 4, NC 5, NC 6, NC7, NC 606, NC 71, NC 72, NC 810, NC BH 129, NC 2002, Neal Smith Madole, OXFORD 207, ‘Perique’ tobacco, PVH03, PVH09, PVH19, PVH50, PVH51, R 610, R 630, R 7-11, R 7-12, RG 17, RG 81, RG H51, RGH 4, RGH 51, RS 1410, Speight 168, Speight 172, Speight 179, Speight 210, Speight 220, Speight 225, Speight 227, Speight 234, Speight G-28, Speight G-70, Speight H-6, Speight H20, Speight NF3, TI 1406, TI 1269, TN 86, TN86LC, TN 90, TN 97, TN97LC, TN D94, TN D950, TR (Tom Rosson) Madole, VA 309, or VA359, Maryland 609, HB3307PLC, HB4488PLC, KT206LC, KT209LC, KT210LC, KT212LC, R610LC, PVH2310, NC196, KTD14LC, KTD6LC, KTD8LC, PD7302LC, PD7305LC, PD7309LC, PD7318LC, PD7319LC, PD7312LC, and ShireyLC.
 40. The cured tobacco material of claim 33, wherein the cured tobacco material is selected from the group consisting of sun-cured tobacco material, air-cured tobacco material, and fire-cured tobacco material.
 41. The cured tobacco material of claim 34, wherein the cured tobacco leaf comprises a higher leaf grade than a control cured tobacco leaf from the tobacco variety LA BU
 21. 42. A tobacco blend comprising the cured tobacco material of claim
 33. 43. The tobacco blend of claim 42, wherein the cured tobacco material constitutes at least 10% of the tobacco blend by volume.
 44. A tobacco product comprising cured tobacco leaf from a tobacco plant comprising: (a) a first knockout mutant allele in a putrescine N-methyltransferase (PMT)1a gene (PMT1a), wherein a wildtype allele of the PMT1a gene encodes the polypeptide of SEQ ID NO: 12, and wherein the first knockout mutant allele in the PMT1a gene comprises the sequence of SEQ ID NO: 432; and (b) a second knockout mutant allele in a PMT1b gene, wherein a wildtype allele of the PMT1b gene encodes the polypeptide of SEQ ID NO: 11; and (c) a third knockout mutant allele in a PMT2 gene, wherein a wildtype allele of the PMT2 gene encodes the polypeptide of SEQ ID NO: 13; and (d) a fourth knockout mutant allele in a PMT3 gene, wherein a wildtype allele of the PMT3 gene encodes the polypeptide of SEQ ID NO: 14; and (e) a fifth knockout mutant allele in a PMT4 gene, wherein a wildtype allele of the PMT4 gene encodes the polypeptide of SEQ ID NO: 15; wherein the tobacco plant produces a leaf comprising a nicotine level less than the nicotine level of a leaf from a control tobacco plant not having each of the first, second, third, fourth, and fifth knockout mutant alleles when grown and processed under comparable conditions
 45. The tobacco product of claim 43, wherein the tobacco product is selected from the group consisting of a cigarette, a cigarillo, a non-ventilated recess filter cigarette, a vented recess filter cigarette, a cigar, snuff, pipe tobacco, cigar tobacco, cigarette tobacco, chewing tobacco, leaf tobacco, shredded tobacco, and cut tobacco.
 46. The tobacco product of claim 43, wherein the tobacco product is a smokeless tobacco product.
 47. The tobacco product of claim 45, wherein the smokeless tobacco product is selected from the group consisting of loose leaf chewing tobacco, plug chewing tobacco, moist snuff, snus, and nasal snuff.
 48. The tobacco product of claim 43, wherein the tobacco product further comprises a flavoring.
 49. The tobacco product of claim 43, wherein the tobacco product further comprises a filler.
 50. The tobacco product of claim 48, wherein the filler comprises reconstituted tobacco.
 51. The tobacco product of claim 48, wherein the filler comprises expanded tobacco.
 52. The tobacco product of claim 48, wherein the filler comprises non-tobacco plant material. 